



This is a repository copy of *Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/194156/>

Version: Published Version

Article:

Kuehn, R., Stoesser, N., Eyre, D. et al. (3 more authors) (2022) Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. *Cochrane Database of Systematic Reviews*, 2022 (11). CD010452. ISSN 1469-493X

<https://doi.org/10.1002/14651858.cd010452.pub2>

This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2022, Issue 11. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.' + ' Kuehn, Rebecca; Stoesser, Nicole; Eyre, David; Darton, Thomas C.; Basnyat, Buddha; Parry, Christopher Martin. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. *Cochrane Database of Systematic Reviews* 2022, Issue 11. Art. No.: CD010452. DOI: <http://dx.doi.org/10.1002/14651858.CD010452>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



Cochrane
Library

Cochrane Database of Systematic Reviews

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM

Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM.
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Cochrane Database of Systematic Reviews 2022, Issue 11. Art. No.: CD010452.
DOI: [10.1002/14651858.CD010452.pub2](https://doi.org/10.1002/14651858.CD010452.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	9
OBJECTIVES	11
METHODS	11
RESULTS	14
Figure 1.	15
Figure 2.	17
Figure 3.	18
DISCUSSION	24
AUTHORS' CONCLUSIONS	26
ACKNOWLEDGEMENTS	26
REFERENCES	27
CHARACTERISTICS OF STUDIES	33
DATA AND ANALYSES	78
Analysis 1.1. Comparison 1: Cefixime versus fluoroquinolone, Outcome 1: Clinical failure	80
Analysis 1.2. Comparison 1: Cefixime versus fluoroquinolone, Outcome 2: Microbiological failure	81
Analysis 1.3. Comparison 1: Cefixime versus fluoroquinolone, Outcome 3: Relapse	82
Analysis 1.4. Comparison 1: Cefixime versus fluoroquinolone, Outcome 4: Time to defervescence	83
Analysis 2.1. Comparison 2: Ceftriaxone versus azithromycin, Outcome 1: Clinical failure	84
Analysis 2.2. Comparison 2: Ceftriaxone versus azithromycin, Outcome 2: Microbiological failure	84
Analysis 2.3. Comparison 2: Ceftriaxone versus azithromycin, Outcome 3: Relapse	84
Analysis 2.4. Comparison 2: Ceftriaxone versus azithromycin, Outcome 4: Time to defervescence	85
Analysis 3.1. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 1: Clinical failure	87
Analysis 3.2. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 2: Microbiological failure	88
Analysis 3.3. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 3: Relapse	89
Analysis 3.4. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 4: Time to defervescence	90
Analysis 3.5. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 5: Convalescent faecal carriage	90
Analysis 4.1. Comparison 4: Ceftriaxone versus cefixime, Outcome 1: Clinical failure	91
Analysis 4.2. Comparison 4: Ceftriaxone versus cefixime, Outcome 2: Microbiological failure	91
Analysis 4.3. Comparison 4: Ceftriaxone versus cefixime, Outcome 3: Relapse	91
Analysis 4.4. Comparison 4: Ceftriaxone versus cefixime, Outcome 4: Time to defervescence	92
Analysis 5.1. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 1: Clinical failure	92
Analysis 5.2. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 2: Microbiological failure	93
Analysis 5.3. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 3: Relapse	93
Analysis 5.4. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 4: Time to defervescence	93
Analysis 5.5. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 5: Convalescent faecal carriage	94
Analysis 6.1. Comparison 6: Cefixime versus chloramphenicol, Outcome 1: Clinical failure	94
Analysis 6.2. Comparison 6: Cefixime versus chloramphenicol, Outcome 2: Microbiological failure	94
Analysis 6.3. Comparison 6: Cefixime versus chloramphenicol, Outcome 3: Time to defervescence	95
Analysis 7.1. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 1: Clinical failure	95
Analysis 7.2. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 2: Relapse	95
Analysis 7.3. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 3: Time to defervescence	96
Analysis 7.4. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 4: Convalescent faecal carriage	96
Analysis 8.1. Comparison 8: Cefixime versus cefpodoxime, Outcome 1: Clinical failure	96
Analysis 8.2. Comparison 8: Cefixime versus cefpodoxime, Outcome 2: Time to defervescence	97
Analysis 9.1. Comparison 9: Cefixime versus aztreonam, Outcome 1: Relapse	97
Analysis 9.2. Comparison 9: Cefixime versus aztreonam, Outcome 2: Time to defervescence	97
Analysis 10.1. Comparison 10: Ceftriaxone versus aztreonam, Outcome 1: Relapse	98
Analysis 10.2. Comparison 10: Ceftriaxone versus aztreonam, Outcome 2: Time to defervescence	98

Analysis 11.1. Comparison 11: Short versus long course ceftriaxone, Outcome 1: Clinical failure	99
Analysis 11.2. Comparison 11: Short versus long course ceftriaxone, Outcome 2: Relapse	99
Analysis 11.3. Comparison 11: Short versus long course ceftriaxone, Outcome 3: Time to defervescence	99
ADDITIONAL TABLES	99
APPENDICES	100
HISTORY	102
CONTRIBUTIONS OF AUTHORS	102
DECLARATIONS OF INTEREST	102
SOURCES OF SUPPORT	103
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	103
INDEX TERMS	103

[Intervention Review]

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins

Rebecca Kuehn¹, Nicole Stoesser², David Eyre³, Thomas C Darton⁴, Buddha Basnyat^{2,5}, Christopher Martin Parry^{1,2}

¹Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. ²Nuffield Department of Medicine, University of Oxford, Oxford, UK. ³Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. ⁴Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK. ⁵Oxford Clinical Research Unit/Patan Academy of Health Science, Nepal International Clinic, Kathmandu, Nepal

Contact: Christopher Martin Parry, christopher.parry@lstmed.ac.uk.**Editorial group:** Cochrane Infectious Diseases Group.**Publication status and date:** New, published in Issue 11, 2022.**Citation:** Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. *Cochrane Database of Systematic Reviews* 2022, Issue 11. Art. No.: CD010452. DOI: [10.1002/14651858.CD010452.pub2](https://doi.org/10.1002/14651858.CD010452.pub2).

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the [Creative Commons Attribution-Non-Commercial Licence](https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

ABSTRACT

Background

Typhoid and paratyphoid (enteric fever) are febrile bacterial illnesses common in many low- and middle-income countries. The World Health Organization (WHO) currently recommends treatment with azithromycin, ciprofloxacin, or ceftriaxone due to widespread resistance to older, first-line antimicrobials. Resistance patterns vary in different locations and are changing over time. Fluoroquinolone resistance in South Asia often precludes the use of ciprofloxacin. Extensively drug-resistant strains of enteric fever have emerged in Pakistan. In some areas of the world, susceptibility to old first-line antimicrobials, such as chloramphenicol, has re-appeared. A Cochrane Review of the use of fluoroquinolones and azithromycin in the treatment of enteric fever has previously been undertaken, but the use of cephalosporins has not been systematically investigated and the optimal choice of drug and duration of treatment are uncertain.

Objectives

To evaluate the effectiveness of cephalosporins for treating enteric fever in children and adults compared to other antimicrobials.

Search methods

We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, the WHO ICTRP and ClinicalTrials.gov up to 24 November 2021. We also searched reference lists of included trials, contacted researchers working in the field, and contacted relevant organizations.

Selection criteria

We included randomized controlled trials (RCTs) in adults and children with enteric fever that compared a cephalosporin to another antimicrobial, a different cephalosporin, or a different treatment duration of the intervention cephalosporin. Enteric fever was diagnosed on the basis of blood culture, bone marrow culture, or molecular tests.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were clinical failure, microbiological failure and relapse. Our secondary outcomes were time to defervescence, duration of hospital admission, convalescent faecal carriage, and adverse effects. We used the GRADE approach to assess certainty of evidence for each outcome.

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Main results

We included 27 RCTs with 2231 total participants published between 1986 and 2016 across Africa, Asia, Europe, the Middle East and the Caribbean, with comparisons between cephalosporins and other antimicrobials used for the treatment of enteric fever in children and adults. The main comparisons are between antimicrobials in most common clinical use, namely cephalosporins compared to a fluoroquinolone and cephalosporins compared to azithromycin.

Cephalosporin (cefixime) versus fluoroquinolones

Clinical failure, microbiological failure and relapse may be increased in patients treated with cefixime compared to fluoroquinolones in three small trials published over 14 years ago: clinical failure (risk ratio (RR) 13.39, 95% confidence interval (CI) 3.24 to 55.39; 2 trials, 240 participants; low-certainty evidence); microbiological failure (RR 4.07, 95% CI 0.46 to 36.41; 2 trials, 240 participants; low-certainty evidence); relapse (RR 4.45, 95% CI 1.11 to 17.84; 2 trials, 220 participants; low-certainty evidence). Time to defervescence in participants treated with cefixime may be longer compared to participants treated with fluoroquinolones (mean difference (MD) 1.74 days, 95% CI 0.50 to 2.98, 3 trials, 425 participants; low-certainty evidence).

Cephalosporin (ceftriaxone) versus azithromycin

Ceftriaxone may result in a decrease in clinical failure compared to azithromycin, and it is unclear whether ceftriaxone has an effect on microbiological failure compared to azithromycin in two small trials published over 18 years ago and in one more recent trial, all conducted in participants under 18 years of age: clinical failure (RR 0.42, 95% CI 0.11 to 1.57; 3 trials, 196 participants; low-certainty evidence); microbiological failure (RR 1.95, 95% CI 0.36 to 10.64, 3 trials, 196 participants; very low-certainty evidence). It is unclear whether ceftriaxone increases or decreases relapse compared to azithromycin (RR 10.05, 95% CI 1.93 to 52.38; 3 trials, 185 participants; very low-certainty evidence). Time to defervescence in participants treated with ceftriaxone may be shorter compared to participants treated with azithromycin (mean difference of -0.52 days, 95% CI -0.91 to -0.12; 3 trials, 196 participants; low-certainty evidence).

Cephalosporin (ceftriaxone) versus fluoroquinolones

It is unclear whether ceftriaxone has an effect on clinical failure, microbiological failure, relapse, and time to defervescence compared to fluoroquinolones in three trials published over 28 years ago and two more recent trials: clinical failure (RR 3.77, 95% CI 0.72 to 19.81; 4 trials, 359 participants; very low-certainty evidence); microbiological failure (RR 1.65, 95% CI 0.40 to 6.83; 3 trials, 316 participants; very low-certainty evidence); relapse (RR 0.95, 95% CI 0.31 to 2.92; 3 trials, 297 participants; very low-certainty evidence) and time to defervescence (MD 2.73 days, 95% CI -0.37 to 5.84; 3 trials, 285 participants; very low-certainty evidence). It is unclear whether ceftriaxone decreases convalescent faecal carriage compared to the fluoroquinolone gatifloxacin (RR 0.18, 95% CI 0.01 to 3.72; 1 trial, 73 participants; very low-certainty evidence) and length of hospital stay may be longer in participants treated with ceftriaxone compared to participants treated with the fluoroquinolone ofloxacin (mean of 12 days (range 7 to 23 days) in the ceftriaxone group compared to a mean of 9 days (range 6 to 13 days) in the ofloxacin group; 1 trial, 47 participants; low-certainty evidence).

Authors' conclusions

Based on very low- to low-certainty evidence, ceftriaxone is an effective treatment for adults and children with enteric fever, with few adverse effects. Trials suggest that there may be no difference in the performance of ceftriaxone compared with azithromycin, fluoroquinolones, or chloramphenicol. Cefixime can also be used for treatment of enteric fever but may not perform as well as fluoroquinolones.

We are unable to draw firm general conclusions on comparative contemporary effectiveness given that most trials were small and conducted over 20 years previously. Clinicians need to take into account current, local resistance patterns in addition to route of administration when choosing an antimicrobial.

PLAIN LANGUAGE SUMMARY

Cephalosporin antibiotics for the treatment of enteric fever (typhoid fever)

Key messages

- There may be no difference in the performance of ceftriaxone (a type of cephalosporin) compared with azithromycin, fluoroquinolones, or chloramphenicol (other antimicrobial medicines) for adults and children with enteric fever (typhoid fever).
- Cefixime (another type of cephalosporin) can also be used for treatment of enteric fever in adults and children but may not be as effective as fluoroquinolones.
- Policymakers and clinicians need to consider local antibiotic resistance patterns when considering treatment options for enteric fever.

What is enteric fever?

Enteric fever is a common term for two similar illnesses known individually as typhoid fever and paratyphoid fever. These illnesses only occur in people and are caused by bacteria known as *Salmonellatyphi* and *Salmonella paratyphi* A, B or C. These illnesses are most common in low- and middle-income countries where water and sanitation may be inadequate. Enteric fever typically causes fever and headache with diarrhoea, constipation, abdominal pain, nausea and vomiting, or loss of appetite. If left untreated, some people can develop serious complications and may die.

What are cephalosporins and how might they work?

The cephalosporins are a large family of antimicrobial medicines, which are commonly used to treat a variety of infectious diseases. Individual cephalosporins (such as cefixime and ceftriaxone) vary in the specific bacteria they can treat, how they are given - by mouth (orally) or injected (intravenously) - and when they were developed. Some cephalosporins can treat *Salmonellatyphi* and *Salmonella paratyphi* A, B, or C, the bacteria causing enteric (typhoid) fever.

In the past, enteric fever responded extremely well to other types of antimicrobial medicines, such as chloramphenicol. However, bacterial resistance to multiple antimicrobial medicines has become a major public health problem in many areas, especially Asia and Africa. Specific cephalosporins are now often used to treat enteric fever due to evolving drug resistance to other antimicrobials.

What did we want to find out?

We wanted to discover whether cephalosporins are better or worse in treating adults and children with enteric fever compared to other commonly given antimicrobials such as fluoroquinolones and azithromycin. To discover this, we wanted to know if treatment with cephalosporins would lead to persisting symptoms of disease (clinical failure), persisting *Salmonellatyphi* and *Salmonella paratyphi* A, B, or C bacteria in blood (microbiological failure), or return of symptoms or *Salmonellatyphi* and *Salmonella paratyphi* A, B, or C in the blood (relapse).

We also wanted to know how long cephalosporins take to reduce fever, if they reduce the length of time a patient needs to stay in hospital, whether patients' faeces (stool) would still carry the bacteria and thus remain infectious, and whether they cause any unwanted effects in patients.

What did we do?

We searched for studies that compared the treatment of a cephalosporin antimicrobial to another type of antimicrobial, or compared the treatment of a cephalosporin antimicrobial to another different cephalosporin antimicrobial, in adults or children who had enteric fever diagnosed through a laboratory test, such as blood culture.

What did we find?

We identified 27 studies involving 2231 adults and children from Africa, Asia, Europe, the Middle East, and the Caribbean that compared cephalosporin antimicrobial treatment in enteric fever with other antimicrobials.

Ceftriaxone was found to be an effective treatment for enteric fever, with few unwanted effects, and was similar to azithromycin, fluoroquinolones and chloramphenicol in its ability to treat enteric fever.

Cefixime can also be used to treat enteric fever but may not perform as well when compared to fluoroquinolone antimicrobials.

These findings only apply if the bacteria causing the enteric fever infection is vulnerable to the antimicrobial given to treat the infection; that is, the bacteria is not resistant to the antimicrobial.

What are the limitations of the evidence?

We have low confidence in our estimates, for these findings because of the low number of patients in the included studies. Also, in most included studies patients and doctors knew which antimicrobial the patient was receiving, which could have biased the results.

How up to date is this evidence?

These results are current up to 24 November 2021.

SUMMARY OF FINDINGS

Summary of findings 1. Cefixime versus fluoroquinolones for treating enteric fever

Population: adults and children with enteric fever

Setting: inpatients and outpatients; Nepal, Pakistan, Vietnam (July 1995 to September 2005)

Intervention: oral cefixime

Comparator: oral fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin)

Outcomes	Illustrative comparative risks (95% CI)		Relative effect (95% CI)	Number of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Assumed risk*	Comparative risk				
	Fluoroquinolone	Cefixime				
Clinical failure	2 per 100	21 per 100 (5 to 88)	RR 13.39 (3.24 to 55.39)	240 (2 trials)	Low ^a	Cefixime may result in an increase in clinical failure
Microbiological failure	0 in 126 ^b	3 in 114 ^c	RR 4.07 (0.46 to 36.41)	240 (2 trials)	Low ^d	Cefixime may result in an increase in microbiological failure
Relapse	2 per 100	7 per 100 (2 to 29)	RR 4.45 (1.11 to 17.84)	220 (2 trials)	Low ^d	Cefixime may result in an increase in relapse
Time to defervescence	The mean time to defervescence across fluoroquinolone groups ranged from 2.5 to 4.38 days	The mean time to defervescence in the cefixime group was 1.74 days longer (0.5 days longer to 2.98 days longer)	MD 1.74 (0.50 to 2.98)	425 (3 trials)	Low ^e	Cefixime may increase the time to defervescence
Duration of hospital stay	-	-	-	-	-	No trials reported duration of hospital stay
Convalescent faecal carriage	No events reported in the fluoroquinolone group	No events reported in the cephalosporin group	Analysis not possible ^f	-	-	No trials reported any cases of persistent convalescent faecal carriage

Serious adverse events	No events reported in the fluoroquinolone group	No events reported in the cephalosporin group	Analysis not possible ^f	-	-	No trials reported any cases of serious adverse events
-------------------------------	---	---	------------------------------------	---	---	--

*The **assumed risk** is from the median control group risk across trials. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio; **MD:** mean difference

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

Footnotes

^aDowngraded one level due to serious risk of bias and one level for serious imprecision due to few participants and very wide CIs.

^bNumber as reported in the trials.

^cNumber as reported in the trials. It was not possible to calculate the corresponding risk using the RR due to zero risk in the control group.

^dDowngraded one level due to serious risk of bias and one level for serious imprecision due to few participants and wide CIs.

^eDowngraded one level due to serious risk of bias and one level for inconsistency due to statistical heterogeneity.

^fAnalysis not possible due to zero events in control and intervention groups.

Summary of findings 2. Ceftriaxone versus azithromycin for treating enteric fever

Population: children under 18 years of age with enteric fever

Setting: inpatient; Egypt and India

Intervention: parenteral ceftriaxone

Comparator: oral azithromycin

Outcomes	Illustrative comparative risks (95% CI)		Relative effect (95% CI)	Number of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Assumed risk ^a	Comparative risk				
	Azithromycin	Ceftriaxone				
Clinical failure	7 per 100	3 per 100 (1 to 11)	RR 0.42 (0.11 to 1.57)	196 (3 trials)	Low ^a	Ceftriaxone may result in a decrease in clinical failure

Microbiological failure	1 per 100	2 per 100 (0 to 11)	RR 1.95 (0.36 to 10.64)	196 (3 trials)	Very low ^b	There may be no difference in microbiological failure in participants treated with ceftriaxone compared to azithromycin, but the evidence is very uncertain
Relapse	0 in 89 ^c	15 in 96 ^d	RR 10.05^e (1.93 to 52.38)	185 (3 trials)	Very low ^f	Ceftriaxone may result in an increase in relapse compared to azithromycin, but the evidence is very uncertain
Time to defervescence	The mean time to defervescence across azithromycin groups ranged from 4.1 to 5.5 days .	The mean time to defervescence in the cefixime group was 0.52 days fewer (0.91 days fewer to 0.12 days fewer)	MD -0.52 (-0.91 to -0.12)	196 (3 trials)	Low ^a	Ceftriaxone may result in a shorter time to defervescence compared to azithromycin
Duration of hospital stay	-	-	-	-	-	No trials reported duration of hospital stay
Convalescent faecal carriage	No events in the azithromycin group	No events in the ceftriaxone group	Analysis not possible ^g	-	-	No trials reported any cases of persistent convalescent faecal carriage
Serious adverse events	No events in the azithromycin group	No events in the ceftriaxone group	Analysis not possible ^g	-	-	No trials reported any serious adverse events

*The **assumed risk** is from the median control group risk across trials. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio; **MD:** mean difference

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

Footnotes

^aDowngraded one level due to serious risk of bias and one level for serious imprecision due to low participant numbers.

^bDowngraded one level due to serious risk of bias and two levels for serious imprecision due to low participant numbers and low number of events.

^cNumbers as reported in the trial.

^dNumbers as reported in the trial. It was not possible to calculate the corresponding risk using the RR due to zero risk in the control group.

^eIt was possible to calculate RR as continuity correction of 0.5 was applied.

^fDowngraded one level due to serious risk of bias and two levels for serious imprecision due to low number of events, low participant numbers, and wide CIs.
^gAnalysis not possible due to zero events in the intervention and control groups.

Summary of findings 3. Ceftriaxone versus fluoroquinolones for treating enteric fever

Population: adults and children with enteric fever

Setting: inpatient and outpatient; India, Nepal, Vietnam, (1992 to 2014)

Intervention: parenteral ceftriaxone

Comparator: oral fluoroquinolone

Outcomes	Illustrative comparative risks (95% CI)		Relative effect (95% CI)	Number of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Assumed risk*	Comparative risk				
	Fluoroquinolone	Ceftriaxone				
Clinical failure	10 per 100	38 per 100 (7 to 100)	RR 3.77 (0.72 to 19.81)	359 (4 trials)	Very low ^a	The evidence is very uncertain about the effect of ceftriaxone on clinical failure
Microbiological failure	1 per 100	2 per 100 (1 to 9)	RR 1.65 (0.40 to 6.83)	316 (3 trials)	Very low ^b	There may be no difference in microbiological failure in participants treated with ceftriaxone compared to fluoroquinolone, but the evidence is very uncertain
Relapse	3 per 100	3 per 100 (1 to 10)	RR 0.95 (0.31 to 2.92)	297 (3 trials)	Very low ^c	There may be no difference in relapse in participants treated with ceftriaxone compared to fluoroquinolone, but the evidence is very uncertain
Time to defervescence	The mean time to defervescence across fluoroquinolone groups ranged from 3.38 to 4 days	The mean time to defervescence in the ceftriaxone group was 2.73 days longer (0.37 days shorter to 5.84 days longer)	MD 2.73 (-0.37 to 5.84)	285 (3 trials)	Very low ^d	The evidence is very uncertain about the effect of ceftriaxone on the time to defervescence
Duration of hospital stay	The mean duration of hospital stay in the fluoroquinolone (ofloxacin) group was	The mean duration of hospital stay in the ceftriaxone group was 12 days (range 7 to 23 days).	Analysis not possible ^e	47 (1 trial)	Low ^f	Ceftriaxone may result in a shorter duration of hospital stay

	9 days (range 6 to 13 days).					
Convalescent faecal carriage	2 in 35 ^g	0 in 38 ^g	RR 0.18 (0.01 to 3.72)	73 (1 trial)	Very low ^c	Ceftriaxone may result in a decrease in convalescent faecal carriage rate, but the evidence is very uncertain
Serious adverse events	No events in the fluoroquinolone group	No events in the cephalosporin group	Analysis not possible ^h	-	-	No serious adverse events were reported

*The **assumed risk** is from the median control group risk across trials. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio; **MD:** mean difference

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

Footnotes

^aDowngraded one level for serious risk of bias, one level for serious inconsistency due to moderate statistical heterogeneity and two levels for serious imprecision due to low participant numbers, low number of events and wide CIs.

^bDowngraded one level for serious risk of bias and two levels for serious imprecision due to low participant numbers, wide CIs and low number of events.

^cDowngraded one level for serious risk of bias and two levels for serious imprecision due to low participant numbers and low number of events.

^dDowngraded one level for serious risk of bias, one level for inconsistency due to high statistical heterogeneity and one level for serious imprecision due to low participant numbers.

^eAnalysis not possible due unavailable data on standard deviation and 95% CIs.

^fDowngraded one level for serious risk of bias and one level for serious imprecision due to data arising from one trial with low participant numbers.

^gNumbers as reported in the trial.

^hAnalysis not possible due to no events in the intervention or control groups.

BACKGROUND

Enteric fever, also referred to as typhoid fever, is a systemic infection caused by either *Salmonella enterica* serovar *typhi* (*S typhi*; typhoid fever) or *Salmonella enterica* serovar *paratyphi* (*S paratyphi*) A, B, or C (paratyphoid fever), and results in a bacteraemic febrile illness specific to humans. The bacteria are transmitted between humans via the faecal-oral route, usually through contaminated food and water. It is most common in regions with inadequate water and sanitation infrastructure. The highest burden of disease occurs in South Asia and in sub-Saharan Africa in children five to nine years of age (Stanaway 2019). Enteric fever is difficult to diagnose in endemic settings, leading to a high rate of misdiagnosis; cases of typhoid fever may thus be over- or underestimated. Frequent use of antimicrobials for febrile illnesses, including suspected enteric fever, contributes to the emergence of antimicrobial resistance through frequent empirical use of antimicrobials for febrile illnesses. Increasing antimicrobial resistance in both *S typhi* or *S paratyphi* A, B, or C, is now a serious public health concern. Lack of timely antimicrobial treatment can lead to life-threatening complications. Therapeutic options are sparse due to increasing antimicrobial resistance. Antimicrobial options for multiple-drug-resistant strains include cefixime (an oral cephalosporin), azithromycin (an oral macrolide), fluoroquinolones, and ceftriaxone (a parenteral cephalosporin).

Description of the condition

Epidemiology

In 2017 the global number of cases of typhoid and paratyphoid fever was estimated to be 14.3 million, with *Styphi* causing 76.3% of cases, in the Global Burden of Disease trial (Stanaway 2019). This overall represented a decline from previous estimates ranging between 11.9 million to 27.1 million cases per year (Antillón 2017; Buckle 2012; Crump 2004; Kim 2017; Mogasale 2014). Global deaths from typhoid and paratyphoid fever were estimated at approximately 135,900 (76,900 to 218,900) in 2017, and higher in typhoid compared to paratyphoid cases (Stanaway 2019). Regions with the highest estimated burden of disease are South Asia, Southeast Asia, and sub-Saharan Africa (Garrett 2022; Marks 2017; Meiring 2021). In some areas estimates are limited by lack of data, most notably from Oceania and Latin America. Cases occur in high-income countries in returned travellers from endemic countries or in those in close contact with people recently returned from endemic countries, and occasionally food-borne outbreaks occur. Overall, typhoid and paratyphoid fevers were responsible for 9.8 million (5.6 to 15.8) disability-adjusted life-years (DALYs) in 2017, 67.0% (61.6 to 72.4) occurring amongst children younger than 15 years of age (Stanaway 2019).

Prevention

Disease burden can be reduced by provision of adequate water and sanitation infrastructure and through typhoid vaccination. The World Health Organization (WHO) has approved three typhoid vaccines which, until recently, have not been part of national routine immunization programmes. Several countries are now introducing the typhoid Vi conjugate vaccine following evidence from recent randomized controlled trials (RCTs; Patel 2021; Qadri 2021; Shakya 2021). There are no paratyphoid fever vaccines (WHO 2019).

Clinical

Infection is caused by consumption of food or water contaminated with *S typhi* or *S paratyphi* during preparation where insufficient food hygiene and handwashing facilities are practised (Crump 2019). Contamination occurs when bacteria are shed in the faeces of individuals who are acutely unwell, convalescing or are chronic carriers (Bhan 2005). Risk of transmission is increased by lack of access to clean drinking water, insufficient food hygiene practices and poor sanitation including inadequate handwashing. The severity of the infection depends on the initial infective dose, the virulence of the organism, the host's co-morbidities and immune response (Tsolis 1999). The bacteria usually penetrate the intestinal mucosa and proliferate in the underlying lymphoid tissue, from where they disseminate via the lymphatic system or are released into the bloodstream, or both, resulting in spread to other organs. The organs most commonly affected include the liver, spleen, bone marrow and gall bladder (Parry 2002; Raffatellu 2008).

The clinical features of enteric fever typically include progressive intermittent fever, headache, abdominal discomfort, anorexia, hepatomegaly and splenomegaly (Bhan 2005; Walia 2006). It is not possible to distinguish between typhoid and paratyphoid fever on the basis of clinical symptoms. Complications of enteric fever occur in 10% to 15% of cases, are more frequent in patients whose illness has lasted over two weeks, and can affect multiple organ systems (Bhan 2005; Parry 2002). Intestinal perforation and haemorrhage, shock, pancreatitis, cholecystitis, pneumonia, myocarditis and encephalopathy are possible (Bhan 2005).

Between 1% to 5% of patients develop chronic carriage of salmonellae following infection (defined as excretion of bacteria in faeces or urine for more than 12 months; Ferreccio 1988). Chronic carriage occurs more frequently in women, and in patients with gallstones or other biliary tract abnormalities (Levine 1982). Biliary carriage has been associated with an increased risk of cancer, particularly of the biliary system (Caygill 1994).

Diagnosis

Typhoid and paratyphoid fever present a challenge to diagnose clinically, especially in children, as symptoms overlap with other causes of fever. The optimum method to confirm diagnosis is through blood or bone marrow culture, which can take days for a result, and are often not easily available in low-resource, endemic regions (Baker 2010). A negative blood culture does not exclude the diagnosis. Culture of faeces, urine or bile can be undertaken, however a positive result may indicate chronic carriage rather than acute infection (Wain 1998).

Bacterial culture facilitates antimicrobial susceptibility testing which is helpful in guiding the appropriate antibiotic therapy. Disc diffusion and minimal inhibitory concentration (MIC) breakpoints incorporate an 'intermediate' or decreased ciprofloxacin susceptibility (DCS) category as well as a resistant category (CLSI 2021). Older options for detecting the intermediate category include a test for nalidixic acid susceptibility or perfloxacin susceptibility: nalidixic acid-resistant (NaR) or perfloxacin-resistant organisms have intermediate susceptibility to ciprofloxacin (CLSI 2021; Crump 2003). It is important to note that the possibility of an 'intermediate' or DCS category was not appreciated when fluoroquinolones were first evaluated in RCTs and so was not determined in the isolates in these early trials. Susceptibility breakpoints for azithromycin have been proposed based on MIC

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

distributions and limited clinical data (CLSI 2021; Sjolund-Karlsson 2011).

The benefit of serological tests for the diagnosis of enteric fever is limited by the persistence of positive results following from previous infection. Newer diagnostic tests using enzyme-linked immunosorbent assay (ELISA), immunochromatographic platforms and nucleic acid amplification are in development, but none have proven to be sensitive and specific enough to be widely adopted in routine clinical diagnostics (Neupane 2021; Parry 2002). Further, serological tests, such as the Widal test and commercial rapid diagnostic tests, are not confirmatory in the acute phase of illness. The Widal test lacks sensitivity and specificity, and the moderate sensitivity and specificity of available rapid diagnostic tests (such as Typhidot-M, TUBEX, and Test-it typhoid tests) does not support their use as a replacement for blood culture for diagnosing enteric fever (Levine 1982; Parry 1999; Wijedoru 2017).

Prognosis

Stanaway 2019 estimated a mean all-age global case fatality of 0.95% (0.54 to 1.53) in 2017, consistent with expert opinion of case fatality being approximately 1% with treatment (Buckle 2012; Crump 2004). Higher case fatality estimates were seen in children and older adults, and in lower-income countries (Stanaway 2019). Typhoid fever has a low mortality when it is recognized early and treated with effective antimicrobials; delays in treatment, ineffective antimicrobial treatment, or lack of quality medical care leads to a significant increase in complications and case-fatality rate (Wain 2015).

Treatment

Antimicrobial monotherapy is usually used to treat enteric fever, but the optimal choice of drug and duration of therapy depend on locally prevalent antimicrobial resistance patterns. Common resistance patterns include combined plasmid resistance to the older antimicrobials (chloramphenicol, amoxicillin and trimethoprim-sulphamethoxazole - multidrug resistance), intermediate susceptibility or resistance (non-susceptibility) to fluoroquinolones and to azithromycin, usually mediated by target site gene mutations, and resistance to ceftriaxone and cefixime caused by extended spectrum beta lactamase genes. The occurrence of different resistance patterns has varied and continues to evolve by location and over time. In a recent systematic review of trials published between 1990 and 2018, resistance was widespread and has increased for all antimicrobials in all regions, except for a decline of multiple-drug-resistant (MDR) *S typhi* in South Asia between 1990 and 2018 (Browne 2020). Global resistance patterns are characterized by data gaps, incomplete reporting, and problems with quality assurance.

Combination antimicrobial therapy is a potential treatment option. Combinations such as ceftriaxone/ciprofloxacin, have been commonly used in the USA (Crump 2008), a small comparative trial of monotherapy versus combination therapy in Nepal included ceftriaxone/azithromycin and cefixime/azithromycin combinations (Zmora 2018), and combination therapy is currently being evaluated in an ongoing multi-centre RCT (NCT04349826). The benefits of combination antimicrobial combination therapy have not been conclusively proven.

Current recommendations for the duration of antimicrobial treatment include 5 to 10 days for oral treatment with

a fluoroquinolone or azithromycin, and 7 to 14 days for cephalosporins. Intravenous treatment with carbapenems are often used when ceftriaxone resistance occurs in patients with severe disease. Duration of antimicrobial therapy aims to continue treatment for two to three days post defervescence (Nabarro 2022). Choice of drug is influenced by disease severity, drug availability, availability of facilities to administer intravenous medication, and local resistance patterns.

Description of the intervention

Cephalosporins are beta-lactam compounds in which the beta-lactam ring has been fused to a 6-membered dihydrothiazine ring, forming the cephem nucleus. Although historically they have been divided into generations, depending on their antibacterial spectrum of activity, it is now considered more helpful to consider the individual characteristics and spectrum of activity for each cephalosporin (Bazan 2011; Kalman 1990).

Cephalosporins inhibit cell wall synthesis by binding to penicillin-binding proteins, and are bactericidal. They have time-dependent killing activity, which requires levels that are continuously above the MIC of the pathogen being treated. Dosing frequency is variable, but some cephalosporins such as ceftriaxone have a distinct advantage in having a half-life sufficiently long to be given once daily (Kalman 1990).

Most cephalosporins distribute well into the extracellular fluid of most tissues, and some cephalosporins also sufficiently penetrate into cerebrospinal fluid and can be used in the treatment of central nervous system infections. Penetration of cephalosporins into the intracellular compartment is poor. Elimination is mostly through the renal system, although significant biliary excretion is a feature of some cephalosporins, such as ceftriaxone and cefoperazone. They are generally well-tolerated, although some patients may display hypersensitivity; hepatic dysfunction and interstitial nephritis (Kalman 1990).

Certain cephalosporins, historically referred to as extended-spectrum cephalosporins or third- and fourth-generation cephalosporins, typically have activity against salmonellae and can be used in the management of enteric fever. A number of cephalosporin-beta lactamase-inhibitor combination drugs (for example, ceftazidime-avibactam; ceftolazone-tazobactam) have recently become available and may become valuable for the treatment of extended-spectrum beta-lactamase-producing salmonellae. They have yet to be evaluated for enteric fever in clinical trials.

How the intervention might work

Effective treatment of enteric fever is hampered by the development of multiple-drug resistance to first-line agents (amoxicillin/ampicillin, cotrimoxazole and chloramphenicol) worldwide in the late 1980s and 1990s (Karkey 2018; Rowe 1997). This has led to the use of fluoroquinolones (ciprofloxacin, ofloxacin, fleroxacin, perfloxacin, and gatifloxacin). However, since the late 1990s, intermediate and full fluoroquinolone resistance has emerged, especially in South Asia (Karkey 2018). In fluoroquinolone-resistant isolates, treatment with an extended-spectrum cephalosporin, including ceftriaxone (intramuscular or intravenous) and cefixime (oral), or treatment with azithromycin

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

(an oral macrolide), is often the treatment of choice (Basnyat 2007; Basnyat 2010).

Why it is important to do this review

Effective antimicrobials are required to treat enteric fever and to reduce disease transmission in the context of ongoing and emerging antimicrobial resistance patterns in different parts of the world (Browne 2020).

Sporadic cases of *S typhi* resistant to first-line agents, fluoroquinolones and third-generation cephalosporins have now originated in Iraq, Bangladesh, India, and Pakistan (Ahmed 2012; Gul 2017; Kleine 2017; Munir 2016; Pfeifer 2009). Subsequently, the large-scale emergence of temporally clustered cases of extensively drug-resistant (XDR) *S typhi* strains, (resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins), with a large number of resistance determinants, were reported in Pakistan (Klemm 2018). The only active treatments for XDR strains documented in Pakistan are oral azithromycin and intravenous carbapenems (Chatham-Stephens 2019; Qureshi 2020). Intravenous treatment with carbapenems is not available or affordable for most patients in countries where enteric fever is endemic, and recently azithromycin-resistant cases of *S typhi* have been reported in Bangladesh, Pakistan, and Nepal (Duy 2020; Hooda 2019; Iqbal 2020). Azithromycin resistance has not yet been reported in XDR organisms. The potential spread of XDR and azithromycin-resistant *S typhi* strains is thus a major clinical concern, and it is of importance to have more than one therapeutic option to treat this disease.

Ceftriaxone and cefixime are currently widely used in the management of enteric fever (Nabarro 2022; WHO 2021). The safety profile of cephalosporins is considered to be good in children, whereas enough concern exists in relation to the safety profile of fluoroquinolones in paediatric medicine for them to remain unapproved for the treatment of enteric fever by the US Food and Drug Administration (FDA). Developing a more comprehensive understanding of how these drugs can be best used in the treatment of enteric fever will have an impact on the cost of treatment, the improvement of clinical outcomes and the provision of baseline data for the development of future clinical trials.

Cochrane Reviews of the use of fluoroquinolones and azithromycin in the treatment of typhoid have previously been undertaken (Effa 2011), but the use of broad-spectrum beta-lactams such as ceftriaxone and cefixime in the era of *S typhi* and *S paratyphi* resistance has not been systematically investigated to date.

OBJECTIVES

To evaluate the effectiveness of cephalosporins for treating enteric fever in children and adults compared to other antimicrobials.

METHODS

Criteria for considering studies for this review

Types of studies

Randomized controlled trials (RCTs)

Types of participants

Adults and children diagnosed with typhoid or paratyphoid fever on the basis of blood culture, bone marrow culture or molecular tests.

Types of interventions

Intervention

Treatment with a cephalosporin antimicrobial of any dose or duration.

Cephalosporins considered in this review are shown in Table 1.

Control

- Other antimicrobials, including:
 - fluoroquinolones
 - azithromycin
 - aztreonam
 - chloramphenicol
- Different cephalosporins
- Different treatment durations of the intervention cephalosporin

Types of outcome measures

Primary outcomes

- Clinical failure: defined as the presence of symptoms or development of complications that necessitate a change in antimicrobial therapy or prolongation of existing therapy at the time period specified by trial authors; or, death related to the disease within the trial time period as opposed to an adverse event arising from any therapy administered.
- Microbiological failure: defined as a positive culture from blood, bone marrow or any sterile anatomical site during the period specified by the trial authors.
- Relapse: defined as the recurrence of symptoms with a positive culture from blood, bone marrow or any sterile anatomical site to the point of follow-up defined by the trial author.

Secondary outcomes

- Time to defervescence: defined as the time in days taken to defervesce from the start of the intervention or control drug with the definition of fever clearance as defined by the trial authors.
- Length of hospital stay: defined as the time in days from trial entry until discharge from hospital
- Convalescent faecal carriage: defined as a positive faecal culture detected at any time after the end of treatment up to one year of follow-up.

Adverse events

We sought any adverse events or effects reported. Serious adverse events are defined as any untoward events occurring in the trial time period that result in death, are life-threatening, require patient hospitalization or prolongation of existing hospitalization, or result in persistent or significant disability/incapacity or require intervention to prevent permanent impairment or damage. We also sought events requiring the discontinuation of treatment.

Search methods for identification of studies

We attempted to identify all potential trials regardless of language or publication status (published, unpublished, in press, and in progress).

Electronic searches

Databases

We searched the following electronic databases using the search terms and strategies described in [Appendix 1](#):

- Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10), published in the Cochrane Library, searched 24 November 2021;
- MEDLINE Ovid (1946 to 23 November 2021);
- Embase Ovid (1996 to 2021, Week 46, searched 24 November 2021); and
- LILACS (BIREME) 1982 to 23 November 2021, searched 24 November 2021.

We also searched [ClinicalTrials.gov](#), and the WHO International Clinical Trials Registry Platform (ICTRP).

Searching other resources

Conference proceedings

We handsearched abstracts from the following annual meetings: International Symposium on Typhoid Fever and Other Salmonellosis; the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); the Infectious Diseases Society of America (IDSA); the Western Pacific Congress on Chemotherapy and Infectious Diseases; the European Congress of Clinical Microbiology and Infectious Diseases; and the American Society of Tropical Medicine and Hygiene.

Researchers

We contacted researchers in the field to identify additional trials that may be eligible for inclusion.

Reference lists

We checked reference lists of all trials identified by the above methods.

Data collection and analysis

Selection of studies

Two review authors independently screened the title, abstract, and keywords of each record identified from the searches; Nicole Stoesser (NS) and David Eyre (DE) screened the search results obtained in February 2013; Thomas Darton (TD) and Christopher Parry (CP) screened the search results obtained in April 2017; and Rebecca Kuehn (RK) and CP screened the search results obtained in November 2021. We retrieved the full-text articles of all potentially relevant trials and all trials where the relevance was unclear from screening.

Two review authors independently applied the inclusion criteria to each of the full-text articles obtained following screening; NS and DE for the February 2013 searches; TD and CP for the April 2017 searches; and RK and CP for the November 2021 searches.

We resolved any disagreements through discussion between review authors. If there were further doubts, we attempted to contact the trial authors for further information. We have listed the excluded trials and reasons for exclusion in the [Characteristics of excluded studies](#) section. We entered the data from each eligible trial only once.

Data extraction and management

Two review authors (NS and DE) independently extracted data from trials identified in the February 2013 searches using a standardized, pre-tested data extraction form incorporating information about the trial population, intervention used (type of drug, means of administration, duration of treatment) and outcomes (side effects, success of treatment). TD and CP completed the same data extraction process for trials identified in the April 2017 search and CP and RK completed the same data extraction process for trials identified in the November 2021 search.

For dichotomous outcomes, we extracted data concerning clinical failure, the total number of participants randomized, the number of participants analysed and the total number of participants who experienced that event.

For continuous outcomes, we extracted data concerning time to defervescence, the total number of participants, arithmetic means, and standard deviations. If trials did not report the standard deviation, we used the confidence interval (CI) to calculate it.

We contacted trial authors for additional data when they were unavailable or not in the format required to undertake the analyses.

We compared extracted data between review authors to identify errors. Any conflicts were resolved by discussion with CP or BB.

Two review authors (NS and RK) entered data into the Review Manager file ([RevMan Web 2022](#)), and DE and CP verified data entry was correct.

Assessment of risk of bias in included studies

Two review authors independently assessed the risk of bias for each included trial: NS and DE for the 2013 search, TD and CP for the April 2017 search, and RK and CP for the 2021 search, using the Cochrane risk of bias tool, RoB 1 ([Higgins 2011](#)). We used the tool to assess whether adequate steps were taken to reduce the risk of bias across six domains: sequence generation, allocation concealment, blinding (of participants, personnel and outcome assessors), incomplete outcome data (follow-up was considered adequate if 90% or more of the randomized culture-positive participants were in the final analysis and inadequate if this figure was less than 90%), selective outcome reporting and other sources of bias. We categorized judgements as either 'yes' (low risk of bias), 'no' (high risk of bias), or 'unclear'. We compared entries and resolved disagreements by discussion between review authors.

We summarized the risk of bias judgements in tables.

Measures of treatment effect

We presented and compared dichotomous data using risk ratios (RR), and continuous data using mean difference (MD).

All results are presented with the corresponding 95% CI.

Unit of analysis issues

For trials where more than two different antimicrobials were compared to each other, we separated data for each different antimicrobial so each antimicrobial was compared to a different antimicrobial as an individual pairwise comparison.

We undertook a count of adverse and serious adverse events by participant, associated with the antimicrobial administered.

We did not identify any cluster-RCTs for inclusion in this review.

Dealing with missing data

We planned to apply intention-to-treat (ITT) principles to data extraction, but data were insufficient.

We assessed trials for high loss of participants to follow-up, or a lack of balance between groups, and we used evaluable participants only.

Assessment of heterogeneity

We assessed for heterogeneity by visually inspecting the forest plots, by comparing the heterogeneity statistic, Q , with the Chi^2 distribution, and reported the amount of heterogeneity using the I^2 statistic (Deeks 2022; Higgins 2003).

Statistical heterogeneity was declared if the P value was less than 0.1 for the Chi^2 statistic, or if the I^2 statistic was equal to or greater than 40% (40% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable heterogeneity; Deeks 2022).

Assessment of reporting biases

We planned to assess the presence of publication bias by looking for funnel plot asymmetry if there were 10 or more trials available for analysis of each primary outcome, but this was not possible due to the low number of trials.

Data synthesis

We analysed data using RevMan Web 2022.

We analysed data using pairwise comparisons. We compared each cephalosporin with each comparator antimicrobial class and subgrouped by the specific antimicrobial.

The data are organized into the following comparisons:

- cefixime versus fluoroquinolones
- ceftriaxone versus azithromycin
- ceftriaxone versus fluoroquinolones
- ceftriaxone versus cefixime
- ceftriaxone versus chloramphenicol
- cefixime versus chloramphenicol
- cefixime versus cefpodoxime
- cefoperazone versus chloramphenicol
- cefixime versus aztreonam
- ceftriaxone versus aztreonam
- duration of ceftriaxone

If clinical and methodological characteristics of individual trials were sufficiently homogeneous, we pooled the data in meta-

analyses. When there were no concerns of clinical or statistical heterogeneity we used the fixed-effect model in meta-analyses. Where clinical or statistical heterogeneity was detected, and we still considered it appropriate to pool the data, we used the random-effects model.

Subgroup analysis and investigation of heterogeneity

We planned to investigate heterogeneity by conducting subgroup analyses according to age (paediatric populations 0 to 16 years and adults over 17 years), hospitalization status, presence of MDR/NaR/intermediate ciprofloxacin susceptibility and duration of treatment. We tried to make contact with the trial authors if these distinctions were unclear from the data.

These planned subgroup analyses were not possible due to the limited number of trials in each comparison.

Sensitivity analysis

We planned to assess the robustness of the data by performing a sensitivity analysis for each of the risk of bias assessment factors, but were again unable to do this due to the low number of trials.

Summary of findings and assessment of the certainty of the evidence

We presented the main results of the review in summary of findings tables, including a rating of the certainty of evidence based on the GRADE approach. We followed current GRADE guidance as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Schünemann 2022).

We rated each outcome as described by Balshem 2011 as either:

- High: we are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect.
- Low: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
- Very low: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

We created separate summary of findings tables for the comparisons of cephalosporins with antimicrobials that are in common use for the treatment of enteric fever and with chloramphenicol:

- cefixime versus fluoroquinolones
- ceftriaxone versus azithromycin
- ceftriaxone versus fluoroquinolones

The summary of findings tables included all primary and secondary outcomes that the included trials reported.

RESULTS


Description of studies

Results of the search

We assessed the full texts of 63 trials for eligibility following separate searches conducted in February 2013, April 2017, and

November 2021. We included 27 trials and excluded 30. The trial selection process following PRISMA guidelines is available in [Figure 1](#). Five trials are awaiting classification - one of these is only published as an abstract with insufficient detail to classify it ([Studies awaiting classification](#)). We identified one ongoing trial ([Ongoing studies](#)).

Figure 1.



Included studies

The 27 trials included 2231 participants. Most trials were small and lacked statistical power to detect differences between the treatment regimens. The smallest trial had 25 participants and the largest had 382 participants.

Fifteen trials reported drug susceptibility patterns, with data on MDR strains in 13 trials and NaR in one trial. See [Characteristics of included studies](#) for further details of reported microbiology and susceptibility data.

Trial setting

The trials were conducted in Bahrain (1), Bangladesh (3), Egypt (4), Haiti (1), India (2), Italy (1), Nepal (4), Pakistan (5), the Philippines (1), South Africa (1), Turkey (1), and Vietnam (3).

Trials were published between 1986 and 2016.

Most trials were conducted in an inpatient setting; three trials were conducted on outpatients ([Arjyal 2016](#); [Pandit 2007](#); [Rizvi 2007](#)).

Participants

Eleven trials (666 participants) were exclusively in children under 16 years old ([Bhutta 1994](#); [Bhutta 2000](#); [Cao 1999](#); [Girgis 1995](#); [Kumar 2007](#); [Memon 1997](#); [Moosa 1989](#); [Pape 1986](#); [Rabbani 1998](#); [Shakur 2007](#); [Tatli 2003](#)); two trials (176 participants) included participants up to the age of 17 years ([Frenck 2000](#); [Frenck 2004](#)); and one trial (54 participants) included participants up to the age of 18 years ([Nair 2017](#)). Four trials (177 participants) were exclusively in adults over 15 years old ([Butler 1993](#); [Lasserre 1991](#); [Smith 1994](#); [Wallace 1993](#)). Nine trials (1158 participants) included children and adults ([Acharya 1995](#); [Arjyal 2016](#); [Girgis 1990](#); [Islam 1988](#); [Islam 1993](#); [Morelli 1988](#); [Pandit 2007](#); [Rizvi 2007](#); [Tran 1994](#)).

Most trials were conducted on patients with uncomplicated typhoid fever at trial entry with only a few including patients with severe or complicated disease at the time of trial entry.

Most trials recruited patients on the basis of blood culture or bone marrow cultures or both. Most trials only reported outcomes for the culture-positive patients and few reported on the basis of intention to treat, including patients who were randomized but were culture-negative.

Interventions

Fifteen trials compared ceftriaxone with an antimicrobial from an alternative class: azithromycin (3 trials), ciprofloxacin (1

trial), fleroxacin (1 trial), ofloxacin (1 trial), gatifloxacin (1 trial), chloramphenicol (7 trials), aztreonam (1 trial). All trials comparing ceftriaxone with azithromycin were conducted in participants under 18 years old.

Nine trials compared cefixime with an antimicrobial from an alternative class: ciprofloxacin (1 trial), ofloxacin (2 trials), gatifloxacin (1 trial), chloramphenicol (3 trials), aztreonam (1 trial), and cefpodoxime (1 trial). No trials compared cefixime with azithromycin.

Two trials compared ceftriaxone with cefixime.

Two trials compared cefoperazone with chloramphenicol.

No trials directly compared different dosages of cephalosporins. One trial directly compared a longer and shorter duration of ceftriaxone.

Outcomes

Most trials reported our primary outcomes: clinical failure (26 trials); microbiological failure (21 trials) and relapse (21 trials).

The definition of outcomes varied between trials; some did not define outcomes at all. The time period at which outcomes were assessed also varied considerably between trials, for example, some trials defined time to defervescence as the first documented 'normal' body temperature and other trials as an axillary temperature of less than 37.5 °C for at least 48 hours. In some trials it was not clear whether the adverse events recorded were considered due to the antimicrobial received or the disease process itself. Further details are presented in [Characteristics of included studies](#) section.

We received data from one author group to calculate the mean time to defervescence in the comparison of cefixime versus fluoroquinolones ([Pandit 2007](#)).

Excluded studies

Of the 30 excluded trials, we excluded 24 because they were not randomized, or it was unclear if they were randomized. For further details see [Characteristics of excluded studies](#) section.

Risk of bias in included studies

See summary of risk of bias assessment in [Figure 2](#) and [Figure 3](#).

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials




Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): All outcomes	Blinding of outcome assessment (detection bias): All outcomes	Incomplete outcome data (attrition bias): All outcomes	Selective reporting (reporting bias)	Other bias
Acharya 1995	+	+	-	-	+	+	?
Arjyal 2016	+	+	-	-	?	+	+
Bhutta 1994	?	?	?	?	+	+	+
Bhutta 2000	+	+	?	?	+	+	?
Butler 1993	+	+	?	?	+	-	?
Cao 1999	?	+	?	?	-	+	?
Frenck 2000	+	+	-	-	?	+	?
Frenck 2004	+	+	-	-	-	+	?
Girgis 1990	+	?	?	?	+	-	+
Girgis 1995	+	?	?	?	-	-	+
Islam 1988	+	?	?	?	+	+	?
Islam 1993	+	+	?	?	+	+	+
Kumar 2007	?	?	?	?	+	-	?
Lasserre 1991	+	?	?	?	+	?	?
Memon 1997	?	?	-	-	-	-	+
Moosa 1989	?	?	-	-	+	?	-
Morelli 1988	+	?	-	-	+	?	?

Figure 3. (Continued)

Morelli 1988	+	?	-	-	+	?	?
Nair 2017	+	+	-	-	?	?	+
Pandit 2007	+	+	-	-	?	+	+
Pape 1986	?	?	?	?	?	-	?
Rabbani 1998	?	?	?	?	+	-	?
Rizvi 2007	?	?	?	?	-	-	?
Shakur 2007	+	?	+	+	?	+	?
Smith 1994	?	+	-	-	-	-	?
Tatli 2003	?	+	-	-	-	+	?
Tran 1994	?	?	?	?	-	?	?
Wallace 1993	?	?	-	-	+	+	+

Allocation

We judged random sequence generation to be at low risk of bias in 15 trials that used computer-generated random allocation methods or randomized number tables. Twelve trials did not report details concerning how they randomized participants, leading to the judgement of an unclear risk of bias.

We judged the method used to generate the allocation sequence to be satisfactory, leading to a judgement of a low risk of bias in 12 trials, all of which used a sealed envelope method of allocation concealment. The risk of allocation bias was unclear in 15 trials due to lack of reporting on the method used, if any.

Blinding

One trial was double-blinded, which we assessed as low risk of bias, 12 trials were open and we judged them to be at high risk of bias, and 14 trials did not give any details on the presence or absence of blinding and we judged the risk of bias to be unclear.

Incomplete outcome data

Outcome data were incomplete in eight trials and we judged them to be at high risk of bias. Six trials did not clearly report details on outcome data, leading a judgement of unclear risk of bias, and we judged 13 trials to be low risk of bias due to all participant data accounted for at follow-up.

Selective reporting

We judged 13 trials to be at low risk of reporting bias as they reported data for all stipulated outcomes. We judged nine trials to be at high risk of bias as they did not report data for at least one prespecified outcome. We judged five trials to be at unclear risk of bias as they did not clearly report data on prespecified outcomes.

Other potential sources of bias

One trial reported that a pharmaceutical company had supplied the intervention antimicrobial and provided "assistance" with the trial, so we judged it to be at high risk of other bias.

We judged 17 trials to be at unclear risk of bias due either to the trials receiving antimicrobial donations or funding, or both, from pharmaceutical companies without further information regarding the involvement of the pharmaceutical company in the trial, or not reporting conflicts of interest. We judged nine trials to be at low risk of bias as all authors declared no conflict of interest and we did not identify any other sources of bias.

Effects of interventions

See: [Summary of findings 1 Cefixime versus fluoroquinolones for treating enteric fever](#); [Summary of findings 2 Ceftriaxone versus azithromycin for treating enteric fever](#); [Summary of findings 3 Ceftriaxone versus fluoroquinolones for treating enteric fever](#)

Comparisons 1 to 3 relate to questions pertaining to common, currently used antimicrobial treatments for enteric fever and correspond to [Summary of findings 1](#), [Summary of findings 2](#), and [Summary of findings 3](#). Comparison 4 compares cefixime with ceftriaxone.

Comparisons 5 to 7 concern cephalosporins compared with chloramphenicol. These comparisons may be relevant in regions of the world where chloramphenicol susceptibility has recovered.

Comparison 8 compares cefixime with cefpodoxime, comparison 9 compares cefixime with aztreonam and comparison 10 compares ceftriaxone with aztreonam. These comparisons may be relevant in regions where these drugs are in use.

Comparison 11 concerns the question pertaining to the duration of treatment of enteric fever with ceftriaxone.

1. Cefixime versus fluoroquinolones

Three trials published more than 14 years ago provided comparisons between cefixime and a fluoroquinolone in adults and children. One trial compared cefixime with ciprofloxacin ([Rizvi 2007](#)); two with ofloxacin ([Cao 1999](#); [Rizvi 2007](#)); and one with gatifloxacin ([Pandit 2007](#)). Two of the three trials reported that the bacterial isolates were susceptible to the trial antimicrobials ([Cao 1999](#); [Pandit 2007](#)).

Clinical failure

Clinical failure was higher in participants treated with cefixime compared with participants treated with a fluoroquinolone (28/114 (25%) participants treated with cefixime compared to 2/126 (1.6%) participants with fluoroquinolones; RR 13.39, 95% CI 3.24 to 55.39; 2 trials, 240 participants; low-certainty evidence; [Analysis 1.1](#)). One trial, which compared participants treated with cefixime with participants treated with ciprofloxacin and participants treated with ofloxacin reported no cases of clinical failure in either the intervention group or control groups ([Rizvi 2007](#)).

Microbiological failure

Microbiological failure was reported in 3 of 114 (2.6%) participants treated with cefixime compared with zero cases in 126 participants treated with fluoroquinolones (RR 4.07, 95% CI 0.46 to 36.41; 2 trials, 240 participants; low-certainty evidence; [Analysis 1.2](#)). One trial, which compared participants treated with cefixime to participants treated with ciprofloxacin and participants treated with ofloxacin reported no cases of microbiological failure in either the intervention group or control groups ([Rizvi 2007](#)).

Relapse

Relapse was higher in participants in the cefixime group compared to participants in the fluoroquinolone group (RR 4.45, 95% CI 1.11 to 17.84; two trials, 220 participants; low-certainty evidence; [Analysis 1.3](#)).

Time to defervescence

Time to defervescence was longer in participants treated with cefixime compared to participants treated with fluoroquinolones (MD 1.74 days, 95% CI 0.50 to 2.98; 3 trials, 425 participants; low-certainty evidence; [Analysis 1.4](#)). The mean time to defervescence in participants treated with ceftriaxone was 4.26 days compared to a mean time of 4.97 days in participants treated with ofloxacin in one trial; we were unable to calculate the mean difference in time to defervescence in this trial due to unreported ranges and SDs ([Kumar 2007](#)).

Convalescent faecal carriage

No persistent convalescent faecal carriage was detected in the one trial that reported this outcome (130/158 stool cultures were obtained from participants at six months' follow-up. We were unable to separate data by intervention and control group ([Pandit 2007](#)).

Length of hospital stay

No trials reported length of hospital stay.

Adverse events

In one trial a participant in the ofloxacin group died unexpectedly on the second day of treatment; a post-mortem clinical diagnosis of myocarditis was made ([Cao 1999](#)). It is unknown whether this was due to the drug or the disease process. In a further trial, a participant in the cefixime group died ([Pandit 2007](#)). Treatment with cefixime had started on day 14 of illness. Severe thrombocytopenia and gastrointestinal bleeding developed on day 6 of treatment, progressing to an acute respiratory distress syndrome with disseminated intravascular coagulation from which the participant did not recover. This deterioration was considered

to be due to progression of the disease. No other serious adverse events were reported.

Excessive vomiting requiring intravenous fluids and antiemetics was noted in 2/92 participants and nausea in 23/92 participants receiving gatifloxacin compared to zero cases for both symptoms in the cefixime group ([Pandit 2007](#)). A skin rash requiring an oral antihistamine was noted in 1/77 participants in the cefixime group ([Pandit 2007](#)).

2. Ceftriaxone versus azithromycin

Two older trials and one more recent trial compared ceftriaxone and azithromycin ([Frenck 2000](#); [Frenck 2004](#); [Nair 2017](#)). The trial participants were all under 18 years of age. Two of the three trials reported that the bacterial isolates were susceptible to the trial antimicrobials ([Frenck 2000](#); [Frenck 2004](#)).

Clinical failure

Clinical failure was reported in 3/100 (3%) of participants treated with ceftriaxone compared to 7/96 (7.3%) treated with azithromycin (RR 0.42, 95% CI 0.11 to 1.57; 3 trials, 196 participants; low-certainty evidence; [Analysis 2.1](#)).

Microbiological failure

Microbiological failure was reported in 3/100 (3%) of participants in the ceftriaxone group compared to 1/96 (1%) of participants in the azithromycin group (RR 1.95, 95% CI 0.36 to 10.64; 3 trials, 196 participants; very low-certainty evidence; [Analysis 2.2](#)).

Relapse

Relapse was reported in 15 of 96 participants in the ceftriaxone group compared to zero cases in 89 participants in the azithromycin group (RR 10.05, 95% CI 1.93 to 52.38; 3 trials, 185 participants; very low-certainty evidence; [Analysis 2.3](#)).

Time to defervescence

Time to defervescence was shorter in participants treated with ceftriaxone compared to participants treated with chloramphenicol (MD -0.52 days, 95% CI -0.91 to -0.12; 3 trials, 196 participants; low-certainty evidence; [Analysis 2.4](#)).

Convalescent faecal carriage

Convalescent faecal carriage of *Salmonella* was not detected in any participant on day 10 following treatment in either intervention or control group in one trial ([Frenck 2000](#)). Two trials reported that no participants were found to have *S typhi* in stool culture at one month follow-up ([Frenck 2004](#); [Nair 2017](#)).

Length of hospital stay

No trials reported length of hospital stay.

Adverse events

No serious adverse outcomes were reported.

Two trials reported that transient vomiting occurred more frequently in participants treated with azithromycin than those treated with ceftriaxone ([Frenck 2000](#); [Frenck 2004](#)). One trial reported that 6/30 participants experienced pain at the site of ceftriaxone injection up to 24 hours later ([Frenck 2000](#)). Two trials reported non-severe asymptomatic thrombocytosis in a few

participants in both treatment groups (Frenck 2000; Frenck 2004). One trial reported diarrhoea in 10/32 (3.2%) participants treated with azithromycin compared to 15/36 (5.4%) participants treated with ceftriaxone (Frenck 2004). One trial reported vomiting and diarrhoea in a few participants in each treatment group; this may have been due to the disease or the drug (Nair 2017).

3. Ceftriaxone versus fluoroquinolones

Three older trials and two more recent trials compared ceftriaxone with fluoroquinolones in adults and children: one compared with ciprofloxacin (Wallace 1993); one with fleroxacin (Tran 1994); two with ofloxacin (Kumar 2007; Smith 1994); and one with gatifloxacin (Arjyal 2016). The three older trials reported that all bacterial isolates were susceptible to the trial antibiotics (Smith 1994; Tran 1994; Wallace 1993). In the two more recent trials, resistance was reported in 2/93 (2.2%) bacterial isolates to ceftriaxone and 7/93 (7.5%) bacterial isolates to ofloxacin (Kumar 2007), and resistance to gatifloxacin in 14/112 (12%) bacterial isolates but no resistance to ceftriaxone (Arjyal 2016).

Two trials used a maximum dose of 2 g of ceftriaxone daily (Arjyal 2016; Tran 1994), and two trials used a maximum dose of 2.5 g daily (Smith 1994; Wallace 1993). In one trial including children only, the maximum dose of ceftriaxone was not reported; dose information given was 100 mg per day (Kumar 2007).

Clinical failure

Three trials conducted over 20 years earlier reported clinical failure in 15/62 (24.2%) participants treated with ceftriaxone compared to 0/58 (0%) participants treated with a fluoroquinolone (Smith 1994; Tran 1994; Wallace 1993); a more recent trial (Arjyal 2016), reported 19/119 (16.0%) participants with clinical failure in the ceftriaxone group compared with 18/120 (15.0%) participants in the fluoroquinolone group (RR 3.77, 95% CI 0.72 to 19.81; 4 trials, 359 participants; very low-certainty evidence; Analysis 3.1). One trial reported no cases of clinical failure in participants receiving ceftriaxone and no cases in participants receiving ofloxacin (Kumar 2007). No clear relationship was seen on analysis according to ceftriaxone dose (2 g daily compared to more than 2 g daily).

Microbiological failure

Microbiological failure was not significantly different in participants in the ceftriaxone group compared to participants in the fluoroquinolone group (RR 1.65, 95% CI 0.40 to 6.83; 3 trials, 316 participants; very low-certainty evidence; Analysis 3.2). No clear relationship was seen on analysis according to ceftriaxone dose (2 g daily compared to more than 2 g daily).

Relapse

Relapse was not significantly different in participants in the ceftriaxone group compared to participants in the fluoroquinolone group (RR 0.95, 95% CI 0.31 to 2.92; 3 trials, 297 participants; very low-certainty evidence; Analysis 3.3). One trial reported that no participant in either the ceftriaxone or ofloxacin group experienced clinical relapse with fever (Kumar 2007). No clear relationship was seen on analysis according to ceftriaxone dose (2 g daily compared to more than 2 g daily).

Time to defervescence

Average time to defervescence was 2.73 days longer in participants treated with ceftriaxone compared to participants treated with fluoroquinolones, but the analysis was underpowered and we are uncertain if this is a true difference (MD 2.73 days, 95% CI -0.37 to 5.84; 3 trials, 285 participants; very low-certainty evidence; Analysis 3.4). No clear relationship was seen on analysis according to ceftriaxone dose (2 g daily compared to more than 2 g daily). We were unable to calculate the mean time to defervescence calculated in one trial due to missing data on standard deviation (Kumar 2007).

Convalescent faecal carriage

Convalescent faecal carriage was not detected in 0/38 (0%) participants treated with ceftriaxone compared to detection in 2/35 (5.7%) participants treated with gatifloxacin (RR 0.18, 95% CI 0.01 to 3.72; 1 trial, 73 participants; very low-certainty evidence; Analysis 3.5).

Length of hospital stay

The mean length of hospital stay was longer in participants treated with ceftriaxone compared to participants treated with ofloxacin. However, there was overlap in the ranges between treatment groups (mean of 12 days (range 7 to 23 days) in the ceftriaxone group compared to a mean of 9 days (range 6 to 13 days) in the ofloxacin group; 1 trial, 47 participants; low-certainty evidence, Smith 1994). We were unable to calculate the mean difference due to unknown standard deviations in each group.

Adverse events

One trial reported a 'probable' anaphylactic reaction in 1 of 15 participants in the ceftriaxone group (Tran 1994). One trial reported a mild skin rash in 2 of 25 participants in the ceftriaxone group and pruritis in 1 of 22 participants in the ofloxacin group (Smith 1994). One trial reported complications of hepatitis (9/62 participants), intestinal bleeding (3/62 participants) and pleural effusion (1/62 participants); it was not stated which treatment was received by participants experiencing these complications or whether they were considered due to the drug or the disease process (Kumar 2007).

4. Ceftriaxone versus cefixime

Two older trials compared ceftriaxone with cefixime (Bhutta 1994; Girgis 1995). The trial participants were all under 18 years of age. The trials reported that all bacterial isolates were susceptible to the trial antimicrobials.

Clinical failure

Clinical failure was reported in 3/68 (4.4%) participants treated with ceftriaxone compared to 3/75 (4.0%) treated with cefixime (RR 1.00, 95% CI 0.22 to 4.49; 143 participants; 2 trials; Analysis 4.1).

Microbiological failure

Microbiological failure was reported in 2/68 (2.9%) of participants in the ceftriaxone group compared to 1/75 (1%) of participants in the cefixime group (RR 2.00, 95% CI 0.19 to 20.67; 2 trials, 143 participants; Analysis 4.2).

Relapse

Relapse was reported in 5/68 (7.4%) participants in the ceftriaxone group compared to 4/75 participants in the cefixime group (RR 1.36, 95% CI 0.37 to 4.98; 2 trials, 143 participants; [Analysis 4.3](#)).

Time to defervescence

Time to defervescence was shorter in participants treated with ceftriaxone compared to participants treated with chloramphenicol (MD -1.48 days, 95% CI -2.13 to -0.83; 2 trials, 143 participants; [Analysis 4.1](#)).

Convalescent faecal carriage

Neither trial reported convalescent faecal carriage of *Salmonella*.

Length of hospital stay

Neither trial reported length of hospital stay.

Adverse events

No serious adverse outcomes were reported.

5. Ceftriaxone versus chloramphenicol

Eight trials conducted between 1988 and 2003 compared ceftriaxone and chloramphenicol ([Acharya 1995](#); [Butler 1993](#); [Girgis 1990](#); [Islam 1988](#); [Islam 1993](#); [Lasserre 1991](#); [Moosa 1989](#); [Tatli 2003](#)). The trial participants include adults and children. Seven of the eight trials reported that the bacterial isolates were susceptible to the trial antimicrobials.

Clinical failure

Clinical failure was reported in 15/202 (7.4%) of participants treated with ceftriaxone compared to 10/185 (5.4%) treated with chloramphenicol (RR 1.43, 95% CI 0.68 to 3.00; 7 trials, 387 participants; [Analysis 5.1](#)).

Microbiological failure

There were no microbiological failures in participants in either group ([Analysis 5.2](#)).

Relapse

Relapse was reported in 5/189 (2.6%) of participants treated with ceftriaxone compared to 13/176 (7.4%) participants in the chloramphenicol group (RR 0.45, 95% CI 0.20 to 1.04; 7 trials, 365 participants; [Analysis 5.3](#)).

Time to defervescence

Time to defervescence was shorter in participants treated with ceftriaxone compared to participants treated with chloramphenicol (MD -2.54 days, 95% CI -3.13 to -1.95; 55 participants, 1 trial; [Analysis 5.4](#)).

Convalescent faecal carriage

Convalescent faecal carriage was detected in two participants treated with ceftriaxone compared to none treated with chloramphenicol (RR 3.20, 95% CI 0.34 to 29.94; 2 trials, 118 participants; [Analysis 5.5](#)).

Length of hospital stay

No trials reported length of hospital stay.

Adverse events

In one trial, one participant died with pneumonia and hypotension among the 32 participants in the ceftriaxone group; one death due to pneumonia and one intestinal perforation was reported in the 31 participants in the chloramphenicol group ([Islam 1988](#)).

Several trials reported decreases in the haemoglobin concentration, white cell and platelet count in the participants during treatment with chloramphenicol that were greater than in those treated with ceftriaxone ([Acharya 1995](#); [Butler 1993](#); [Islam 1993](#)). Chloramphenicol was discontinued because of increasing leucopenia or thrombocytopenia, or both in 3/23 (13.0%) participants in [Acharya 1995](#); and 2/14 (14.3%) participants in [Butler 1993](#).

One participant in each of two trials developed a skin rash that disappeared after discontinuation of ceftriaxone ([Islam 1993](#); [Lasserre 1991](#)).

6. Cefixime versus chloramphenicol

Three trials conducted between 1997 and 2007 compared cefixime and chloramphenicol ([Memon 1997](#); [Rabbani 1998](#); [Rizvi 2007](#)). The trial participants include adults and children. One trial observed resistance to chloramphenicol in 66/85 (78%) bacterial isolates ([Memon 1997](#)). The other two trials did not clearly present the levels of in vitro resistance to chloramphenicol.

Clinical failure

Clinical failure was reported in 4/107 (3.7%) participants treated with cefixime compared to 51/108 (47.2%) treated with chloramphenicol (RR 0.09, 95% CI 0.04 to 0.23; 3 trials, 215 participants; [Analysis 6.1](#)).

Microbiological failure

One trial reported microbiological failures, with no failures in the participants treated with cefixime but 9/44 (20.4%) failures in those treated with chloramphenicol (RR 0.05, 95% CI 0.00 to 0.84; 1 trial, 90 participants; [Analysis 6.2](#)).

Relapse

No trials reported relapse.

Time to defervescence

Time to defervescence was shorter in participants treated with cefixime compared to participants treated with chloramphenicol (mean difference of -2.50 days, 95% CI -3.23 to -1.77; 1 trial, 90 participants; [Analysis 6.3](#)).

Convalescent faecal carriage

No trials reported convalescent faecal carriage.

Length of hospital stay

No trials reported length of hospital stay.

Adverse events

There were no severe adverse events.

In the 41 participants in the cefixime group in one trial, abdominal distension was reported in two participants, urticaria

in one participant, and epistaxis with thrombocytopenia in one participant (Memon 1997). In a further trial, nausea and vomiting was reported in 3/46 participants (Rizvi 2007).

Side effects attributed to chloramphenicol in one trial were abdominal distension in 3/44 participants and diarrhoea in 1/44 participants (Memon 1997). In a further trial, nausea and vomiting was reported in 4/44 participants and anaemia in 2/44 participants (Rizvi 2007).

7. Cefoperazone versus chloramphenicol

Two trials compared cefoperazone with chloramphenicol (Morelli 1988; Pape 1986). One trial was conducted in adolescents and adults in Italy (Morelli 1988), and the other trial was conducted in children in Haiti (Pape 1986).

Clinical failure

Clinical failure was reported in 2/40 (5%) participants treated with cefoperazone compared to 3/41 (7.3%) participants treated with chloramphenicol (RR 0.74, 95% CI 0.10 to 5.36; 2 trials, 81 participants; Analysis 7.1).

Microbiological failure

One trial reported no cases of microbiological failure in either treatment group at the end of treatment (Morelli 1988). One trial did not report the number of participants in each treatment group who experienced microbiological failure (Pape 1986).

Relapse

Relapse was reported in 2/27 (7.4%) participants treated with cefoperazone compared to 4/28 (14.3%) participants in the chloramphenicol group (RR 0.52, 95% CI 0.10 to 2.60; 1 trial, 55 participants; Analysis 7.2).

One trial reported no cases of relapse in either treatment group (Pape 1986).

Time to defervescence

Time to defervescence was shorter in participants treated with cefoperazone compared to chloramphenicol (MD -2.3 days, 95% CI -2.89 to -1.71; 1 trial, 21 participants; Analysis 7.3).

We were unable to calculate the mean time to defervescence in one trial due to missing data on standard deviation (Morelli 1988).

Convalescent faecal carriage

Convalescent faecal carriage was detected in one participant treated with cefoperazone compared to four participants treated with chloramphenicol (RR 0.25, 95% CI 0.03 to 2.10; 1 trial, 56 participants; Analysis 7.4).

One trial reported no cases of positive stool culture in either treatment group six weeks after completion of treatment in one trial (Pape 1986).

Length of hospital stay

Neither trial reported length of hospital stay.

Adverse events

In one trial there were three deaths out of 13 participants in the chloramphenicol group and one death out of 12 participants in the cefoperazone group; the trial authors reported the causes of death to be gastrointestinal bleeding and perforation (2 participants), hypotension and severe diarrhoea (1 participant) and presumed myocarditis with arrhythmias (1 participant; Pape 1986). The trial authors reported that all patients in the trial had an abnormal state of consciousness on trial enrolment, and that three participants out of 13 in the chloramphenicol group and one participant out of 12 in the cefoperazone group were additionally noted to be in shock on trial enrolment (Pape 1986).

In one trial, one participant experienced nausea and reflux in the chloramphenicol group (Morelli 1988).

8. Cefixime versus cefpodoxime

One small trial of 40 participants conducted in Bangladesh compared cefixime with cefpodoxime (Shakur 2007). All participants were children.

Clinical failure

Clinical failure was reported in 1/19 (5.3%) participants treated with cefixime compared to 1/21 (4.8%) participants treated with cefpodoxime (RR 1.11, 95% CI 0.07 to 16.47; 1 trial, 40 participants; Analysis 8.1).

Microbiological failure

No cases of microbiological failure were reported in either group (1 trial, 40 participants).

Relapse

No cases of relapse were reported in either group at three months of follow-up (1 trial, 40 participants).

Time to defervescence

Time to defervescence was shorter in participants treated with cefixime compared to cefpodoxime (MD -0.6 days, 95% CI -2.03 to 0.83; 1 trial, 40 participants; Analysis 8.2).

Convalescent faecal carriage

Convalescent faecal carriage was not reported.

Length of hospital stay

Length of hospital stay was not reported.

Adverse events

No serious adverse outcomes were reported. One participant in the cefixime group developed mild, self-limiting diarrhoea; one participant in the cefpodoxime group developed a mild, self-limiting maculopapular rash (Shakur 2007).

9. Cefixime versus aztreonam

One small trial conducted in participants less than 16 years of age in Egypt compared cefixime with aztreonam (Girgis 1995).

Clinical failure

No cases of clinical failure were reported in any participant in either treatment group at four weeks of follow-up (1 trial, 81 participants).

Microbiological failure

No cases of microbiological failure were reported in either treatment group at four weeks of follow-up (1 trial, 81 participants).

Relapse

Relapse was reported in 3/50 (6%) participants treated with cefixime compared to 2/31 (6.5%) participants in the aztreonam group (RR 0.93, 95% CI 0.16 to 5.26; 1 trial, 81 participants; [Analysis 9.1](#)).

Time to defervescence

Time to defervescence was shorter in participants treated with aztreonam compared to cefixime (MD 0.2 days, 95% CI -0.42 to 0.82; 81 participants; 1 trial; [Analysis 9.2](#)).

Convalescent faecal carriage

No cases of positive stool culture were reported in either treatment group at four weeks of follow-up (1 trial, 81 participants).

Length of hospital stay

We were unable to differentiate data concerning length of hospital stay from data concerning duration of participant illness.

Adverse events

No serious adverse events were reported. trial authors reported that mild reactions including nausea, vomiting and abdominal pain were observed in some participants in both treatment groups.

10. Ceftriaxone versus aztreonam

One small trial conducted in participants less than 16 years of age in Egypt compared ceftriaxone with aztreonam ([Girgis 1995](#)).

Clinical failure

No cases of clinical failure were reported in any participant in either treatment group at four weeks of follow-up (1 trial, 74 participants).

Microbiological failure

No cases of microbiological failure were reported in either treatment group at four weeks of follow-up (1 trial, 74 participants).

Relapse

Relapse was reported in 2/43 (4.7%) participants treated with ceftriaxone compared to 2/31 (6.5%) participants in the aztreonam group (RR 0.72, 95% CI 0.11 to 4.84; 1 trial, 74 participants; [Analysis 10.1](#)).

Time to defervescence

Time to defervescence was shorter in participants treated with ceftriaxone compared to aztreonam (MD -1.4 days, 95% CI -2.44 to -0.36; 1 trial, 74 participants; [Analysis 10.2](#)).

Convalescent faecal carriage

No cases of positive stool culture were reported in either treatment group at four weeks of follow-up (1 trial, 74 participants).

Length of hospital stay

We were unable to differentiate data concerning length of hospital from data concerning duration of participant illness.

Adverse events

No serious adverse events were reported. trial authors reported that mild reactions including nausea, vomiting and abdominal pain were observed in some participants in both treatment groups.

11. Duration of treatment with third-generation cephalosporins

One small trial published over 20 years ago directly compared duration of therapy of ceftriaxone ([Bhutta 2000](#)). This is the only drug with a direct comparison on treatment length.

Clinical failure

Clinical failure was reported in 2/29 (6.9%) participants treated with a seven-day course of ceftriaxone compared with 1/28 (3.6%) participants treated with a 14-day course of ceftriaxone (RR 1.93, 95% CI 0.19 to 20.12; 1 trial, 57 participants; [Analysis 11.1](#)).

Relapse

Relapse was reported in 4/29 (13.8%) participants treated with a seven-day course of ceftriaxone compared with zero cases in 28 participants treated with a 14-day course of ceftriaxone (RR 8.70, 95% CI 0.49 to 154.49; 1 trial, 57 participants; [Analysis 11.2](#)).

Time to defervescence

Time to defervescence was reduced in the 14-day course of ceftriaxone group compared to the group treated with seven days of ceftriaxone (MD 0.20 days, 95% CI -1.46 to 1.86; 1 trial, 57 participants; [Analysis 11.3](#)).

DISCUSSION

Antimicrobials in common use for the treatment of enteric fever are cefixime, ceftriaxone, azithromycin, and the fluoroquinolones. Resistance to all these antimicrobial classes has emerged in the last 10 years.

Summary of main results

This Cochrane Review included 27 trials with 2231 participants investigating cephalosporins compared to other antimicrobials for the treatment of enteric fever in adults and children. The main findings of this review regarding ceftriaxone and cefixime compared to other first-line antimicrobials used most commonly for the treatment of enteric fever are summarized in [Summary of findings 1](#) (cefixime versus fluoroquinolones), [Summary of findings 2](#) (ceftriaxone versus azithromycin), and [Summary of findings 3](#) (ceftriaxone versus fluoroquinolones). The number of trials per outcome was low, 19 of 27 included trials were conducted over 20 years ago and many lacked statistical power to detect differences between the treatment regimens. The certainty of evidence is low to very low across all outcomes.

Clinical failure, microbiological failure and relapse may be slightly increased in patients treated with cefixime compared to fluoroquinolones (low-certainty evidence). Of note, one quarter of participants treated with cefixime were clinical failures.

It is very uncertain whether clinical failure is increased in patients treated with ceftriaxone compared to fluoroquinolones (very low-certainty evidence). There may be no difference in microbiological failure and relapse in participants treated with ceftriaxone compared to fluoroquinolones (low-certainty evidence).

Ceftriaxone may result in a decrease in clinical failure and an increase in microbiological failure compared to azithromycin in patients under 18 years of age (low-certainty evidence). Relapse may be slightly decreased in patients treated with ceftriaxone compared to treatment with fluoroquinolones (low-certainty evidence), and may be increased in patients < 18 years of age treated with ceftriaxone compared to azithromycin (low-certainty evidence). Ceftriaxone may result in a decrease in convalescent faecal carriage compared to fluoroquinolones (low-certainty evidence).

There may be no difference in clinical failure, microbiological failure and relapse in participants under 18 years of age treated with ceftriaxone compared to cefixime (low-certainty evidence). In addition, there may be no difference in clinical failure, microbiological failure and relapse in participants treated with ceftriaxone compared to chloramphenicol (low-certainty evidence).

Clinical failure and microbiological failure may be decreased in patients treated with cefixime compared to chloramphenicol (low-certainty evidence) although this result may be confounded by high levels of resistance to chloramphenicol in at least one trial.

Ceftriaxone and cefixime and all comparator antimicrobials were generally well tolerated. One death in a child receiving oxofloxacin (a fluoroquinolone) was reported in one trial (Cao 1999); it is unknown whether this death was due to the drug or the disease process. An adult receiving cefixime died in a further trial (Pandit 2007), with the death considered to be due to progression of the disease process. Two participants died, one in each arm of a trial comparing ceftriaxone and chloramphenicol, probably due to the disease process (Islam 1988). In a further trial in Haiti, in which all recruited children had severe typhoid fever with altered consciousness, there were three deaths out of 13 participants in the chloramphenicol group and one death out of 12 participants in the cefoperazone group; the trial authors reported the causes of death to be gastrointestinal bleeding and perforation (2 participants), hypotension and severe diarrhoea (1 participant) and presumed myocarditis with arrhythmias (1 participant; Pape 1986). A 'probable' anaphylactic reaction in one participant receiving ceftriaxone was reported in one trial (Tran 1994). Chloramphenicol was discontinued because of increasing leucopenia or thrombocytopenia, or both, in five participants in two trials (Acharya 1995; Butler 1993).

The optimal antimicrobial, dose and duration of therapy, cannot be determined from these review findings. One trial directly compared different doses of ceftriaxone however no conclusion can be drawn as the trial was underpowered (Bhutta 2000).

No trials comparing ceftriaxone with azithromycin were conducted in participants over 18 years old and no included trials directly compared cefixime with azithromycin.

Overall completeness and applicability of evidence

In general, participants with typhoid fever responded to cephalosporin treatment provided that the isolate was susceptible to the antimicrobial used. But we were unable to draw any definite conclusions on the presence or absence of important differences between cephalosporins and other antimicrobials in the treatment of enteric fever. There are too few trials within each comparison, and the trials themselves are underpowered. Data are especially lacking concerning the outcome of convalescent faecal carriage and duration of hospital stay across all antimicrobial comparisons. Some included trials are over two decades old, and took place when trial methodology was not as developed as in contemporary trials, although they were performed at a time when *S typhi* and *S paratyphi* isolates were still susceptible to older antimicrobials, allowing the efficacy assessment of older antimicrobials. In addition, antimicrobial susceptibility data were incompletely reported in some trials.

For contemporary treatment decisions, local resistance patterns need to be carefully considered. The threat of further spread of XDR strains highlights the importance of the implementation of antimicrobial stewardship policies in endemic areas.

There are no included trials comparing cefixime with azithromycin; we identified one trial during screening that compared cefixime with azithromycin, however there was disparity in the reported duration of treatment with azithromycin received by participants. Unfortunately, we did not receive a response from the trial authors requesting clarification on this discrepancy, and we excluded this trial (Amin 2021).

Certainty of the evidence

The certainty of evidence for the main comparisons' outcomes presented in the summary of findings tables were low (see [Summary of findings 1](#)) or ranged between very low and low (see [Summary of findings 2](#); [Summary of findings 3](#)). There was a lack of standardization across outcomes and the quality of reporting was inconsistent.

We downgraded all outcomes by one level for serious risk of bias. Only one trial out of 28 was blinded. Details of the risk of bias assessments are reported in the [Assessment of risk of bias in included studies](#) section.

A significant limitation for the certainty of evidence was the low number of participants, events, or both leading to wide CIs and low certainty in the estimated effects. We downgraded almost all outcomes by one or two levels for imprecision.

We did not downgrade any outcomes for indirectness. In all cases, the effect estimates were based on comparisons of interest, on the population of interest, and on outcomes of interest (where reported). We did not assess publication bias due to the low number of trials within comparisons.

Potential biases in the review process

The search methods were thorough and included searching the proceedings of international typhoid conferences. However, it is possible that we did not capture randomized clinical trials conducted in China or Latin America due to language barriers.

No included trials directly compared cefixime with azithromycin; we approached the authors of one trial undertaking this comparison for clarification of data, however this approach was not successful (Amin 2021).

Agreements and disagreements with other studies or reviews

A Cochrane Review including the comparisons of fluoroquinolones to cefixime, fluoroquinolones to ceftriaxone, and cefixime to azithromycin has been published (Effa 2011); our review findings are in agreement.

AUTHORS' CONCLUSIONS

Implications for practice

Ceftriaxone can effectively treat enteric fever in adults and children with few adverse effects, and may be superior to alternatives in some settings. The evidence for the efficacy of cefixime in randomized controlled trials (RCTs) is limited. We were unable to draw firm general conclusions on comparative contemporary effectiveness in the context of antimicrobial resistance differing by geographical location and over time, and many trials were small. Clinicians need to take into account current, local resistance patterns when choosing an antimicrobial.

Implications for research

In light of the importance of the need for effective antimicrobials to treat enteric fever in a context of increasing antimicrobial resistance, we need multi-centred, adequately powered trials testing new antimicrobials or new combinations of antimicrobials, with robust methods and analytical design. Data reporting should be stratified by bacterial antimicrobial resistance and vaccination status, where possible.

Future research may be guided by the results of the one identified, ongoing RCT in South Asia, which is examining the benefit of adding cefixime to azithromycin compared with azithromycin alone in uncomplicated, clinically suspected enteric fever in a planned sample size of 1500 participants (Ongoing studies).

Definitions of outcomes and their measurement (development of a core outcome set) should also be standardized to make more effective comparisons and adaptability across regions.

Research and development of low-cost, sensitive and specific diagnostic tests for typhoid fever would improve diagnostic accuracy and decrease the use of unnecessary or incorrect antibiotic treatment, impacting antimicrobial resistance compromising treatment in many areas of the world.

ACKNOWLEDGEMENTS

Editorial and peer reviewer contributions

The following people conducted the editorial process for this article:

- Sign-off Editor: Professor Mical Paul
- Managing Editor (selected peer reviewers, collated peer reviewer comments, provided editorial guidance to authors, edited the article): Dr Deirdre Walshe
- Copy Editor (copyediting and production): Denise Mitchell
- Peer reviewers (provided comments and recommended an editorial decision):
 - protocol stage: Ms Meike-Kathrin Zuske, Swiss Tropical and Public Health Institute, Basel, Switzerland;
 - review stage: Emmanuel Effa, Department of Internal Medicine, University of Calabar, Nigeria (content peer reviewer); Ami Neuberger, M.D. Unit of Infectious Diseases in Rambam Medical Center & Technion, Faculty of Medicine, both in Haifa, Israel (content peer reviewer); Priscilla Rupali MD, DTM&H, FRCP (content peer reviewer); Kerry Dwan, Cochrane Methods Support Unit (statistical peer reviewer).

We thank Cochrane Infectious Diseases Group's (CIDG) Information Specialist Vittoria Lutje for her assistance with the search strategy and searches.

Rebecca Kuehn is supported by the Research, Evidence and Development Initiative (READ-It). READ-It (project number 300342-104) is funded by UK aid from the UK government; however, the views expressed do not necessarily reflect the UK government's official policies.

The CIDG editorial base is funded by UK aid from the UK government for the benefit of low- and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government's official policies.

REFERENCES

References to studies included in this review

Acharya 1995 {published data only}

Acharya G, Butler T, Ho M, Sharma PR, Tiwari M, Adhikari RK, et al. Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol. *American Journal of Tropical Medicine and Hygiene* 1995;**52**(2):162-5.

Arjyal 2016 {published data only}

Arjyal A, Basnyat B, Nhan HT, Koirala S, Giri A, Joshi MN, et al. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. *Lancet Infectious Diseases* 2016;**16**(5):535-45.

Bhutta 1994 {published data only}

* Bhutta ZA, Khan IA, Molla AM. Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone. *Pediatric Infectious Disease Journal* 1994;**13**(11):990-4.

Bhutta ZA, Mansoorali N, Hussain R. Plasma cytokines in paediatric typhoidal salmonellosis: correlation with clinical course and outcome. *Journal of Infection* 1997;**35**(3):253-6.

Bhutta 2000 {published data only}

Bhutta ZA, Khan IA, Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. *Antimicrobial Agents and Chemotherapy* 2000;**44**(2):450-2.

Butler 1993 {published data only}

Butler T, Ho M, Acharya G, Tiwari M, Gallati H. Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. *Antimicrobial Agents and Chemotherapy* 1993;**37**(11):2418-21.

Cao 1999 {published data only}

Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. *Paediatric Infectious Disease Journal* 1999;**18**(3):245-8.

Frenck 2000 {published data only}

Frenck RW Jr, Nakhla I, Sultan Y, Bassily SB, Girgis YF, David J, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. *Clinical Infectious Diseases* 2000;**31**(5):1134-8.

Frenck 2004 {published data only}

Frenck RW Jr, Mansour A, Nakhla I, Sultan Y, Putnam S, Wierzbica T, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. *Clinical Infectious Diseases* 2004;**38**(7):951-7.

Girgis 1990 {published data only}

Girgis NI, Kilpatrick ME, Farid Z, Mikhail IA, Bishay E. Ceftriaxone versus chloramphenicol in the treatment of enteric fever. *Drugs under Experimental and Clinical Research* 1990;**16**(12):607-9.

Girgis 1995 {published data only}

Girgis NI, Sultan Y, Hammad O, Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant *Salmonella typhi* septicemia in children. *Pediatric Infectious Disease Journal* 1995;**14**(7):603-5.

Islam 1988 {published data only}

Islam A, Butler T, Nath SK, Alam NH, Stoeckel K, Houser HB, et al. Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. *Journal of Infectious Diseases* 1988;**158**(4):742-7.

Islam 1993 {published data only}

Islam A, Butler T, Kabir I, Alam NH. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. *Antimicrobial Agents and Chemotherapy* 1993;**37**(8):1572-5.

Kumar 2007 {published data only}

Kumar R, Gupta N, Shalini. Multidrug-resistant typhoid fever. *Indian Journal of Pediatrics* 2007;**74**(1):39-42.

Lasserre 1991 {published data only}

Lasserre R, Sangalang RP, Santiago L. Three-day treatment of typhoid fever with two different doses of ceftriaxone, compared to 14-day therapy with chloramphenicol: a randomized trial. *Journal of Antimicrobial Chemotherapy* 1991;**28**(5):765-72.

Memon 1997 {published data only}

Memon IA, Billoo AG, Memon HI. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. *Southern Medical Journal* 1997;**90**(12):1204-7.

Moosa 1989 {published data only}

Moosa A, Rubidge CJ. Once daily ceftriaxone vs. chloramphenicol for treatment of typhoid fever in children. *Pediatric Infectious Disease Journal* 1989;**8**(10):696-9.

Morelli 1988 {published data only}

Morelli G, Guerriero M, Cristiano P, Galderisi P, Postiglione A, Paradisi F. Cefoperazone compared with chloramphenicol in the treatment of typhoid fever. *Chemotherapy* 1988;**34**(1):71-6.

Nair 2017 {published data only}

Nair BT, Simalti AK, Sharma S. Study comparing ceftriaxone with azithromycin for the treatment of uncomplicated typhoid fever in children of India. *Annals of Tropical Medicine and Public Health* 2017;**10**(1):205-10.

Pandit 2007 {published and unpublished data}

Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. *PLOS One* 2007;**2**(6):e542.

Pape 1986 {published data only}

Pape JW, Gerdes H, Oriol L, Johnson WD Jr. Typhoid fever: successful therapy with cefoperazone. *Journal of Infectious Diseases* 1986;**153**(2):272-6.

Rabbani 1998 {published data only}

Malik MS, Iqbal I, Rabbani W. A comparative study of cefixime and chloramphenicol in children with typhoid fever. *Journal of Pakistan Medical Association* 1998;**48**(4):106-7.

* Rabbani MW, Iqbal I, Malik MS. A comparative study of cefixime and chloramphenicol in children with typhoid fever. *Journal of the Pakistan Medical Association* 1998;**48**(6):163-4.

Rizvi 2007 {published data only}

Rizvi Q. Effectiveness of anti-typhoid drugs currently used in Pakistan. *Pakistan Journal of Surgery* 2007;**23**(1):57-64.

Shakur 2007 {published data only}

Shakur MS, Arzuman SA, Hossain J, Mehdi H, Ahmed M. Cefpodoxime proxetil compared with cefixime for treatment of typhoid fever in children. *Indian Pediatrics* 2007;**44**(11):838-41.

Smith 1994 {published data only}

Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, Diep TS, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. *Antimicrobial Agents and Chemotherapy* 1994;**38**(8):1716-20.

Tatli 2003 {published data only}

Tatli MM, Aktas G, Kosecik M, Yilmaz A. Treatment of typhoid fever in children with a flexible-duration of ceftriaxone, compared with 14-day treatment with chloramphenicol. *International Journal of Antimicrobial Agents* 2003;**21**(4):350-3.

Tran 1994 {published data only}

Tran TH, Nguyen MD, Huynh DH, Nguyen TT, To SD, Le TP, et al. A randomized comparative study of fleroxacin and ceftriaxone in enteric fever. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1994;**88**(4):464-5.

Wallace 1993 {published data only}

Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. *European Journal of Clinical Microbiology & Infectious Diseases* 1993;**12**(12):907-10.

References to studies excluded from this review
Arjyal 2011 {published data only}

Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, et al. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. *Lancet Infectious Diseases* 2011;**11**(6):445-54.

Begue 1998 {published data only}

Begue P, Astruc J, Francois P, Floret D. Comparison of ceftriaxone and cefotaxime in severe pediatric bacterial infection: a multicentric study. *Médecine et Maladies Infectieuses* 1998;**27**:300-6.

Begum 2014 {published data only}

Begum B, Haque MA, Ahmed MS, Islam MN, Ahsan MM, Khan AH, et al. Comparison between azithromycin and cefixime in the treatment of typhoid fever in children. *Mymensingh Medical Journal* 2014;**23**(3):441-8.

De Carvalho 1982 {published data only}

De Carvalho EM, Martinelli R, De Oliveira MMG, Rocha H. Cefamandole treatment of Salmonella bacteremia. *Antimicrobial Agents and Chemotherapy* 1982;**21**(2):334-5.

Ebright 1983 {published data only}

Ebright JR, Franson TR, Moore EC. Comparative trial of ceftizoxime and cefamandole in therapy of bacterial pneumonia. *Current Therapeutic Research* 1983;**33**(1):39-45.

Farid 1987 {published data only}

Farid Z, Girgis N, Abu el Ella A. Successful treatment of typhoid fever in children with parenteral ceftriaxone. *Scandinavian Journal of Infectious Diseases* 1987;**19**(4):467-8.

Gnassingbe 2010 {published data only}

Gnassingbe K, Akakpo-Numado GK, Attipou K, Kanassoua K, Tekou H. Typhoid intestinal perforation in children: renewed interest in the Veillard technique in tropical zones [Les perforations typhiques du grêle chez l'enfant: un regain d'intérêt de la technique de Veillard en milieu tropical]. *Médecine Tropicale* 2010;**70**(5-6):524-8.

Jiangli 1995 {published data only}

Jiangli Z, Zheng G. Studies on the pharmacodynamics and clinical usage of domestic intravenous preparation of ciprofloxacin lactate. *Chinese Journal of Antibiotics* 1995;**20**(2):112-7.

Khichi 2001 {published data only}

Khichi QK, Channer MS. Parenteral chloramphenicol versus chloramphenicol plus dexamethasone in the treatment of typhoid fever. *Pakistan Pediatric Journal* 2001;**25**(2):55-8.

Lan 1986 {published data only}

Lan CK, Cheng DL, Lasserre R. Two to three days treatment of typhoid fever with ceftriaxone. *Southeast Asian Journal of Tropical Medicine and Public Health* 1986;**17**(1):119-24.

Medina 2000 {published data only}

Medina Santillán R, Reyes García G, Herrera Benavente I, Mateos García E. Efficacy of cefixime in the therapy of typhoid fever. *Proceedings of the Western Pharmacology Society* 2000;**43**:65-6.

Meloni 1988 {published data only}

Meloni T, Marinaro AM, Desole MG, Forteleoni G, Argiolas L. Ceftriaxone treatment of salmonella enteric fever. *Pediatric Infectious Disease Journal* 1988;**7**(10):734-5.

Morelli 1992 {published data only}

Morelli G, Mazzoli S, Tortoli E, Simonetti MT, Perruna F, Postiglione A. Fluoroquinolones versus chloramphenicol in the therapy of typhoid fever: a clinical and microbiological study. *Current Therapeutic Research* 1992;**52**(4):532-42.

Nagaraj 2016 {published data only}

Nagaraj P, Sivanthu S, Manickam K, Kumar S, Kumar S, Sampath S. To study the effectiveness of oral azithromycin as compared to paraenteral ceftriaxone in the treatment of uncomplicated enteric fever. *Journal of Pediatric Infectious Diseases* 2016;**11**(4):113-7.

Naveed 2016 {published data only}

Naveed A, Ahmed Z. Treatment of typhoid fever in children: comparison of efficacy of ciprofloxacin with ceftriaxone. *European Scientific Journal* 2016;**12**(6):346-55.

Nelson 1967 {published data only}

Nelson JD, Haltalin KC. Broad-spectrum penicillins in enteric infections of children. *Annals of the New York Academy of Sciences* 1967;**145**(2):414-22.

Park 1985 {published data only}

Park SC, Lee CH, Kim SY, Park CH, Kim TW, Seok SE, et al. Clinical trial of cefotaxime in patients with typhoid fever. *Clinical Therapeutics* 1985;**7**(4):448-51.

Raoult 1984 {published data only}

Raoult D, Gallais H, Fosse T, Xeridat B, David MF, Casanova P. Treatment of typhoid fever with cefoperazone [Traitement de la fièvre typhoïde par la céfopérazone]. *Pathologie Biologie* 1984;**32**(5 Pt 2):573-5.

Rolston 1992 {published data only}

Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. *Archives of Internal Medicine* 1992;**152**(2):283-91.

Singh 1993 {published data only}

Singh CP, Singh N, Brar GK, Lal G, Kumar H. Efficacy of ciprofloxacin and norfloxacin in multidrug resistant enteric fever in adults. *Journal of the Indian Medical Association* 1993;**91**(6):156-7.

Sirinavin 2003 {published data only}

Sirinavin S, Thavornnunth J, Sakchainanont B, Bangtrakulnonth A, Chongthawonsatid S, Junumporn S. Norfloxacin and azithromycin for treatment of nontyphoidal salmonella carriers. *Clinical Infectious Diseases* 2003;**37**(5):685-91.

Soe 1987 {published data only}

Soe GB, Overturf GD. Treatment of typhoid fever and other systemic salmonellosis with cefotaxime, ceftriaxone, cefoperazone and other newer cephalosporins. *Reviews of Infectious Diseases* 1987;**9**(4):719-36.

Thaver 2009 {published data only}

Thaver D, Zaidi AK, Critchley J, Azmatullah A, Madni SA, Bhutta ZA. A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis. *BMJ* 2009;**338**:b1865.

Ti 1985 {published data only}

Ti TY, Monteiro EH, Lam S, Lee HS. Ceftriaxone therapy in bacteremic typhoid fever. *Antimicrobial Agents and Chemotherapy* 1985;**28**(4):540-3.

Trivedi 2012 {published data only}

Trivedi NA, Shah PC. A meta-analysis comparing the safety and efficacy of azithromycin over the alternate drugs used for treatment of uncomplicated enteric fever. *Journal of Postgraduate Medicine* 2012;**58**(2):112-8.

Uwaydah 1976 {published data only}

Uwaydah M. Cefazolin in the treatment of acute enteric fever. *Antimicrobial Agents and Chemotherapy* 1976;**10**(1):52-6.

Uwaydah 1984 {published data only}

Uwaydah M, Nassar NT, Harakeh H, Vartivarian S, Talhouk A, Kantarjian H. Treatment of typhoid fever with cefamandole. *Antimicrobial Agents and Chemotherapy* 1984;**26**(3):426-7.

Vinh 2005 {published data only}

Vinh H, Duong NM, Phuong le T, Truong NT, Bay PV, Wain J, et al. Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children. *Annals of Tropical Paediatrics* 2005;**25**(1):17-22.

Yi 1995 {published data only}

Yi L, Huilin Z, Guoyao M, Dungong Q, Peirong H. Clinical study of intravenous enoxacin versus cefotaxime in acute infectious diseases. *Chinese Journal of Antibiotics* 1995;**20**(2):123-8.

Zmora 2018 {published data only}

Zmora N, Shrestha S, Neuberger A, Paran Y, Tamraker R, Shrestha A, et al. Open label comparative trial of mono versus dual antibiotic therapy for typhoid fever in adults. *PLOS Neglected Tropical Diseases* 2018;**12**(4):e0006380.

References to studies awaiting assessment
Amin 2021 {published data only}

Amin MR, Das SK, Kabir A, Islam MR, Ahmed SM, Hasan MJ. Open label randomized controlled comparison of three alternative regimens of ciprofloxacin, azithromycin and cefixime for treatment of uncomplicated typhoid fever in Bangladesh. *Mymensingh Medical Journal* 2021;**30**(3):725-37.

Hamidullah 2019 {published data only}

Hamidullah, Haq SU, Ahmad I, Ali S. Comparison of the clinical effectiveness of azithromycin versus ceftriaxone in treatment of enteric fever. *Medical Forum Monthly* 2019;**30**(1):40-4.

Huai 2000 {published data only}

Huai Y, Zhu Q, Wang X. Ceftriaxone vs norfloxacin in the treatment of resistant typhoid fever in 60 children. *Chinese Journal of Pediatrics* 2000;**38**(6):386-8.

Thapaet 2019 {published data only}

Thapaet RK, Raghu PS, Khanal DP. Efficacy of azithromycin and ceftriaxone for the treatment of enteric fever in two tertiary

care hospitals of Kathmandu Nepal. *Journal of Global Trends in Pharmaceutical Sciences* 2019;**10**(3):6361-7.

Welch 1986 {published data only}

References to ongoing studies

NCT04349826 {unpublished data only}

NCT04349826. The azithromycin and cefixime treatment of typhoid in South Asia trial (ACT-South Asia Trial) [Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia; a randomised controlled trial]. clinicaltrials.gov/show/NCT04349826 (first received 16 April 2020).

Additional references

Ahmed 2012

Ahmed D, Hoque A, Mazumder R, Nahar K, Islam N, Gazi SA, et al. Salmonella enterica serovar typhi strain producing extended-spectrum beta-lactamases in Dhaka, Bangladesh. *Journal of Medical Microbiology* 2012;**61**(Pt 7):1032-3.

Antillón 2017

Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. *PLOS Neglected Tropical Diseases* 2017;**11**(2):e0005376.

Baker 2010

Baker S, Favorov M, Dougan G. Searching for the elusive typhoid diagnostic. *BMC Infectious Diseases* 2010;**10**:45.

Balshem 2011

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines – 3: rating the quality of evidence. *Journal of Clinical Epidemiology* 2011;**64**(4):401-6.

Basnyat 2007

Basnyat B. The treatment of enteric fever. *Journal of the Royal Society of Medicine* 2007;**100**(4):161-2.

Basnyat 2010

Basnyat B. Typhoid fever in the United States and antibiotic choice. *Journal of the American Medical Association* 2010;**303**(1):34.

Bazan 2011

Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. *Medical Clinics of North America* 2011;**95**(4):743-60.

Bhan 2005

Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. *Lancet* 2005;**366**(9487):749-62.

Browne 2020

Browne AJ, Kashef Hamadani BH, Kumaran EA, Rao P, Longbottom J, Harriss E, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. *BMC Medicine* 2020;**18**(1):1-22. [DOI: <https://doi.org/10.1186/s12916-019-1443-1>]

Buckle 2012

Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. *Journal of Global Health* 2012;**2**(1):010401.

Caygill 1994

Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. *Lancet* 1994;**343**(8889):83-4.

Chatham-Stephens 2019

Chatham-Stephens K, Medalla F, Hughes M, Appiah GD, Aubert RD, Caidi H, et al. Emergence of extensively drug-resistant Salmonella typhi infections among travelers to or from Pakistan - United States, 2016-2018. *MMWR Morbidity and Mortality Weekly Reports* 2019;**68**(1):11-3.

CLSI 2021

Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard (M07-A9). 31st edition. Wayne, Pennsylvania: CLSI, 2021.

Crump 2003

Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi Salmonellae. *Clinical Infectious Diseases* 2003;**37**(1):75-81.

Crump 2004

Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bulletin of the World Health Organization* 2004;**82**(5):346-53.

Crump 2008

Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, et al. Clinical response and outcome of infection with Salmonella enterica serotype typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. *Antimicrobial Agents and Chemotherapy* 2008;**52**(4):1278-84.

Crump 2019

Crump JA. Progress in typhoid fever epidemiology. *Clinical Infectious Diseases* 2019;**68** Suppl 1:S4-9.

Deeks 2022

Deeks JJ, Higgins JP, Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.

Duy 2020

Duy PT, Dongol S, Giri A, Nguyen To NT, Dan Thanh HN, Nhu Quynh NP, et al. The emergence of azithromycin-resistant *Salmonella typhi* in Nepal. *JAC Antimicrobial Resistance* 2020;**2**(4):dlaa109.

Effa 2011

Effa EE, Lassi ZS, Critchley JA, Garner P, Sinclair D, Olliaro PL, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). *Cochrane Database of Systematic Reviews* 2011, Issue 10. Art. No: CD004530. [DOI: [10.1002/14651858.CD004530.pub4](https://doi.org/10.1002/14651858.CD004530.pub4)]

Ferreccio 1988

Ferreccio C, Morris JG Jr, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. *Journal of Infectious Diseases* 1988;**157**(6):1235-9.

Garrett 2022

Garrett DO, Longley AT, Aiemojoy K, Yousafzai MT, Hemlock C, Alexander TY, et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project. *Lancet Global Health* 2022;**10**(7):e978-88. [DOI: [10.1016/S2214-109X\(22\)00119-X](https://doi.org/10.1016/S2214-109X(22)00119-X)]

Gul 2017

Gul D, Potter RF, Riaz H, Ashraf ST, Wallace MA, Munir T, et al. Draft genome sequence of a *Salmonella enterica* serovar typhi strain resistant to fourth-generation cephalosporin and fluoroquinolone antibiotics. *Microbiology Resource Announcements* 2017;**5**(42):e00850-17.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011

Higgins JP, Altman DG, Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. training.cochrane.org/handbook/archive/v5.1/.

Hooda 2019

Hooda Y, Sajib MS, Rahman H, Luby SP, Bondy-Denomy J, Santosham M, et al. Molecular mechanism of azithromycin resistance among typhoidal *Salmonella* strains in Bangladesh identified through passive pediatric surveillance. *PLOS Neglected Tropical Diseases* 2019;**13**(11):e0007868.

Iqbal 2020

Iqbal J, Dehraj IF, Carey ME, Dyson ZA, Garrett D, Seidman JC, et al. A race against time: reduced azithromycin susceptibility in *Salmonella enterica* serovar typhi in Pakistan. *MSphere* 2020;**5**(4):e00215-20.

Kalman 1990

Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. *Texas Heart Institute Journal* 1990;**17**(3):203-15.

Karkey 2018

Karkey A, Thwaites GE, Baker S. The evolution of antimicrobial resistance in *Salmonella typhi*. *Current Opinion in Gastroenterology* 2018;**34**(1):25-30.

Kerr 1992

Kerr JR, Barr JG, Smyth ET, O'Hare J. Techniques for calculation of true costs of antibiotic therapy. *European Journal of Clinical Microbiology & Infectious Diseases* 1992;**11**:823-7.

Kim 2017

Kim JH, Mogasale V, Im J, Ramani E, Marks F. Updated estimates of typhoid fever burden in sub-Saharan Africa. *Lancet Global Health* 2017;**5**(10):e969.

Kleine 2017

Kleine CE, Schlabe S, Hischebeth GT, Molitor E, Pfeifer Y, Wasmuth JC, et al. Successful therapy of a multidrug-resistant extended-spectrum beta-lactamase-producing and fluoroquinolone-resistant *Salmonella enterica* subspecies enterica serovar typhi infection using combination therapy of meropenem and fosfomycin. *Clinical Infectious Diseases* 2017;**65**(10):1754-6.

Klemm 2018

Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant *Salmonella enterica* serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio* 2018;**9**(1):e00105-18.

Levine 1982

Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of *Salmonella typhi* in Santiago, Chile, an endemic area. *Journal of Infectious Diseases* 1982;**146**(6):724-6.

Marks 2017

Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali M, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. *Lancet Global Health* 2017;**5**(3):e310-23. [DOI: [10.1016/S2214-109X\(17\)30022-0](https://doi.org/10.1016/S2214-109X(17)30022-0)]

Meiring 2021

Meiring JE, Shakya M, Khanam F, Voysey M, Phillips MT, Tonks S, et al. Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. *Lancet Global Health* 2021;**9**(12):e1688-96. [DOI: [10.1016/S2214-109X\(21\)00370-3](https://doi.org/10.1016/S2214-109X(21)00370-3)]

Mogasale 2014

Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based

update with risk-factor adjustment. *Lancet Global Health* 2014;**2**(10):e570-80.

Munir 2016

Munir T, Lodhi M, Ansari JK, Andleeb S, Ahmed M. Extended spectrum beta lactamase producing cephalosporin resistant *Salmonella typhi*, reported from Rawalpindi, Pakistan. *Journal of the Pakistan Medical Association* 2016;**66**(8):1035-6.

Nabarro 2022

Nabarro LE, McCann N, Herdman MT, Dugan C, Ladhani S, Patel D, et al. British infection association guidelines for the diagnosis and management of enteric fever in England. *Journal of Infection* 2022;**84**(4):469-89. [DOI: [10.1016/j.jinf.2022.01.014](https://doi.org/10.1016/j.jinf.2022.01.014)]

Neupane 2021

Neupane DP, Dulal HP, Song J. Enteric fever diagnosis: current challenges and future directions. *Pathogens* 2021;**10**(4):410.

Parry 1999

Parry CM, Hoa NT, Diep TS, Wain J, Chinh NT, Vinh H, et al. Value of a single-tube Widal test in diagnosis of typhoid fever in Vietnam. *Journal of Clinical Microbiology* 1999;**37**(9):2882-6.

Parry 2002

Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *New England Journal of Medicine* 2002;**347**(22):1770-82.

Patel 2021

Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. *New England Journal of Medicine* 2021;**385**(12):1104-15. [DOI: [10.1056/NEJMoa2035916](https://doi.org/10.1056/NEJMoa2035916)]

Pfeifer 2009

Pfeifer Y, Matten J, Rabsch W. *Salmonella enterica* serovar typhi with CTX-M beta-lactamase, Germany. *Emerging Infectious Diseases* 2009;**15**(9):1533-5.

Qadri 2021

Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. *Lancet* 2021;**398**(10301):01124-7. [DOI: [10.1016/S0140-6736](https://doi.org/10.1016/S0140-6736)]

Qureshi 2020

Qureshi S, Naveed AB, Yousafzai MT, Ahmad K, Ansari S, Lohana H, et al. Response of extensively drug resistant *Salmonella typhi* to treatment with meropenem and azithromycin, in Pakistan. *PLOS Neglected Tropical Diseases* 2020;**14**(10):e0008682.

Raffatellu 2008

Raffatellu M, Wilson RP, Winter SE, Bäumler AJ. Clinical pathogenesis of typhoid fever. *Journal of Infection in Developing Countries* 2008;**2**(4):260-6.

RevMan Web 2022 [Computer program]

The Cochrane Collaboration Review Manager Web (RevMan Web). Version 4.11.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.

Rowe 1997

Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant *Salmonella typhi*: a worldwide epidemic. *Clinical Infectious Diseases* 1997;**24** Suppl 1:S106-9.

Schünemann 2022

Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook.

Shakya 2021

Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. *Lancet Global Health* 2021;**9**(11):e1561-8.

Sjolund-Karlsson 2011

Sjölund-Karlsson M, Joyce K, Blickenstaff K, Ball T, Haro J, Medalla FM, et al. Antimicrobial susceptibility to azithromycin among *Salmonella enterica* isolates from the United States. *Antimicrobial Agents and Chemotherapy* 2011;**55**(9):3985-9.

Stanaway 2019

Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infectious Diseases* 2019;**19**(4):369-81.

Tsolis 1999

Tsolis RM, Kingsley RA, Townsend SM, Ficht TA, Adams LG, Bäumler AJ. Of mice, calves, and men. Comparison of the mouse typhoid model with other *Salmonella* infections. *Advances in Experimental Medicine and Biology* 1999;**473**:261-74.

Wain 1998

Wain J, Diep TS, Ho VA, Walsh AM, Nguyen TT, Parry CM, et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. *Journal of Clinical Microbiology* 1998;**36**(6):1683-7.

Wain 2015

Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. *Lancet* 2015;**385**(9973):1136-45.

Walia 2006

Walia M, Gaiind R, Paul P, Mehta R, Aggarwal P, Kalaivani M. Age-related clinical and microbiological characteristics of enteric fever in India. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2006;**100**(10):942-8.

WHO 2019

World Health Organization. Typhoid vaccines: WHO position paper, March 2018 – Recommendations. *World Health Organization* 2019;**37**(2):214-6. [DOI: [10.1016/j.vaccine.2018.04.022](https://doi.org/10.1016/j.vaccine.2018.04.022)]

WHO 2021

World Health Organization. Model List of Essential Medicines - 22nd List, 2021. WHO/MHP/HPS/EML/2021.02. [who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02](https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02).

Wijedoru 2017

Wijedoru L, Mallett S, Parry CM. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. *Cochrane Database*

of Systematic Reviews 2017, Issue 5. Art. No: CD008892. [DOI: [10.1002/14651858.CD008892.pub2](https://doi.org/10.1002/14651858.CD008892.pub2)]

References to other published versions of this review
Stoesser 2013

Stoesser N, Eyre D, Basnyat B, Parry C. Treatment of enteric fever (typhoid and paratyphoid fever) with third and fourth generation cephalosporins. *Cochrane Database of Systematic Reviews* 2013, Issue 3. Art. No: CD010452. [DOI: [10.1002/14651858.CD010452](https://doi.org/10.1002/14651858.CD010452)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Acharya 1995
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: unclear Duration of follow-up: 21 days
Participants	Setting: hospital emergency/out-patient departments Location: Kathmandu, Nepal Age: adults and children (15 and 8 in each treatment group, respectively). Mean age (\pm SD) was 18.1 (\pm 4.8) in ceftriaxone group, 19.4 (\pm 6.2) in chloramphenicol group Gender: male = 39, female = 7 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • fever $>$ 38.5 °C for $>$ 4 days and • one or more of the following: <ul style="list-style-type: none"> ◦ abdominal pain/tenderness ◦ splenomegaly ◦ rose spots ◦ relative bradycardia; • blood culture also had to be positive for <i>S typhi</i> or <i>S paratyphi</i> Exclusion criteria: <ul style="list-style-type: none"> • antimicrobial therapy for \geq 2 days in the week before clinical presentation that had led to clinical improvement; • severe/complicated presentations including hypotension, pneumonia, rectal bleeding, altered consciousness, suspected intestinal perforation
Interventions	<ul style="list-style-type: none"> • Chloramphenicol, adults and children: oral, 60 mg/kg/day 4 times/day until defervescence; dose subsequently reduced to 40 mg/kg/day to complete a 14-day regimen • Ceftriaxone, adults: IV, given over 30 min, 2 g once/day for 3 days

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Acharya 1995 (Continued)

Ceftriaxone, children: IV, given over 30 min, 50 mg/kg once/day for 3 days. Children > 40 kg in weight were dosed as for adults

Outcomes	<ul style="list-style-type: none"> Clinical cure: resolution of fever, clinical symptoms and signs; no need for re-treatment; no relapse during trial period Bacteriological cure: blood culture negative at end of treatment Relapse: return of fever with isolation of <i>S typhi/paratyphi</i> within 2 months of starting therapy Treatment failure: persistence of fever with no other cause, or persistent bacteraemia Adverse events: adverse drug reactions such as urticaria/rash, phlebitis, nausea and vomiting were monitored daily until discharge from hospital Faecal carriage: culture on day 21 after start of treatment Haematologic measurements (haemoglobin, white cell count and platelets) days 4 and 15 after start of treatment
Organism type and antimicrobial susceptibility	<p><i>S typhi</i> = 38 (16 in ceftriaxone group, 22 in chloramphenicol group); <i>S paratyphi A</i> = 8 (7 in ceftriaxone group, 1 in chloramphenicol group)</p> <p>Drug resistance: 1 isolate in ceftriaxone group resistant to chloramphenicol; MDR numbers not reported</p>
Notes	<p>Not possible to separate adult from paediatric data</p> <p>Sponsor: research supported by a grant from F. Hoffman LaRoche and company (Roche pharmaceuticals), manufacturers of ceftriaxone</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Low risk	Serially numbered sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open design
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open design
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants followed up as per protocol
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Research supported by a grant from F. Hoffman LaRoche and company (Roche pharmaceuticals), manufacturers of ceftriaxone

Arjyal 2016

Study characteristics

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: 18 September 2011-14 July 2014</p> <p>Duration of follow-up: 6 months</p>
Participants	<p>Setting: presenting to the outpatient or emergency department of Patan Hospital or the Civil Hospital</p> <p>Location: Lalitpur, Nepal</p> <p>Age: 2-45 years; median age 20 (IQR 14-23.5 years) in ceftriaxone group 19 (IQR 15-23 years) in gatifloxacin group</p> <p>Gender: male = 180, female = 59</p> <p>Health status of participants: not recorded</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • body temperature at least 38.0 °C for ≥ 4 days • no focus of infection as assessed by physical examination and laboratory tests • ability to give written, informed consent (from parent or guardian if patient < 18 years) <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • pregnancy • diabetes mellitus • signs of severe typhoid (e.g., obtundation, shock, clinical jaundice, active gastrointestinal bleeding) • history of hypersensitivity to either of the trial drugs, or had been given a fluoroquinolone, a third-generation cephalosporin, or macrolide within the previous week. • Patients who had received chloramphenicol, amoxicillin, or co-trimoxazole within the previous week if the treating clinician reported a clinical response
Interventions	<ul style="list-style-type: none"> • Gatifloxacin 10 mg/kg/day, oral, 7 days • Ceftriaxone 60 mg/kg/day to 2 g/day if 2-13 years old, IV, 7 days OR ceftriaxone 2 g/day if ≥ 14 years, IV, 7 days
Outcomes	<p>Primary endpoint was a composite of treatment failure as ≥ 1 of:</p> <ul style="list-style-type: none"> • prolonged fever clearance time > 7 days after treatment initiation (fever clearance time defined as the time from the first dose of the trial drug until the temperature fell to ≤ 37.5 °C and remained there for at least 2 days) • need for rescue treatment as judged by treating physician • positive blood culture on day 8 of treatment (microbiological failure) • culture-confirmed or syndromic enteric fever relapse within 28 days of treatment initiation • development of enteric fever-related complications (e.g. clinically significant bleed, fall in GCS, GI perforation, admission to hospital within 28 days of treatment initiation) <p>Secondary endpoints were:</p> <ul style="list-style-type: none"> • fever clearance time • time to relapse until day 28 or at any time during follow-up • confirmed and syndromic relapse at day 28 • faecal carriage of <i>S typhi</i> or <i>S paratyphi</i> at 1 month, 3 months, or 6 months after randomization assessed in culture-positive participants only
Organism type and antimicrobial susceptibility	<p><i>S typhi</i> = 81 (43 in gatifloxacin group and 38 in ceftriaxone group); <i>S paratyphi</i> = 35 (19 in gatifloxacin group and 16 in ceftriaxone group). 14 of the 81 <i>S typhi</i> isolates were resistant to gatifloxacin (MIC > 1 µg/mL). None of the isolates were resistant to ceftriaxone.</p>

Arjyal 2016 (Continued)

Notes

725 patients were screened for the trial, with 246 enrolled and randomized. 479 were ineligible, because of being in receipt of antibiotics in the week before trial entry (n = 178), refusal of consent (n = 163), outside the age criteria (n = 53), could not arrange to be followed up (n = 64), pregnant or lactating (n = 6), or other reasons (n = 15). 7 patients were excluded after randomization because of refusing IV medication (n = 3), an alternative diagnosis was confirmed (n = 3), and dropped out before a single dose (n = 1) leaving 239 participants analysed by ITT. 120 participants assigned to receive gatifloxacin, and 62 of these were culture-positive; 119 were assigned to receive ceftriaxone and 54 of these were culture-positive. The trial was designed to randomly assign 300 patients to treatment. The trial was halted prematurely on clinical grounds following the recommendation of the Data and Safety Monitoring Board following the appearance of gatifloxacin-resistant strains and resulting treatment failures.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients were randomized in blocks of 100 from a computer generated randomization list, by an investigator not involved in patient recruitment or assessment."
Allocation concealment (selection bias)	Low risk	"The randomization sequence and block size was concealed from the physicians allocating treatment and managing the patients, prior to patient enrollment. Treatment allocations were kept in sealed opaque envelopes, which were opened only on enrollment of the patient to the trial after all inclusion and exclusion criteria had been checked."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	7 participants dropped out of the trial
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Low risk	No conflicts of interest reported; trial sponsor and funder had no involvement in trial design, process, analyses, or write-up

Bhutta 1994
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: June 1991-May 1992 Duration of follow-up: 12 weeks after cessation of therapy
Participants	Setting: hospital paediatric services Location: Karachi, Pakistan

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Bhutta 1994 (Continued)

Age: children 6 months-13 years of age. Mean age (+/- SD) was 8.4 (+/- 3.1) in ceftriaxone group, 6.6 (+/- 3.5) in cefixime group

Gender: male = 31, female = 19

Health status of participants: not recorded

Inclusion criteria:

- suspected MDR-typhoid, with clinical features suggestive of typhoid and no response to treatment with oral chloramphenicol, amoxicillin or co-trimoxazole for at least 7 days and/or history of close contact with an MDR-culture-positive case

Exclusion criteria:

- vomiting, abdominal distension, ileus, or preceding ceftriaxone or cefixime therapy in the preceding week

Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 60 mg/kg/day once daily for 14 days • Cefixime: oral, 5 mg/kg/day twice daily for 14 days
Outcomes	<ul style="list-style-type: none"> • Treatment failure: persistent pyrexia (≥ 38.5 °C for ≥ 24 h) and toxicity after 10 days of therapy • Time to fever clearance (defervescence): temperature of ≤ 37.5 °C after 48 h of therapy • Relapse: recurrence of clinical features of illness and a positive blood culture within 8 weeks of cessation of therapy • Microbiological failure: not strictly defined, but mentioned as an outcome • Typhoid morbidity score: defined as 0-2 on the basis of fever, sensorium, hepatomegaly, presence of diarrhoea and vomiting, abdominal pain, abdominal examination • Times to loss of irritability, abdominal pain, regression of splenomegaly • Adverse events: monitored during the course of therapy - clinical and laboratory values (not specified)
Organism type and antimicrobial susceptibility	<i>S typhi</i> only. 50/59 children had MDR-typhoid following susceptibility testing.
Notes	80 children with suspected MDR admitted; typhoid confirmed on blood/bone marrow cultures in 59 cases, 9 of which were fully susceptible. Only MDR cases completed protocol and included in outcome analysis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details on randomization process given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias)	Low risk	All participants followed up as per protocol

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Bhutta 1994 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Low risk	No other obvious reasons for bias identified

Bhutta 2000
Study characteristics

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: unclear</p> <p>Duration of follow-up: unclear</p>
Participants	<p>Setting: hospital paediatric services</p> <p>Location: Karachi, Pakistan</p> <p>Age: all children</p> <p>Mean age (+/- SD) was 7.1 (+/- 3.7) in short-course (7 days) ceftriaxone group, 5.6 (+/- 33.4) in conventional (14 days) ceftriaxone group</p> <p>Gender: male = 32, female = 25</p> <p>Health status of participants: not recorded</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> proven MDR typhoid <p>Exclusion criteria:</p> <ul style="list-style-type: none"> none listed
Interventions	<ul style="list-style-type: none"> Ceftriaxone: IV, 65 mg/kg/day once daily for 7 days Ceftriaxone: IV, 65 mg/kg/day once daily for 14 days
Outcomes	<ul style="list-style-type: none"> Clinical failure: persistence of fever along with a <2-point reduction in typhoid morbidity score by day 7 of therapy Time to defervescence: not defined, but results given as an outcome measure Relapse: recurrence of fever along with a positive blood culture for <i>S typhi</i> with a similar antibiogram to the original infecting strain within 8 weeks of the completion of therapy Bacteriological failure: persistence of <i>S typhi</i> in cultures obtained at day 3 or after Typhoid morbidity score - admission, day 3, day 7: score of 0-2 given based on fever, mental state, liver size, diarrhoea, vomiting, abdominal pain and abdominal examination result Time to return of appetite: measured in days Adverse events: not specified
Organism type and antimicrobial susceptibility	MDR- <i>S typhi</i>
Notes	118 consecutive children admitted; alternative diagnosis established in 87 and non-MDR <i>S typhi</i> in 19. 5 children were treated with amoxicillin on the basis of a Widal test, but were culture-negative.

Bhutta 2000 (Continued)

Sponsor: research was supported by an unrestricted grant from Roche pharmaceuticals, the manufacturers of ceftriaxone

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomization used
Allocation concealment (selection bias)	Low risk	Sealed envelopes used
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants followed up as per protocol
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Research was supported by an unrestricted grant from Roche pharmaceuticals, the manufacturers of ceftriaxone

Butler 1993
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: unclear Duration of follow-up: unclear
Participants	Setting: hospital services Location: Kathmandu, Nepal Age: adults ≥ 18 years of age Mean age (+/- SD) was 23.4 (+/- 5.9) in ceftriaxone group, 24.2 (+/- 7.6) in chloramphenicol group Gender: male = 28, female = 1 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • age • ≥ 4 days of preceding fever and

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Butler 1993 (Continued)

- ≥ 2 of the following features:
 - temperature ≥ 38 °C
 - diarrhoea
 - splenomegaly
 - hepatomegaly
 - rose spots

Exclusion criteria:

- effective antimicrobial therapy in the preceding 2 weeks
- allergy to chloramphenicol or cephalosporins
- presence of complicated disease (shock, coma, rectal bleeding, suspected intestinal perforation listed)

Interventions

- Ceftriaxone: IV, 2 g administered over 30 min once daily for 3 consecutive days
- Chloramphenicol: oral, 50 mg/kg/day divided into 4 doses for 14 days

Outcomes

- Clinical cure: afebrile without a major complication (perforation or bleeding), without the need to change antibiotic therapy and no relapse after discharge
- Time to defervescence: the first day the oral temperature fell to < 38 °C for at least 48 h
- Relapse: return of symptoms with isolation of *S typhi* or *S paratyphi A* in the blood within 2 months after the start of therapy
- Bacteriological cure: negative blood culture on days 4 and 15 after start of therapy
- Faecal carriage: faecal cultures performed on days 0, 7, 15 and 21 after start of therapy
- Cytokine measurements: IL-6, gamma interferon, TNF-R concentrations in plasma measured before therapy commenced, on day 4 of therapy and on day 15 of therapy
- Adverse events: not prespecified, discussed as part of results

Organism type and antimicrobial susceptibility

S typhi = 23; *S paratyphi A* = 6. 29 isolates susceptible to ceftriaxone, 28 isolates susceptible to chloramphenicol

Notes

Only data from blood/faecal culture-positive participants included in the analysis

Sponsor: the research was supported by a grant from Hoffman-La Roche pharmaceuticals, who manufactured ceftriaxone.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random numbers table used
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Butler 1993 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants followed up as per protocol
Selective reporting (reporting bias)	High risk	The prespecified outcome of time to defervescence was not reported
Other bias	Unclear risk	The research was supported by a grant from Hoffman-La Roche pharmaceuticals, who manufactured ceftriaxone

Cao 1999
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: July 1995-April 1996 Duration of follow-up: 28 days after completion of treatment
Participants	Setting: hospital paediatric ward Location: Dong Nai, Vietnam 82 participants Age: children \leq 15 years of age Mean age was 6.9 years (SD 3.3. years) Gender: reported as "equal" Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • age • \geq 7 days of preceding fever without contact history • typhoid contact history • Widal O antibody titre of \geq 100 Exclusion criteria: <ul style="list-style-type: none"> • severe disease requiring intensive care • hypersensitivity to third-generation cephalosporins or quinolones • pre-treatment with third-generation cephalosporin or quinolone during this illness • pre-treatment and clinical response with chloramphenicol, ampicillin, first-/second-generation cephalosporins, co-trimoxazole
Interventions	<ul style="list-style-type: none"> • Ofloxacin: oral, 10 mg/kg/day in 2 divided doses for 5 days • Cefixime: oral, 20 mg/kg/day in 2 divided doses for 7 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure: resolution of symptoms and fever, and no evidence of relapse

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Cao 1999 (Continued)

- Clinical failure: deterioration in clinical condition or a failure of resolution of symptoms requiring further treatment
- Microbiological failure: blood culture positive for *S typhi* after completion of treatment
- Relapse: symptoms suggestive of typhoid fever with a blood culture positive for *S typhi* during the 28 days after discharge
- Fever clearance time: time from onset of treatment until fever ≤ 37.5 °C for at least 24 h
- Day at which child able to eat and walk
- Adverse events: not prespecified, discussed as part of response to treatment
- Faecal culture: 28 days after treatment (3 cultures taken)

Organism type and antimicrobial susceptibility	Resistance to ampicillin, chloramphenicol, co-trimoxazole and tetracycline in 70 isolates; no resistance to nalidixic acid or trial drugs detected
Notes	Analysis limited to culture-confirmed cases of infection. 138 participants with clinically suspected typhoid fever; 82 had blood cultures positive for <i>S typhi</i> . Sponsor: Roussel-Uclaf pharmaceuticals donated the ofloxacin tablets used in the trial

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation method not specified
Allocation concealment (selection bias)	Low risk	Serially numbered sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	High risk	1 participant in cefixime group lost to follow-up early (microbiological failure). At 28 days, only 40 participants were available for assessment (exact breakdown unclear)
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Roussel-Uclaf pharmaceuticals donated the ofloxacin tablets used in the trial.

Frenck 2000
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: unclear Duration of follow-up: 4 weeks
---------	--

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Frenck 2000 (Continued)

Participants	<p>Setting: hospital</p> <p>Location: Cairo, Egypt</p> <p>Age: all children 4-17 years of age</p> <p>Mean age (+/- SD) was 9.8 (+/- 2.8 years) overall; in ceftriaxone group, 10.1 (range: 5-14) in azithromycin group</p> <p>Gender: male = 53, female = 55</p> <p>Health status of participants: some underlying illnesses part of exclusion criteria</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • age • documented fever $\geq 38.5^{\circ}\text{C}$ • history of fever for at least 4 days + • at least 2 of the following: <ul style="list-style-type: none"> ◦ abdominal tenderness ◦ hepatomegaly ◦ splenomegaly ◦ rose spots <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • allergy to ceftriaxone, erythromycin or other macrolides • major complications of typhoid fever (e.g. pneumonia, intestinal haemorrhage or perforation, shock, coma) • inability to swallow oral medications • significant underlying illness (e.g. heart disease, asthma requiring chronic medications, immunodeficiencies), • treatment within the last 4 days with either trial medication, or chloramphenicol, co-trimoxazole, or ampicillin • possible pregnancy/lactation
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IM with 1% lidocaine, 75 mg/kg/day once daily (maximum dose 2.5 g) for 7 days • Azithromycin: oral suspension, 10 mg/kg/day once daily (maximum dose 500 mg/day) for 7 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure: resolution of all typhoid-related symptoms or signs by the end of 7 days of therapy • Clinical failure: persistence ≥ 1 typhoid-related symptoms or signs present at trial entry, or as development of a typhoid-related complication after at least 4 days of therapy • Microbiological cure: sterile blood culture on days 4 and 10 of therapy • Relapse: recurrence of fever with signs or symptoms of typhoid fever within 4 weeks of completion of therapy along with isolation of <i>S typhi</i> or <i>S paratyphi</i> from blood culture • Fever clearance time: rectal temperature not $> 38.4^{\circ}\text{C}$ during any 24-h period • Mean laboratory values on day 10 of treatment - full blood count, liver and renal function tests • Blood culture results day 4 and 10 • Faecal culture result day 10 • Adverse events: structured questionnaire administered daily during hospitalization to monitor symptoms (including fever, headache, rash, abdominal pain, constipation, diarrhoea and/or anorexia and other possible adverse events)
Organism type and antimicrobial susceptibility	All <i>S typhi</i> ; 6 MDR- <i>S typhi</i> in ceftriaxone and 5 MDR- <i>S typhi</i> in azithromycin group
Notes	108 individuals enrolled and randomized; data evaluated for only 64 children (34 in azithromycin and 30 in ceftriaxone groups) who were positive for <i>S typhi</i> on blood culture.

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Frenck 2000 (Continued)

Sponsor: financial support from Pfizer Pharmaceuticals

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomization from random list of numbers
Allocation concealment (selection bias)	Low risk	Serially numbered envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	4 azithromycin recipients and 2 ceftriaxone recipients lost to follow-up after hospital discharge
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Financial support from Pfizer Pharmaceuticals

Frenck 2004

Study characteristics

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: unclear</p> <p>Duration of follow-up: 4 weeks</p>
Participants	<p>Setting: hospital</p> <p>Location: Cairo, Egypt</p> <p>Age: all children 3-17 years of age</p> <p>Mean age: 10.8 (+/- 3.35) in ceftriaxone group, 11.8 (+/- 3.6) in azithromycin group</p> <p>Gender: male = 39, female = 29</p> <p>Health status of participants: "significant underlying illness" part of exclusion criteria</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • age • documented fever (rectal temperature ≥ 38.0 °C/oral temperature ≥ 37.5 °C and • at least 2 of the following: <ul style="list-style-type: none"> ◦ abdominal tenderness

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Frenck 2004 (Continued)

- hepatomegaly
- splenomegaly
- a coated tongue

Exclusion criteria:

- allergy to ceftriaxone or macrolides
- major typhoid fever-associated complications
- inability to swallow oral medication
- significant underlying illness
- treatment within the last 4 days with an antibiotic that may be effective against *S typhi*
- possible pregnancy/lactation

Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 75 mg/kg/day once daily (maximum dose 2.5 g) for 5 days • Azithromycin: oral suspension, 20 mg/kg/day once daily (maximum dose 1000 mg/day) for 5 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure: resolution of all typhoid-related symptoms or signs by the end of 7 days of therapy • Clinical failure: persistence of ≥ 2 typhoid-related symptoms or signs present at trial entry, or as development of a typhoid-related complication • Clinical improvement: defined as partial resolution of illness • Microbiological failure: presence of an <i>S typhi</i>-positive blood culture on day 8 of the trial • Microbiological cure: sterile blood culture on day 8 of therapy (3 days after discontinuation of antibiotic therapy) • Persistent bacteraemia: defined as <i>S typhi</i> in blood culture on day 3 after initiating antibiotic therapy • Clinical relapse: recurrence of fever and clinical features of typhoid within 30 days of completion of therapy along with isolation of <i>S typhi</i> from blood culture • Duration of fever: fever defined as rectal temperature $> 38^{\circ}\text{C}$ or oral temperature $> 37.5^{\circ}\text{C}$, absence for clearance not defined, reported as mean number of days • Blood culture positive: blood culture positive for <i>S typhi</i> on day 3/day 8 of the trial • Faecal culture positive: faecal culture positive for <i>S typhi</i> on day 8/day 30 of the trial • Mean laboratory values on day 10 of treatment: full blood count, liver and renal function tests • Adverse events: serious - not defined; minor - listed in results as vomiting, diarrhoea, nausea, abdominal pain, anorexia and cough
Organism type and antimicrobial susceptibility	<i>S typhi</i> - all participants; <i>S paratyphi</i> not included. 1 isolate was MDR; no isolate resistant to ceftriaxone
Notes	<p>128 enrolled; 68 had <i>S typhi</i> isolated from blood or stool culture and constituted the trial group</p> <p>Sponsor: financial support from Pfizer pharmaceuticals</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number generation for blocks of 8 participants
Allocation concealment (selection bias)	Low risk	Serially numbered sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Frenck 2004 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	High risk	11/68 (16.2%) participants lost to follow-up
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Financial support from Pfizer pharmaceuticals

Girgis 1990
Study characteristics

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: 1987-1989</p> <p>Duration of follow-up: 4 weeks</p>
Participants	<p>Setting: hospital</p> <p>Location: Cairo, Egypt</p> <p>Age: adults and children. Mean age (+/- SD) was 13.65 (+/- 7.22) overall</p> <p>Gender: male = 31, female = 24</p> <p>Health status of participants: not recorded</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> signs and symptoms suggestive of acute enteric fever
Interventions	<ul style="list-style-type: none"> Ceftriaxone: IM, dissolved in 2% lidocaine 60-80 mg/kg/day (maximum of 4 g) once daily for 5-7 days Chloramphenicol: oral, 50-80 mg/kg/day in 4 divided doses for 12-14 days
Outcomes	<ul style="list-style-type: none"> Clinical cure: resolution of fever, clinical symptoms and signs; no need for re-treatment; no relapse during trial period Bacteriological cure: blood, urine and stool culture negative at end of treatment Relapse: return of fever with isolation of <i>S typhi</i>/<i>S paratyphi</i> during 4-week follow-up period Treatment failure: persistence of fever with no other cause, or persistent bacteraemia Time to fever clearance: number of days until disappearance of fever, afebrile defined as 37.5 °C Adverse events: not pre-defined, listed as mild (diarrhoea, abdominal pain, injection site pain) Laboratory analyses: Widal test, full blood count, glucose, renal function test and liver function tests Time to resolution of specific symptoms and signs: headache, mental changes, abdominal pain, splenomegaly, hepatomegaly
Organism type and antimicrobial susceptibility	<p><i>S typhi</i> in 25 participants on ceftriaxone, and 27 participants on chloramphenicol. <i>S paratyphi</i> in 3 participants on chloramphenicol</p> <p>All isolates susceptible to ceftriaxone and chloramphenicol</p>

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Girgis 1990 (Continued)

Notes 74 initially randomized; only those with *S typhi/S paratyphi* in blood cultures were included in the analysis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data reported for all stipulated outcome measures
Selective reporting (reporting bias)	High risk	Duration of hospitalization prespecified as an outcome, however no specific values reported
Other bias	Low risk	No obvious conflicts of interest

Girgis 1995
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: unclear, before 1995 Duration of follow-up: 4 weeks
Participants	Setting: hospital Location: Cairo, Egypt Age: children < 16 years. Mean age (+/- SD) was 10.34 (+/- 2.89) in cefixime group, 10.05 (+/- 3.48) in ceftriaxone group, 9.03 (+/- 9.1) in the aztreonam group Gender: male = 67, female = 57 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> signs and symptoms suggestive of acute enteric fever without complications of disease
Interventions	<ul style="list-style-type: none"> Cefixime: oral, 15-20 mg/kg/day in 2 doses for a minimum of 14 days Ceftriaxone: IM in gluteal region, 50-70 mg/kg/day (maximum of 4 g) once daily for 5 days

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Girgis 1995 (Continued)

- Aztreonam: IM in gluteal region, 50-70 mg/kg/dose (maximum of 8 g) every 8 h for 3 days

Antibiotics continued beyond period specified until 2 afebrile days were observed

Outcomes	<ul style="list-style-type: none"> • Clinical cure: definition not specified • Bacteriologic eradication: not specified, but blood, urine and stool cultures taken before therapy, at end of day 3 of therapy, and 2 and 4 weeks post-therapy • Time to defervescence: days until disappearance of fever (afebrile defined as fever < 37.5 °C) • Length of hospital stay: not defined • Mean laboratory values on day 10 of treatment - full blood count, liver and renal function tests before treatment, end of therapy and 2 and 4 weeks post-therapy • Cost analysis of therapy: calculated according to the method specified in Kerr 1992 • Adverse events: not predefined, "side reactions" and adverse events discussed as part of results
Organism type and antimicrobial susceptibility	All MDR- <i>S typhi</i> (resistant to chloramphenicol, ampicillin and co-trimoxazole by disk diffusion)
Notes	165 children enrolled and randomized, but only analysed those 124 participants with MDR- <i>S typhi</i> who completed 4 weeks of follow-up

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Computer-generated" list for randomization
Allocation concealment (selection bias)	Unclear risk	No mention of methods
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	High risk	Some loss to follow-up - exact numbers not clearly reported
Selective reporting (reporting bias)	High risk	Length of hospital stay prespecified as an outcome measure but no clear data were reported Data for culture results at various time points were not reported
Other bias	Low risk	No obvious conflicts of interest reported

Islam 1988
Study characteristics

Methods	Trial design: randomized
---------	--------------------------

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Islam 1988 (Continued)

Time period/duration of trial: June 1984-December 1985

Duration of follow-up: 1 week from date of discharge

Participants

Setting: International Centre for Diarrhoeal Disease Research

Location: Dhaka, Bangladesh

Age: all individuals 6 months-60 years of age (29 adults, 34 children < 16 years of age). Mean age (+/- SD) was 14.6 (+/- 7.4) in chloramphenicol group and 14.7 (+/- 8.2) in ceftriaxone group

Gender: male = 45, female = 18

Health status of participants: not recorded

Inclusion criteria:

- age
- fever for ≥ 4 days
- diarrhoea (at least 3 liquid stools in the preceding 24 h)
- abdominal pain or tenderness
- O agglutinin titre for *S typhi* ≥ 80

Exclusion criteria:

- history of effective antimicrobial therapy within 1 week before hospitalization
- known allergy to penicillin or cephalosporin
- other complications (including GI haemorrhage or perforation, or jaundice)

Interventions

- Ceftriaxone: IV over 30 min, 3 or 4 g for adults and 75 mg/kg/day for children once daily for 7 days
- Chloramphenicol: oral or IV, 60 mg/kg/day in 4 doses until defervescence, then 40 mg/kg/day in 4 divided doses to complete 14 days of therapy

Outcomes

- Clinical cure: if survived, became afebrile without a major complication (perforation, bleeding), did not require treatment for typhoid fever and did not relapse before discharge
- Bacteriologic eradication: blood cultures negative at end of therapy
- Time to defervescence: first afebrile day the participant's rectal temperature dropped to ≤ 37.8 and remained there for > 48 h
- Relapse: return of symptoms and *S typhi* in blood cultures within 2 months after the start of therapy
- Length of hospital stay: not assessed
- Haematologic responses on day 7 and 14 after start of treatment
- End of diarrhoea: defined as day the last liquid stool was passed
- Drug concentrations on treatment: measured using high-performance liquid chromatography on days 3 and 7 of treatment
- Cultures: blood cultures day 3 and 14; faecal culture days 7 and 14
- Adverse events: monitored for urticaria, rashes, nausea, vomiting and phlebitis during therapy; specific complications reported included pneumoniae, peritonitis and intestinal perforation

Organism type and antimicrobial susceptibility

All *S typhi*, no MDR

Notes

Only those with blood or stool cultures positive for *S typhi* were studied.

Sponsor: research supported by a grant from Hoffmann-La Roche, manufacturers of ceftriaxone

Risk of bias

Bias

Authors' judgement

Support for judgement

Islam 1988 (Continued)

Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Unclear risk	Research supported by a grant from Hoffmann-La Roche, manufacturers of ceftriaxone

Islam 1993
Study characteristics

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: 1986-1987</p> <p>Duration of follow-up: 1 week from date of discharge</p>
Participants	<p>Setting: International Centre for Diarrhoeal Disease Research</p> <p>Location: Dhaka, Bangladesh</p> <p>Age: all individuals 6 months-60 years of age. Mean age was 18 years (3.5-35 years) in ceftriaxone group, and 18 years (2-35 years) in the chloramphenicol group</p> <p>Gender: male = 32, female = 27</p> <p>Health status of participants: not recorded</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • age • fever for ≥ 4 days • diarrhoea (at least 3 liquid stools in the preceding 24 h) • abdominal pain or tenderness • O agglutinin titre for <i>S typhi</i> ≥ 80 <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • history of recent antimicrobial therapy • known allergy to penicillin or cephalosporin

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Islam 1993 (Continued)

	<ul style="list-style-type: none"> • other complications (including gastrointestinal haemorrhage or perforation, or jaundice)
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV over 30 min, 4 g for adults (> 14 years) and 75 mg/kg/day for children once daily for 5 days • Chloramphenicol: oral or IV, 60 mg/kg/day in 4 doses until defervescence, then 40 mg/kg/day in 4 divided doses to complete 14 days of therapy
Outcomes	<ul style="list-style-type: none"> • Clinical cure: if survived, became afebrile (temp \leq 37.8 by day 7 of treatment) without a major complication (perforation, bleeding), did not require treatment for typhoid fever and did not relapse before discharge • Bacteriologic eradication: blood cultures negative at end of therapy • Time to defervescence: first afebrile day the patient's rectal temperature dropped to \leq 37.8 and remained there for > 48 h • Relapse: return of symptoms after treatment was completed and <i>S typhi</i> in blood/stool cultures within 2 weeks of start of therapy • Cultures: blood culture on days 3 and 14 of treatment; faecal culture on days 5, 14 of treatment and 1 week after hospital discharge • Haematologic responses on day 5 and 14 after start of treatment • End of diarrhoea: day the last liquid stool was passed • Drug concentrations on treatment • Adverse events: not prespecified, reported as found. Pneumonia and urinary tract infection reported on specifically.
Organism type and antimicrobial susceptibility	All <i>S typhi</i>
Notes	Only those with blood and/or stool cultures positive for <i>S typhi</i> were studied.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up described
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Low risk	No obvious conflicts of interest

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Kumar 2007
Study characteristics

Methods	Trial design: prospective, randomized, controlled, parallel trial Time period/duration of trial: May 2002-April 2004 Duration of follow-up: 3 months
Participants	Setting: Department of Paediatrics, Batra Hospital and Medical Research Centre Location: New Delhi, India Age: 0-12 years Gender: male = 40, female = 22 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> clinical presentation of typhoid fever without localising signs and a positive blood culture for <i>S typhi</i> informed consent Exclusion criteria: <ul style="list-style-type: none"> effective antibiotic therapy 1 week prior to admission known allergy to penicillin/chloramphenicol/quinolones/cephalosporins immunization with typhoid vaccine
Interventions	All given chloramphenicol (75 mg/kg/day) by oral or IV route until culture results known <ul style="list-style-type: none"> Ofloxacin: 20 mg/kg/day; number of doses/route of administration/duration not specified Ceftriaxone: 100 mg/kg/day; number of doses/route of administration/duration not specified
Outcomes	<ul style="list-style-type: none"> Clinical cure: no deterioration and response to treatment within 7-10 days of starting specific therapy Time to defervescence: time interval from starting an appropriate antimicrobial chemotherapy until the documentation of normal body temperature Relapse: defined as fever or complications in 3 months of follow-up Complications: unclear whether these were considered outcomes of treatment or specific complications of underlying infection
Organism type and antimicrobial susceptibility	All MDR <i>S typhi</i>
Notes	99 blood-culture-proven <i>S typhi</i> cases, 62 of which were MDR <i>S typhi</i> . Only MDR <i>S typhi</i> cases considered for randomization

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Kumar 2007 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	High risk	No breakdown of complication/adverse events data for treatment groups
Other bias	Unclear risk	Conflicts of interest not reported

Lasserre 1991
Study characteristics

Methods	Trial design: RCT Time period/duration of trial: July 1985-May 1987 Duration of follow-up: minimum of 21 days after the end of treatment
Participants	Setting: San Lazaro Hospital Location: Manila, Philippines Age: "Adult" patients Gender: male = 31, female = 28 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> clinical signs and symptoms compatible with uncomplicated typhoid fever (absence of intestinal bleeding, perforation or pneumonia) blood culture positive for <i>S typhi</i> or <i>S paratyphiA</i> or <i>B</i> Exclusion criteria: <ul style="list-style-type: none"> none specified (specifically mention that prior antibiotic treatment and severe disease were not reasons for exclusion)
Interventions	<ul style="list-style-type: none"> Ceftriaxone: IV over 10-15 min, 3 g/day once daily for 3 days Ceftriaxone: IV over 10-15 min, 4 g/day once daily for 3 days Chloramphenicol: orally, 3 g/day in 4 divided doses for first 2 days and then 2 g/day for 12 days
Outcomes	<ul style="list-style-type: none"> Clinical cure: disappearance of clinical signs of typhoid fever, absence of complications such as bleeding or perforation and negative blood, urine and stool cultures at the end of treatment Time to defervescence: axillary temperature < 37.5 °C for at least 48 h Relapse: reappearance of fever and a positive blood culture within 3 weeks after completing antibiotic therapy Culture: blood and urine cultures days 3, 4, 8 and 15 of treatment. Faecal cultures on 3 consecutive days at end of treatment and days 8, 15 in ceftriaxone group; days 3, 4 and 8 of treatment and 3 consecutive days at end of treatment in chloramphenicol group Disappearance of toxic signs was defined by 2 of the following: restoration of appetite, regression of fatigue and cessation of headache "Standard" laboratory blood and urine tests at end of treatment Reinfection: reappearance of typhoid after 3 weeks Adverse events: not prespecified, discussed as part of results section

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Lasserre 1991 (Continued)

Organism type and antimicrobial susceptibility *S typhi* = 55 (MDR *S typhi* = 0), *S paratyphi* = 6. All strains susceptible to ceftriaxone and chloramphenicol

Notes Antibiotic treatment started at the time the blood culture was positive - trial authors note this was usually around the third or 4th day of hospitalization

Excluded 2 participants in group 1 - 1 had only 2 days of follow-up after treatment, and 1 because of a skin rash and switch in therapy to chloramphenicol

Sponsor: ceftriaxone provided by Hoffman-La Roche pharmaceuticals

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Computerised randomisation list"
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Loss to follow-up of 1 case. This lost case was excluded from the analysis.
Selective reporting (reporting bias)	Unclear risk	"Standard laboratory blood and urine tests were performed just before antibiotic treatment and the day following its termination". No further details on this testing were reported.
Other bias	Unclear risk	Ceftriaxone provided by Hoffman-La Roche pharmaceuticals

Memon 1997
Study characteristics

Methods	Trial design: prospective, RCT Time period/duration of trial: November 1993-October 1994 Duration of follow-up: 2 weeks after the completion of antibiotic therapy
Participants	Setting: Department of Paediatrics, Civil Hospital and Lyari General Hospital Location: Karachi, Pakistan Age: all patients < 15 years of age Gender: male = 59, female = 26 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> probable clinical diagnosis of enteric fever (fever > 5 days, nausea, vomiting, hepatomegaly, splenomegaly, hepatic tenderness)

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Memon 1997 (Continued)

- ability to take oral medications

Exclusion criteria:

- antibiotic use in the preceding 72 h
- allergy to trial antibiotics
- previous documentation of resistance to trial antibiotics
- concomitant infection (e.g. TB, UTI, malaria, other liver disease)

Interventions	<ul style="list-style-type: none"> • Cefixime: route of administration unspecified, 10 mg/kg/day to 12 mg/kg/day in 2 divided doses for 2 weeks • Chloramphenicol: route of administration unspecified, 100 mg/kg/day in 4 divided doses for 2 weeks
Outcomes	<ul style="list-style-type: none"> • Clinical cure: failure of antibiotic therapy defined as persistence of fever and/or clinically toxic appearance even after 7 days of antibiotic therapy; participants then switched to other treatment group • Time to defervescence: defervescence defined as body temperature < 38 °C for 24 h without use of anti-pyretics • Relapse: not defined, reported as part of the results • Laboratory parameters: tests taken not prespecified, reported on only in discussion: "None of the patients had elevated liver enzymes at the end of therapy" • Cost of therapy: calculated as cost of antibiotic given to each participant according to the manufacturer's suggested retail price • Adverse events: not prespecified, reported as part of results
Organism type and antimicrobial susceptibility	Exact breakdown unclear, but 66/85 isolates were MDR <i>Salmonella</i> species. Only 11 strains susceptible to chloramphenicol, amoxicillin and cotrimoxazole. Unclear what proportion of participants with chloramphenicol-resistant isolates were being treated in the chloramphenicol arm
Notes	242 evaluated as probable cases; 140 had no microbiologic confirmation or had other exclusion criteria. 17 participants with culture-proved enteric fever did not complete trial in accordance with protocol or were lost to follow-up. 85 completed trial and evaluated. Those that failed in each group were then treated with the other antibiotic being evaluated, or ceftriaxone as third-line treatment (n = 2)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	High risk	17/85 (20%) participants did not complete trial as per protocol or were lost to follow-up

Memon 1997 (Continued)

Selective reporting (re-reporting bias)	High risk	At least half of outcomes not prespecified or reported on
Other bias	Low risk	No conflicts of interest reported

Moosa 1989
Study characteristics

Methods	Trial design: prospective, randomized, open Time period/duration of trial: unclear, before June 1989 Duration of follow-up: unclear, at least 6 weeks after initial eradication
Participants	Setting: admitted to children's ward at King Edward VII Hospital Location: Durban, South Africa Age: not defined - "children" Gender: male = 6, female = 23 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • bacteriologically confirmed typhoid fever Exclusion criteria: <ul style="list-style-type: none"> • no organisms grown from pretherapy cultures • on concomitant antibiotics • severe disease (e.g. shock) or complications or severe renal impairment • known hypersensitivity to penicillins or cephalosporins
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IM with 1% lidocaine, approximately 80 mg/kg/day for 5 days • Chloramphenicol: oral, 50 mg/kg/day in 4 divided doses for 3 weeks
Outcomes	<ul style="list-style-type: none"> • Clinical cure: fever subsided at 5 days and no clinical/bacteriological evidence of infection for 6 weeks • Bacteriologic eradication: not defined • Time to defervescence: time in days until absence of fever (defined as temperature > 37.5 °C) • Relapse: cultures (blood, urine or faeces) positive within 6 weeks after initial eradication with or without return of clinical symptoms • Clinical improvement: condition improved, blood culture negative by day 3 but fever persisted for > 5 days) • Treatment failure: signs and symptoms of infection remained unchanged or worsened or if cultures not negative by day 7 • Laboratory parameters: full blood count, liver enzymes, urea and electrolytes checked on admission and at least once a week • Cultures: blood culture on admission, days 3 and 7 as a minimum; urine and faecal culture on admission and after completion of therapy • Adverse events: not prespecified, discussed as part of results

Moosa 1989 (Continued)

Organism type and antimicrobial susceptibility *S typhi* = 59 (MDR *S typhi* = not specified), *S paratyphi* = none

Notes 1 participant in trial did not have a positive blood culture (urine and faeces were positive on day 15)

 Blood cultures also positive with other organisms in 4 participants, including *Salmonella enteritidis* and *Shigella* species.

Sponsor: Roche products supplied ceftriaxone and provided "assistance" with the trial

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	No reported loss to follow-up
Selective reporting (reporting bias)	Unclear risk	Data on laboratory tests (blood count, urea etc.) were not reported
Other bias	High risk	Pharmaceutical company Roche supplied ceftriaxone and provided "assistance" with the trial

Morelli 1988
Study characteristics

Methods Trial design: randomized, open
 Time period/duration of trial: January 1985-November 1985
 Duration of follow-up: 8 weeks after treatment

Participants Setting: hospital, Ospedale per Malattie Infettive
 Location: Naples, Italy
 Age: all (mean age 25.9, range: 12-45)
 Gender: male = 36, female = 20
 Health status of participants: not recorded
 Inclusion criteria:

- blood culture positive for *S typhi*,

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Morelli 1988 (Continued)

- "toxic symptomatology"
- fever > 39 °C

Exclusion criteria:

- clinical or laboratory findings suggestive of other infections
- known or suspected hypersensitivity to cephalosporins
- any other antibiotic treatment

Interventions

- Cefoperazone: IV, 2 g in 100 mL of saline every 8 h for adults and 100 mg/kg/day for children; duration unspecified
- Chloramphenicol: oral, 500 mg every 6 h for adults, 50 mg/kg/day for children; duration unspecified

Outcomes

No prespecified outcomes

Blood cultures and faecal cultures taken at start and end of treatment

Organism type and antimicrobial susceptibility

S typhi = 56. Details only on MICs for cefoperazone and chloramphenicol (2 isolates in chloramphenicol treatment group were resistant to cefoperazone)

Notes

Cure, relapse, culture positivity and defervescence time reported on in results, but not defined.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerized list
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up reported
Selective reporting (reporting bias)	Unclear risk	No prespecified outcomes given
Other bias	Unclear risk	Conflicts of interest not reported

Nair 2017

Study characteristics

Methods	<p>Trial design: randomized, open</p> <p>Time period/duration of trial: not stated</p> <p>Duration of follow-up: 30 days after enrolment</p>
Participants	<p>Setting: presenting to Department of Paediatrics, Army College of Medical Sciences, New Delhi, India and admitted to paediatric ward</p> <p>Location: New Delhi, India</p> <p>Age: 3 to 18 years</p> <p>Gender: male = 28, female = 36</p> <p>Health status of participants: not recorded</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • patients with documented fever (a rectal temperature > 38.0 °C or an oral temperature > 37.5 °C) of > 4 days and • having > any 2 of the following symptoms or signs: <ul style="list-style-type: none"> ◦ splenomegaly ◦ hepatomegaly ◦ abdominal tenderness ◦ a coated tongue. • Ability for parent/guardian to give written informed consent. • Only patients with blood and/or stool cultures positive for <i>S typhi</i> were evaluated <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • patients who had inability to swallow oral medications • having major typhoid complications like pneumonia, shock, coma, intestinal haemorrhage, perforation • significant underlying illness • patients who had received antibiotics that were effective against <i>S typhi</i> in the past 4 days • allergic to either ceftriaxone or azithromycin
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 75 mg/kg/day once daily (maximum dose 2.5 g) for 7 days • Azithromycin: oral, 20 mg/kg/day once daily (maximum dose 1000 mg/day) for 7 days
Outcomes	<p>Primary outcome</p> <ul style="list-style-type: none"> • Clinical success - response defined as becoming afebrile within 7 days of starting treatment <p>Secondary outcomes</p> <ul style="list-style-type: none"> • Fever clearance time • Microbiological cure (negative blood culture) by day 7 and day 30 • Relapse: fever with recurrent typhoid-related symptoms within 1 month of completing treatment in a patient who had been successfully treated with or without a positive blood culture. Excluded individuals given prolonged or rescue treatment • Cultures: faecal samples taken at 7 and 30 days • Adverse events: not prespecified, listed in the results
Organism type and antimicrobial susceptibility	<p>64 participants with <i>S typhi</i> isolated from blood cultures. In 6 also cultured from faeces. No information concerning antimicrobial susceptibility pattern</p>
Notes	<p>124 clinical cases of suspected enteric fever, with 64 enrolled and randomized. 58 were ineligible, with an alternative diagnosis within 48 h of admission. 2 participants had taken a fluoroquinolone before admission to hospital. 34 participants assigned to receive ceftriaxone, and 30 assigned to azithromycin</p>

Nair 2017 (Continued)

Participants with positive pre-treatment culture analyses were analysed

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Treatment assignments were determined by block randomization based on a random number list."
Allocation concealment (selection bias)	Low risk	"These were sealed in envelopes by a medical professional uninvolved in the treatment trial. At the time of enrolment, the investigator unsealed the envelope to determine which treatment the subject would receive."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	4 participants did not return for post-treatment follow-up evaluation
Selective reporting (reporting bias)	Unclear risk	Stipulated outcome measures not clearly articulated
Other bias	Low risk	No conflicts of interest reported

Pandit 2007
Study characteristics

Methods	Trial design: randomized, open Time period/duration of trial: 5 June 2005-8 September 2005 Duration of follow-up: 6 months after enrolment
Participants	Setting: presenting to the outpatient or emergency department of Patan Hospital Location: Lalitpur, Nepal Age: 2-65 years; median age 17 (range: 2-64 years) Gender: male = 247, female = 135 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • clinically diagnosed enteric fever • residence within 2.5 km of the hospital • ability to take oral medications • no pregnancy/lactation • no history of seizures • ability to stay in the city for the duration of the treatment • no contraindications to quinolones or cephalosporins • ability to give written informed consent Exclusion criteria:

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Pandit 2007 (Continued)

	<ul style="list-style-type: none"> • signs of complicated typhoid defined as the presence of jaundice, gastrointestinal bleeding, peritonism, shock, encephalopathy, convulsions, myocarditis or arrhythmia at the time of enrolment • receipt of a third-generation cephalosporin, fluoroquinolone or macrolide in the week prior to presentation at the clinic
Interventions	<ul style="list-style-type: none"> • Cefixime: oral, 20 mg/kg/day in 2 divided doses for 7 days • Gatifloxacin: oral, 10 mg/kg/day as a single dose for 7 days
Outcomes	<p>Primary outcome</p> <ul style="list-style-type: none"> • Fever clearance time - time to first drop in oral temperature ≤ 37.5 °C and remaining as such for 48 h <p>Secondary outcomes</p> <ul style="list-style-type: none"> • Acute treatment failure: severe complications, persistence of fever > 38 °C, persistence of symptoms for > 7 days after start of therapy, requirement for additional or rescue treatment • Overall treatment failure: acute treatment failure + relapse + death • Relapse: fever with a positive blood culture within 1 month of completing treatment in a patient who had been successfully treated. Excluded individuals given prolonged or rescue treatment • Cultures: faecal samples taken at end of 1st, 3rd and 6th month • Adverse events: not prespecified, listed in the results
Organism type and antimicrobial susceptibility	No breakdown of results by organism/susceptibility
Notes	<p>482 clinical cases of enteric fever, with 390 enrolled and randomized.</p> <p>92 were ineligible, with the commonest reason being receipt of antibiotics in the week before trial entry (n = 49).</p> <p>187 participants assigned to receive cefixime, and 77 of these were culture-positive; 203 were assigned to gatifloxacin and 92 of these were culture-positive</p> <p>Both ITT (all 390 randomized participants) and positive pre-treatment culture analyses (defined as the per protocol participants, with positive pre-treatment culture results).</p> <p>We requested and received data from the trial authors to calculate the mean time to defervescence.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"We randomly assigned patients (1:1) without stratification to either treatment. The randomisation was computer-generated computer with blocks of 4 or six (with equal probability) by a clinical trials pharmacist."
Allocation concealment (selection bias)	Low risk	"We concealed treatment allocations inside opaque sealed envelopes, which were numbered sequentially to correspond to patient enrollment numbers. Envelopes were kept in a locked drawer and were opened in strict numerical order by a trial clinician (who had previously screened the patients and obtained consent)."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias)	High risk	Open trial

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Pandit 2007 (Continued)

All outcomes

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	11/382 (2.9%) participants dropped out of trial
Selective reporting (reporting bias)	Low risk	Data reported for all stipulated outcome measures
Other bias	Low risk	No conflicts of interest reported; trial sponsor and funder had no involvement in trial design, process, analyses, or write-up

Pape 1986
Study characteristics

Methods	Trial design: randomized, unblinded Time period/duration of trial: before May 1985 Duration of follow-up: at least 6 weeks after therapy started
Participants	Setting: Pediatric Service of University Hospital of Haiti Location: Port-Au-Prince, Haiti Age: children, mean age 8.6 years (2-15 years) Gender: male = 10, female = 15 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • all patients with a clinical diagnosis of probable typhoid fever <ul style="list-style-type: none"> ◦ "toxic condition" ◦ fever > 39 °C • no signs or symptoms suggesting other infections Exclusion criteria: <ul style="list-style-type: none"> • appearance of terminal illness • known or suspected allergy/intolerance to cephalosporins • requirement of concomitant antibiotics for other infections • isolation of bacteria other than <i>S typhi</i> from blood cultures • cultures negative for <i>S typhi</i>
Interventions	<ul style="list-style-type: none"> • Cefoperazone: IV or IM, 100 mg/kg/day in 2 divided doses, then reduced to 50 mg/kg/day when the temperature was < 38 °C and the patient was able to tolerate oral feeding, 14 days • Chloramphenicol: IV or oral, 100 mg/kg/day in 4 divided doses, then reduced to 50 mg/kg/day when the temperature was < 38 °C and the patient was able to tolerate oral feeding, 14 days
Outcomes	<ul style="list-style-type: none"> • Efficacy of antimicrobial regimens judged by clinical response to treatment - not strictly defined, but based on fever defervescence and time to sterile blood cultures after initiation of therapy • Microbiological failure: not strictly defined; implicitly described as blood culture negative at 2 weeks • Relapse: not defined, but measured. Just used "clinical or bacterologic relapse" • Time to defervescence: defined in results section as maximum daily rectal temperature < 38 °C for a 24-h period • Culture: blood culture at days 2 and 14 after start of therapy; faecal culture on days 2, 14 and at 6 weeks after initiation of therapy • Time to blood culture-negative in days • Adverse events: not prespecified, described in results

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Pape 1986 (Continued)

 Organism type and antimicrobial susceptibility *S typhi* = 25 (MDR *S typhi* = 0), *S paratyphi* = 0

Notes 5 patients excluded on criteria: 1 died 3 h after hospitalization, 2 had bacteraemia caused by other Enterobacteriaceae and 2 patients had negative sets of cultures. 3 participants given dexamethasone. These participants and participants who died were excluded from the outcomes analysis.

Sponsor: trial supported by Pfizer international

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	4 participants died
Selective reporting (reporting bias)	High risk	It was unclear whether time to a negative blood culture result could be adequately assessed given the specified sampling method in the protocol
Other bias	Unclear risk	Trial supported by grant from Pfizer international

Rabbani 1998
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: August 1994-February 1995 Duration of follow-up: 4 weeks after completion of treatment
Participants	Setting: Department of Paediatric Medicine, Nishtar Hospital Location: Multan, Pakistan Age: children < 15 years of age; mean age 6.2 years (range: 2-12 years) Gender: male = 31, female = 9 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> typhoid fever confirmed by isolation of <i>S typhi</i> from blood or bone marrow culture Exclusion criteria: <ul style="list-style-type: none"> concurrent infections

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Rabbani 1998 (Continued)

- unconsciousness
- culture-negative participants

Interventions	<ul style="list-style-type: none"> • Cefixime: oral, 10 mg/kg/day in 2 divided doses, for 14 days • Chloramphenicol: oral, 50 mg/kg/day in 4 divided doses, for 14 days
Outcomes	<ul style="list-style-type: none"> • Non-response to therapy: defined as persistent pyrexia (not defined) after 7 days of appropriate therapy • Time to defervescence - not strictly defined, measured in days after start of treatment • Adverse events: "side-effects" monitored
Organism type and antimicrobial susceptibility	<i>S typhi</i> = (MDR <i>S typhi</i> = not measured), <i>S paratyphi</i> = 0. All isolates susceptible to cefixime, 37 isolates susceptible to chloramphenicol
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	High risk	Reporting of outcomes that were not prespecified, including "cure rate"
Other bias	Unclear risk	Unclear whether participants with chloramphenicol-resistant isolates were being 'treated' in the chloramphenicol arm

Rizvi 2007
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: January 2003 to January 2004 Duration of follow-up: 28 days
Participants	Setting: outpatient department of the Social Security Hospital Location: Karachi, Pakistan Age: > 12 years of age; mean age 31.7 years (SD +/-8.2 years)

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Rizvi 2007 (Continued)

Gender: male = 112, female = 115

Health status of participants: 16 had diabetes mellitus, 15 hypertension, 9 bronchial asthma, 1 sickle cell anaemia

Inclusion criteria:

- clinical and bacteriological diagnosis of enteric fever, either on positive blood or stool culture, or by positive Typhi-Dot test

Exclusion criteria:

- infection with other organisms
- pregnancy
- known hypersensitivity to trial medications

Interventions	<ul style="list-style-type: none"> • Cefixime: oral, 200 mg twice daily for 7 days • Ciprofloxacin: oral, 500 mg twice daily for 7 days • Ofloxacin: oral, 200 mg twice daily for 7 days • Chloramphenicol: oral, 750 mg 4 times/day for 14 days • Co-trimoxazole: oral, 960 mg twice daily for 14 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure: reduction of maximum daily temperature equal to or < 37 °C and /or disappearance of clinical signs and symptoms at the end of treatment with no clinical evidence of infection during further follow-up • Clinical improvement: all clinical signs and symptoms subsiding significantly within 7 and 14 days, respectively, but with incomplete resolution of clinical evidence of infection • Clinical relapse: reappearance of signs and symptoms after initial disappearance for at least 48 h • Clinical failure: no significant clinical response to therapy • Not assessable: a clinical judgement of cure, improvement or failure could not be made for various reasons such as no follow-up evaluation tests performed, an underlying condition, or premature termination of the treatment • Bacteriological cure: blood/faecal cultures negative for <i>S typhi</i>/<i>S paratyphi</i> by day 7 of treatment and remained negative for up to 3 weeks after treatment • Bacteriological failure: persistence of <i>S typhi</i>/<i>S paratyphi</i> on day 7 or 14 or recurrence of the initial pathogen at the end of treatment • Bacteriological relapse: elimination of pathogen within 7 or 14 days, but reappearance in blood/stool within 3 weeks after the end of treatment • Culture: blood and faeces at days 0, 3, 5, 7, 14 and 28 • Time to defervescence: not prespecified, but measured in days • Adverse events: not prespecified, but recorded in results
Organism type and antimicrobial susceptibility	<i>S typhi</i> = 208 (MDR <i>S typhi</i> =), <i>S paratyphi</i> = 18
Notes	All participants missing > 1 day of therapy were excluded
Risk of bias	
Bias	Authors' judgement Support for judgement
Random sequence generation (selection bias)	Unclear risk No details given
Allocation concealment (selection bias)	Unclear risk No details given

Rizvi 2007 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	High risk	Numbers lost to follow-up were not specified
Selective reporting (reporting bias)	High risk	Data not reported for all stipulated outcome measures
Other bias	Unclear risk	Breakdown of data unclear in tables

Shakur 2007
Study characteristics

Methods	Trial design: randomized, double blind Time period/duration of trial: March 2003-June 2004 Duration of follow-up:
Participants	Setting: Dhaka Shishu (Children) Hospital, Sher-e-Bangla Nagar Location: Dhaka, Bangladesh Age: 6 months-12 years Gender: male = 22, female = 18 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> clinical features consistent with typhoid fever Exclusion criteria: <ul style="list-style-type: none"> participants taking antibiotics for the preceding 72 h suspected complicated typhoid fever-like abdominal distension, ileus, toxic encephalopathy
Interventions	<ul style="list-style-type: none"> Cefpodoxime: oral, 16 mg/kg/day divided every 12 h for 10 days Cefixime: oral, 20 mg/kg/day divided every 12 h for 10 days
Outcomes	<ul style="list-style-type: none"> Clinical cure: complete resolution of all presenting symptoms and signs after 10 days of therapy Bacteriological cure: elimination of all originally isolated pathogens Time to defervescence: defervescence defined as a temperature below 37.5 °C for at least 48 h without anti-pyretics Cost of antibiotic administered according to manufacturers' suggested retail price Adverse events: not prespecified, recorded as part of results
Organism type and antimicrobial susceptibility	No specific details given, assumed all <i>S typhi</i>
Notes	140 initially assessed, 44 randomized, 40 completed trial Sponsor: trial funding provided by Aristopharma

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Shakur 2007 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Simple randomization technique was done using a computer program
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Medicines were supplied in bottles that were similar in size, shape and colour and without commercial labels
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Attending physicians unaware of treatment being given
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	4/40 (10%) participants lost to follow-up
Selective reporting (reporting bias)	Low risk	Data for all stipulated outcome measures reported
Other bias	Unclear risk	Trial funding provided by Aristopharma

Smith 1994
Study characteristics

Methods	Trial design: randomized, open Time period/duration of trial: December 1992-June 1993 Duration of follow-up: 4-6 weeks following end of treatment
Participants	Setting: Centre for Tropical Diseases, Cho Quan Hospital; Infectious diseases referral centre for southern Vietnam Location: Ho Chi Minh City, Vietnam Age: adults, ≥15 years Gender: male = 29, female = 18 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> clinically suspected or culture-confirmed enteric fever Exclusion criteria: <ul style="list-style-type: none"> known hypersensitivity to beta-lactam antibiotics or quinolone compounds previous treatment with a broad-spectrum cephalosporin or quinolone compound within 1 week of hospital admission ampicillin, chloramphenicol, or trimethoprim-sulfamethoxazole treatment with clinical response within 1 week of hospital admission
Interventions	<ul style="list-style-type: none"> Ceftriaxone: IV, 3 g (approximately 60 mg/kg) once daily for 3 days Ofloxacin: oral, 200 mg every 12 h for 5 days

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Smith 1994 (Continued)

Outcomes	<ul style="list-style-type: none"> • Acute treatment failure was defined as continuing symptoms and fever for at least 7 days after starting the treatment regimen. A patient defined as cured if all symptoms improved, fever cleared, and there was no evidence of relapse. • Microbiological failure: not defined; assumed culture-negative at day 8 • Relapse: not defined in methods, assumed culture-negative at day 8 and then positive on follow-up; plasmid analysis and ribotyping of strains to confirm relapse • Time to defervescence: defervescence was defined as a temperature of < 37.5 °C for at least 48 h • Length of hospital stay: mean and range • Culture: blood on days 4, 6, 8 for first 25 participants and 2, 3, 8 for next 35 participants; faeces and urine on day 8 • Laboratory parameters: full blood count and biochemistry tests at day 8 • Adverse events: not prespecified, but discussed in the results
----------	--

Organism type and antimicrobial susceptibility	<i>S typhi</i> = 41 (MDR <i>S typhi</i> = 26), <i>S paratyphi</i> = 6
--	---

Notes	<p>60 participants entered into the trial, 47 participants were culture-positive. Relapse versus re-infection reassessed by plasmid analysis (gel electrophoresis of whole plasmids and restriction endonuclease fragments) and ribotyping.</p> <p>Sponsor: ceftriaxone and ciprofloxacin provided by Roche pharmaceuticals and Russel-UCLAF respectively.</p>
-------	--

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Low risk	Individual sealed envelopes opened at time of randomization
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	High risk	Loss of follow-up in 50% of participants
Selective reporting (reporting bias)	High risk	Data on laboratory parameters day 8 not reported
Other bias	Unclear risk	Ceftriaxone and ciprofloxacin provided by Roche pharmaceuticals and Russel-UCLAF respectively

Tatli 2003
Study characteristics
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Tatli 2003 (Continued)

Methods	Trial design: randomized Time period/duration of trial: September 1998-July 2001 Duration of follow-up: 28 days	
Participants	Setting: Harran University Research Hospital, and the Children's Hospital Location: Sanliurfa, Turkey Age: < 16 years of age Gender: male = 41, female = 31 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • suspected typhoid fever, defined as no other obvious source of infection and high-grade fever (≥ 39 °C) persisting for > 5 days Exclusion criteria: <ul style="list-style-type: none"> • negative blood cultures • history of antimicrobial therapy in previous 10 days 	
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 75 mg/kg per day (maximally 2 g/day) in 2 divided doses until the axillary temperature remained below 37.5°C for at least 24 h, then additional 5 days of therapy at the same dose • Chloramphenicol: 75 mg/kg per days (maximally 2 g/day) in 4 divided doses for 14 days 	
Outcomes	<ul style="list-style-type: none"> • Clinical cure: absence of fever on 7th day of therapy; clinical signs and symptoms resolved and the patient remained well during follow-up • Microbiological failure: blood culture positive for <i>S typhi</i> after completion of therapy • Relapse: high fever (≥ 38.5 °C) and blood culture positive for <i>S typhi</i> during the 28 days after discharge • Defervescence time: time from the onset of treatment until the fever was 37.5 °C or below for at least 24 h • Convalescent faecal carriage: not defined, but assessed • Adverse events: not prespecified, but clinical and biochemical side effects of treatment assessed in results 	
Organism type and antimicrobial susceptibility	<i>S typhi</i> = 72 (MDR <i>S typhi</i> = 0), <i>S paratyphi</i> = 0	
Notes		
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Tatli 2003 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants in ceftriaxone group and 8 in the chloramphenicol group not assessed because of "communication failure"
Selective reporting (reporting bias)	Low risk	Data reported on all stipulated outcomes
Other bias	Unclear risk	Potential conflicts of interest not commented on

Tran 1994
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: 1992-1993 Duration of follow-up: 28 days after treatment	
Participants	Setting: Cho Quan Hospital Location: Ho Chi Minh City, Vietnam Age: all patients (mean age: 24 years (SD 7 years) in fleroxacin group; 29 (SD 15) in ceftriaxone group) Gender: male = 22, female = 9 Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • axillary temperature > 37.5 °C for > 7 days • 'toxic' appearance • negative malaria blood film Exclusion criteria: <ul style="list-style-type: none"> • not specified 	
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 2 g once daily for 5 days • Fleroxacin: oral, 400 mg in a single dose daily for 7 days 	
Outcomes	<ul style="list-style-type: none"> • Clinical cure: reduction of maximum daily axillary temperature to < 37.5 °C and complete disappearance of all other signs and symptoms within 14 days with no clinical evidence of infection during further follow-up • Microbiological failure: microbiological cure defined as initial pathogen eliminated from blood, bone marrow and stool within 14 days, all cultures remaining negative for at least 21 days • Time to defervescence: defervescence defined as axillary temperature < 37.5 °C • Laboratory parameters: blood, renal and hepatological tests before and after treatment • Culture: blood days 0, 3 and end of treatment; faeces day 0 and end of treatment • Adverse events: not prespecified, but assessed as part of the results 	
Organism type and antimicrobial susceptibility	<i>S typhi</i> = 27 (MDR <i>S typhi</i> = 12), <i>S paratyphi A</i> = 4	
Notes	46 patients with a clinical diagnosis randomized; 31 patients had the diagnosis confirmed on culture Sponsor: funded by the Roche Asian Research Foundation	

Risk of bias

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Tran 1994 (Continued)

Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	High risk	Loss to follow-up of 15/31 (48.4%) participants
Selective reporting (reporting bias)	Unclear risk	Data reported on all stipulated outcomes
Other bias	Unclear risk	Funded by the Roche Asian Research Foundation

Wallace 1993
Study characteristics

Methods	Trial design: randomized Time period/duration of trial: unclear, before 1993 Duration of follow-up: 2 months
Participants	Setting: unclear Location: unclear Age: 42 adult participants > 16 years (mean age: 28.2 years in ceftriaxone group, 26.8 years in ciprofloxacin group) Gender: no details given Health status of participants: not recorded Inclusion criteria: <ul style="list-style-type: none"> • blood culture positive • acute <i>S typhi</i> infection Exclusion criteria: <ul style="list-style-type: none"> • inability to take oral medication • possible or proven pregnancy • lack of fever at time of admission
Interventions	<ul style="list-style-type: none"> • Ceftriaxone: IV, 3 g once daily for 7 days • Ciprofloxacin: oral, 500 mg twice daily for 7 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure: clinical failure defined as fever > 38 °C after 7 days of therapy or who deteriorated clinically after 5 full days of therapy; cure if patient afebrile and asymptomatic on or before day 7 and did not require additional therapy during 2 months of follow-up

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Wallace 1993 (Continued)

- Relapse: readmission for typhoid within 2 months of discharge with a positive blood or stool culture for *S typhi* with the same antibiogram as previous
- Convalescent faecal carriage: not defined, but stool culture positivity assessed at 28 days post-enrolment

Organism type and antimicrobial susceptibility *S typhi* = 42 (MDR *S typhi* = 22), *S paratyphi* = 0

Notes The trial was terminated when the clinicians involved in the trial felt that it was no longer ethical to randomize patients to receive ceftriaxone, given the higher cost, need for IV access and perceived lower efficacy of this regimen

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow-up
Selective reporting (reporting bias)	Low risk	Data reported on all stipulated outcome measures
Other bias	Low risk	No potential conflicts of interest reported

GCS: Glasgow Coma Scale; **GI:** gastrointestinal; **IM:** intramuscular(ly) **IQR:** interquartile range; **IL-6:** interleukin 6; **ITT:** intention-to-treat; **IV:** intravenous(ly); **MDR:** multiple-drug resistance; **MIC:** minimal inhibitory concentration; **RCT:** randomized controlled trial; **SD:** standard deviation; **S typhi:** *Salmonella typhi*; **S paratyphi:** *Salmonella paratyphi*; **TB:** tuberculosis; **TNF-R:** tumour necrosis factor receptor; **UTI:** urinary tract infection

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Arjyal 2011	No cephalosporin as an intervention
Begue 1998	Not a RCT
Begum 2014	Not a RCT
De Carvalho 1982	Not a RCT

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Study	Reason for exclusion
Ebright 1983	Not a RCT
Farid 1987	Not a RCT
Gnassingbe 2010	Not a RCT
Jiangli 1995	Not a RCT
Khichi 2001	No cephalosporin as an intervention
Lan 1986	Not a RCT
Medina 2000	Not a RCT
Meloni 1988	Not a RCT
Morelli 1992	No cephalosporin as an intervention
Nagaraj 2016	Not a RCT
Naveed 2016	Participants diagnosed on clinical criteria with no blood cultures performed
Nelson 1967	Not a RCT
Park 1985	Not a RCT
Raoult 1984	Not a RCT
Rolston 1992	Not a RCT
Singh 1993	No cephalosporin as an intervention
Sirinavin 2003	Not a RCT
Soe 1987	Not a RCT
Thaver 2009	Not a RCT
Ti 1985	Not a RCT
Trivedi 2012	Not a RCT
Uwaydah 1976	Not a RCT
Uwaydah 1984	Not a RCT
Vinh 2005	No cephalosporin as an intervention
Yi 1995	Not a RCT
Zmora 2018	Not a RCT

RCT: randomized controlled trial

Characteristics of studies awaiting classification [ordered by study ID]

Amin 2021

Methods	<p>Trial design: randomized</p> <p>Time period/duration of trial: January 2017- December 2017</p> <p>Duration of follow-up: 6 months from discharge</p>
Participants	<p>62 participants</p> <p>Setting: "Medicine ward of Dhaka Medical College Hospital (DMCH) and an outdoor setting in private practice in Dhaka metropolitan city, Mymensingh and Sylhet town." Bangladesh</p> <p>Age: > 15 years and < 65 years</p> <p>Gender:</p> <p>Health status of participants:</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • clinically suspected and • culture-confirmed uncomplicated typhoid fever <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • pregnancy • age < 15 years and > 65 years • history of hypersensitivity to either of the trial drugs • any signs of severe typhoid fever (shock, deep jaundice, encephalopathy, convulsions, bleeding, suspicion or evidence of gut perforation, neurological features, etc) • previously reported treatment with fluoroquinolone antibiotics or, a third-generation cephalosporin or macrolide antibiotics within 1 week prior to hospital admission • patient on active management for Ischaemic heart disease, chronic bronchial asthma and COPD • significant underlying illness (affecting the bone marrow, kidneys, liver, heart, lungs, or nervous system) • known allergy to the experimental drug
Interventions	<p>Intervention:</p> <ul style="list-style-type: none"> • cefixime 16 mg/kg/day for 14 days <p>Comparators:</p> <ul style="list-style-type: none"> • Azithromycin 20 mg/kg. Dose frequency and duration of treatment reported differently throughout the trial • Ciprofloxacin 20 mg/kg/day for 14 days
Outcomes	<ul style="list-style-type: none"> • Clinical cure • Time to defervescence • Complications • Microbiological failure • Relapse
Notes	<p>Dose of azithromycin reported differently throughout the trial</p>

Hamidullah 2019

Methods	<p>Trial design: participants assigned to a treatment group by lottery method</p> <p>Setting: Department of Paediatrics, Hayatabad Medical Complex, Peshawar, Pakistan</p> <p>Time period/duration of trial: November 2015-May 2016</p> <p>Duration of follow-up: not specified</p>
Participants	<p>140 participants</p> <p>Gender: 81 male; 59 female</p> <p>Age: 2 years-12 years old</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> not clearly reported <p>Exclusion criteria:</p> <ul style="list-style-type: none"> not clearly reported
Interventions	<ul style="list-style-type: none"> Intervention: ceftriaxone IV 75 mg/kg/day (maximum dose, 2.5 g/day) twice daily for 10 days Comparator: azithromycin 10 mg/kg/day (maximum dose, 500 mg/day) once daily for 7 days
Outcomes	<ul style="list-style-type: none"> Time to defervescence Clinical failure Complications
Notes	

Huai 2000

Methods	Unable to access trial
Participants	Unable to access trial
Interventions	Unable to access trial
Outcomes	Unable to access trial
Notes	

Thapaet 2019

Methods	<p>Trial design: unclear if randomized. "Patients were enrolled into two treatment groups."</p> <p>Setting: Nepal, Patan Hospital</p> <p>Time period/duration of trial: not specified</p> <p>Duration of follow-up: not specified</p>
Participants	<p>250 participants</p> <p>Age: 4 to 65 years old</p>

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Thapaet 2019 (Continued)

Inclusion criteria:

- fever 38 °C for at least 4 days
- able to take oral medication
- able to consent
- able to attend follow-up visits and contactable via telephone

Exclusion criteria:

- fever for > 10 days
- diabetes mellitus
- pregnancy
- severe infection
- jaundice
- active gastrointestinal bleeding
- shock
- hypersensitivity to drugs
- patient requiring IV treatment

Interventions

Intervention:

- ceftriaxone. Dose and route of administration not clearly reported

Comparator:

- azithromycin. Dose not clearly reported

Outcomes

- Fever clearance time
- Clinical failure
- Microbiological failure

Notes

Welch 1986

Methods

Trial design: randomized

Time period/duration of trial: not specified

Duration of follow-up: 30 days after discharge

Participants

Setting; Paula Jaraquemada Hospital

Location: Santiago, Chile

Age: hospitalized children - age not specified

Gender: no details

Health status of participants: not recorded

Inclusion criteria: bacteriologically confirmed enteric fever (blood or bone marrow culture)

Exclusion criteria: none specified

Interventions

- Ceftriaxone: 80 mg/kg once daily, IV, 6 days

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Welch 1986 (Continued)

- Chloramphenicol: approximately 50 mg/kg/day in 3-4 doses, oral, 14 days

Outcomes

- Clinical cure: not defined but reported
- Microbiological failure: not defined but reported
- Relapse: not defined but reported
- Convalescent faecal carriage: stool cultures taken 30 days after discharge
- Adverse events: not prespecified, assessed as part of results

Notes

Conference abstract/presentation only (Welch E. Ceftriaxone versus chloramphenicol in children suffering from typhoid or paratyphoid fever. Paper presented at 19th International Congress of Infectious and Parasitic Diseases, Munich, July 1986)

COPD: chronic obstructive pulmonary disease

Characteristics of ongoing studies [ordered by study ID]

NCT04349826

Study name

Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia; a randomized controlled trial

Methods

Allocation: randomized

Intervention model: parallel assignment

Masking: quadruple (participant, care provider, investigator, outcomes assessor)

Masking description: double blind

Primary purpose: treatment

Estimated enrolment: 1500

Estimated trial completion date: August 2023

Participants

Ages: 2 years to 65 years

Gender: all

Inclusion criteria:

- history of fever at presentation for ≥ 72 h and a documented fever (≥ 37.5 °C (axillary) or ≥ 38 °C (oral))
- age ≥ 2 years (and ≥ 10 kg) to 65 years
- no clear focus of infection on initial clinical evaluation
- malaria rapid diagnostic test (RDT) negative; dengue nonstructural protein (NS) 1 RDT negative; scrub typhus RDT negative; C-reactive protein (CRP) rapid test ≥ 10 mg/L
- able to take oral treatment
- able to attend for follow-up and can be contacted by telephone
- Written fully informed consent to participate in the trial including assent for children in addition to parental/legal guardian consent.

Exclusion criteria:

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

NCT04349826 (Continued)

- history of fever for > 14 days
- pregnant or positive pregnancy test or breastfeeding
- presence of clinical symptoms or signs indicating a focal infection such as pneumonia; urinary infection, meningitis, eschar
- obtundation, haemodynamic shock, visible jaundice, gastrointestinal bleeding or any signs of severe disease that may require immediate hospitalization
- being treated for TB or HIV or severe acute malnutrition
- patients with cardiac disease
- patient requiring IV antibiotics for any reason
- previous history of hypersensitivity to any of the treatment options
- either of the trial drugs are contraindicated for any reason (e.g. drug interactions)
- has received azithromycin or cefixime in the last 5 days
- receiving another antimicrobial and responding clinically to the treatment as judged by the attending clinician.

Interventions	Active comparator: azithromycin + cefixime <ul style="list-style-type: none"> • Azithromycin 20 mg/kg/day oral dose once daily (maximum 1 g/day) and cefixime 20 to 30 mg/kg/day oral dose in 2 divided doses (maximum 400 mg twice a day) for 7 days Placebo comparator: azithromycin + placebo <ul style="list-style-type: none"> • Azithromycin 20 mg/kg/day oral dose once daily (max 1 g/day) for 7 days and cefixime-matched placebo for 7 days
Outcomes	Primary outcomes <ul style="list-style-type: none"> • Treatment failure Secondary outcomes <ul style="list-style-type: none"> • Fever clearance time (FCT) in participants in each treatment arm • Time from onset of treatment to treatment failure • Time from symptom onset to treatment failure • Adverse event • Faecal carriage of <i>S typhi</i> or <i>S paratyphi</i> • Cost-effectiveness of treatment
Starting date	Recruitment commenced in May 2021 - recruitment ongoing
Contact information	clinicaltrials.gov/ct2/show/NCT04349826
Notes	Sponsor: Oxford University Clinical Research Unit, Vietnam

DATA AND ANALYSES


Comparison 1. Cefixime versus fluoroquinolone

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Clinical failure	3	425	Risk Ratio (M-H, Random, 95% CI)	13.39 [3.24, 55.39]


Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1.1 Cefixime versus ofloxacin	2	173	Risk Ratio (M-H, Random, 95% CI)	6.91 [0.90, 52.77]
1.1.2 Cefixime versus gatifloxacin	1	158	Risk Ratio (M-H, Random, 95% CI)	25.14 [3.46, 182.78]
1.1.3 Cefixime versus ciprofloxacin	1	94	Risk Ratio (M-H, Random, 95% CI)	Not estimable
1.2 Microbiological failure	3	425	Risk Ratio (M-H, Fixed, 95% CI)	4.07 [0.46, 36.41]
1.2.1 Cefixime versus ofloxacin	2	173	Risk Ratio (M-H, Fixed, 95% CI)	4.33 [0.21, 87.56]
1.2.2 Cefixime versus gatifloxacin	1	158	Risk Ratio (M-H, Fixed, 95% CI)	3.76 [0.16, 90.92]
1.2.3 Cefixime versus ciprofloxacin	1	94	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
1.3 Relapse	3	405	Risk Ratio (M-H, Fixed, 95% CI)	4.45 [1.11, 17.84]
1.3.1 Cefixime versus ofloxacin	2	173	Risk Ratio (M-H, Fixed, 95% CI)	2.60 [0.11, 62.01]
1.3.2 Cefixime versus gatifloxacin	1	138	Risk Ratio (M-H, Fixed, 95% CI)	5.12 [1.07, 24.42]
1.3.3 Cefixime versus ciprofloxacin	1	94	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
1.4 Time to defervescence	3	425	Mean Difference (IV, Random, 95% CI)	1.74 [0.50, 2.98]
1.4.1 Cefixime versus ciprofloxacin	1	94	Mean Difference (IV, Random, 95% CI)	0.50 [-0.02, 1.02]
1.4.2 Cefixime versus ofloxacin	2	173	Mean Difference (IV, Random, 95% CI)	2.53 [-0.53, 5.59]
1.4.3 Cefixime versus gatifloxacin	1	158	Mean Difference (IV, Random, 95% CI)	1.61 [0.79, 2.43]


Analysis 1.1. Comparison 1: Cefixime versus fluoroquinolone, Outcome 1: Clinical failure



Analysis 1.2. Comparison 1: Cefixime versus fluoroquinolone, Outcome 2: Microbiological failure



Analysis 1.4. Comparison 1: Cefixime versus fluoroquinolone, Outcome 4: Time to defervescence




Footnotes

(1) Mean values are entered as per our calculations made from the raw study data and differ slightly from the reported study values. Pandit and colleagues reported the cefixime mea


Comparison 2. Ceftriaxone versus azithromycin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Clinical failure	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1.1 Ceftriaxone versus azithromycin	3	196	Risk Ratio (M-H, Fixed, 95% CI)	0.42 [0.11, 1.57]
2.2 Microbiological failure	3	196	Risk Ratio (M-H, Fixed, 95% CI)	1.95 [0.36, 10.64]
2.3 Relapse	3	185	Risk Ratio (M-H, Fixed, 95% CI)	10.05 [1.93, 52.38]
2.4 Time to defervescence	3	196	Mean Difference (IV, Fixed, 95% CI)	-0.52 [-0.91, -0.12]


Analysis 2.1. Comparison 2: Ceftriaxone versus azithromycin, Outcome 1: Clinical failure




Analysis 2.2. Comparison 2: Ceftriaxone versus azithromycin, Outcome 2: Microbiological failure



Analysis 2.3. Comparison 2: Ceftriaxone versus azithromycin, Outcome 3: Relapse



Analysis 2.4. Comparison 2: Ceftriaxone versus azithromycin, Outcome 4: Time to defervescence




Comparison 3. Ceftriaxone versus fluoroquinolone

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Clinical failure	4	359	Risk Ratio (M-H, Random, 95% CI)	3.77 [0.72, 19.81]
3.1.1 Ceftriaxone versus ciprofloxacin	1	42	Risk Ratio (M-H, Random, 95% CI)	11.87 [0.71, 198.13]
3.1.2 Ceftriaxone versus fleroxacin	1	31	Risk Ratio (M-H, Random, 95% CI)	5.31 [0.28, 102.38]
3.1.3 Ceftriaxone versus ofloxacin	1	47	Risk Ratio (M-H, Random, 95% CI)	13.27 [0.80, 219.78]
3.1.4 Ceftriaxone versus gatifloxacin	1	239	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.59, 1.93]
3.2 Microbiological failure	3	316	Risk Ratio (M-H, Fixed, 95% CI)	1.65 [0.40, 6.83]
3.2.1 Ceftriaxone versus fleroxacin	1	30	Risk Ratio (M-H, Fixed, 95% CI)	3.40 [0.15, 77.34]
3.2.2 Ceftriaxone versus ofloxacin	1	47	Risk Ratio (M-H, Fixed, 95% CI)	4.42 [0.22, 87.44]
3.2.3 Ceftriaxone versus gatifloxacin	1	239	Risk Ratio (M-H, Fixed, 95% CI)	0.50 [0.05, 5.49]
3.3 Relapse	3	297	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.31, 2.92]
3.3.1 Ceftriaxone versus ciprofloxacin	1	42	Risk Ratio (M-H, Fixed, 95% CI)	2.74 [0.12, 63.63]
3.3.2 Ceftriaxone versus ofloxacin	1	47	Risk Ratio (M-H, Fixed, 95% CI)	2.65 [0.11, 62.00]
3.3.3 Ceftriaxone versus gatifloxacin	1	208	Risk Ratio (M-H, Fixed, 95% CI)	0.59 [0.14, 2.40]
3.4 Time to defervescence	3	285	Mean Difference (IV, Random, 95% CI)	2.73 [-0.37, 5.84]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.4.1 Ceftriaxone versus fleroxacin	1	29	Mean Difference (IV, Random, 95% CI)	3.29 [1.40, 5.18]
3.4.2 Ceftriaxone versus ofloxacin	1	47	Mean Difference (IV, Random, 95% CI)	4.79 [3.30, 6.28]
3.4.3 Ceftriaxone versus gatifloxacin	1	209	Mean Difference (IV, Random, 95% CI)	0.30 [-0.36, 0.96]
3.5 Convalescent faecal carriage	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.18 [0.01, 3.72]
3.5.1 Ceftriaxone versus gatifloxacin	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.18 [0.01, 3.72]


Analysis 3.1. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 1: Clinical failure



Footnotes

- (1) Dose: 3g intravenously once daily for 7 days
- (2) Dose: 2g intravenously once daily for 5 days
- (3) Dose: 3 g intravenously once daily for 3 days
- (4) Data is derived from a modified intention-to-treat population. Dose: 60 mg/kg/day to 2g/day intravenously for 7 days.


Analysis 3.2. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 2: Microbiological failure



Footnotes

- (1) Dose: 2g intravenously once daily for 5 days
- (2) Dose: 3 g intravenously once daily for 3 days
- (3) Data is derived from a modified intention-to-treat population. Dose: 60 mg/kg/day to 2g/day intravenously, 7 days.


Analysis 3.3. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 3: Relapse



Footnotes

- (1) Dose: 3g intravenously once daily for 7 days
- (2) Dose: 3 g intravenously once daily for 3 days
- (3) Data is derived from a modified intention-to-treat population. Dose: 60 mg/kg/day to 2g/day intravenously for 7 days.


Analysis 3.4. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 4: Time to defervescence



Footnotes

- (1) Dose: 2g intravenously once daily for 5 days
- (2) Dose: 3 g intravenously once daily for 3 days
- (3) Data is derived from a modified intention-to-treat population. Dose: 60 mg/kg/day to 2g/day intravenously for 7 days.

Analysis 3.5. Comparison 3: Ceftriaxone versus fluoroquinolone, Outcome 5: Convalescent faecal carriage



Footnotes


- (1) Dose: 60 mg/kg/day to 2g/day intravenously for 7 days.

Comparison 4. Ceftriaxone versus cefixime


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Clinical failure	2	143	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.22, 4.49]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.2 Microbiological failure	2	143	Risk Ratio (M-H, Fixed, 95% CI)	2.00 [0.19, 20.67]
4.3 Relapse	2	143	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [0.37, 4.98]
4.4 Time to defervescence	2	143	Mean Difference (IV, Fixed, 95% CI)	-1.48 [-2.13, -0.83]


Analysis 4.1. Comparison 4: Ceftriaxone versus cefixime, Outcome 1: Clinical failure




Analysis 4.2. Comparison 4: Ceftriaxone versus cefixime, Outcome 2: Microbiological failure



Analysis 4.3. Comparison 4: Ceftriaxone versus cefixime, Outcome 3: Relapse




Analysis 4.4. Comparison 4: Ceftriaxone versus cefixime, Outcome 4: Time to defervescence



Comparison 5. Ceftriaxone versus chloramphenicol

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Clinical failure	7	387	Risk Ratio (M-H, Fixed, 95% CI)	1.43 [0.68, 3.00]
5.2 Microbiological failure	7	387	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
5.3 Relapse	7	365	Risk Ratio (M-H, Fixed, 95% CI)	0.45 [0.20, 1.04]
5.4 Time to defervescence	1	55	Mean Difference (IV, Random, 95% CI)	-2.54 [-3.13, -1.95]
5.5 Convalescent faecal carriage	2	118	Risk Ratio (M-H, Fixed, 95% CI)	3.20 [0.34, 29.94]

Analysis 5.1. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 1: Clinical failure



Analysis 5.2. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 2: Microbiological failure

Study or Subgroup	Experimental		Control		Weight	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
	Events	Total	Events	Total			
Acharya 1995	0	23	0	23		Not estimable	
Butler 1993	0	15	0	14		Not estimable	
Islam 1988	0	32	0	31		Not estimable	
Islam 1993	0	28	0	31		Not estimable	
Lasserre 1991	0	39	0	20		Not estimable	
Moosa 1989	0	29	0	30		Not estimable	
Tatli 2003	0	36	0	36		Not estimable	
Total (95% CI)		202		185		Not estimable	
Total events:	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Test for subgroup differences: Not applicable							


Analysis 5.3. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 3: Relapse

Study or Subgroup	Cephalosporin		Chloramphenicol		Weight	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
	Events	Total	Events	Total			
Acharya 1995	1	23	0	23	3.1%	3.00 [0.13, 70.02]	
Butler 1993	1	15	0	14	3.2%	2.81 [0.12, 63.83]	
Girgis 1990	0	25	3	30	19.5%	0.17 [0.01, 3.15]	
Islam 1993	1	28	1	31	5.8%	1.11 [0.07, 16.88]	
Lasserre 1991	0	39	3	20	28.0%	0.07 [0.00, 1.38]	
Moosa 1989	2	29	2	30	12.0%	1.03 [0.16, 6.86]	
Tatli 2003	0	30	4	28	28.4%	0.10 [0.01, 1.85]	
Total (95% CI)		189		176	100.0%	0.45 [0.20, 1.04]	
Total events:	5		13				
Heterogeneity: Chi ² = 6.74, df = 6 (P = 0.35); I ² = 11%							
Test for overall effect: Z = 1.87 (P = 0.06)							
Test for subgroup differences: Not applicable							

Analysis 5.4. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 4: Time to defervescence

Study or Subgroup	Cephalosporin			Chloramphenicol			Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total			
Girgis 1990	3.96	0.93	25	6.5	1.28	30	100.0%	-2.54 [-3.13, -1.95]	
Total (95% CI)			25			30	100.0%	-2.54 [-3.13, -1.95]	
Heterogeneity: Not applicable									
Test for overall effect: Z = 8.50 (P < 0.00001)									
Test for subgroup differences: Not applicable									


Analysis 5.5. Comparison 5: Ceftriaxone versus chloramphenicol, Outcome 5: Convalescent faecal carriage




Comparison 6. Cefixime versus chloramphenicol

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Clinical failure	3	215	Risk Ratio (M-H, Fixed, 95% CI)	0.09 [0.04, 0.23]
6.2 Microbiological failure	1	90	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.84]
6.3 Time to defervescence	1	90	Mean Difference (IV, Fixed, 95% CI)	-2.50 [-3.23, -1.77]


Analysis 6.1. Comparison 6: Cefixime versus chloramphenicol, Outcome 1: Clinical failure



Analysis 6.2. Comparison 6: Cefixime versus chloramphenicol, Outcome 2: Microbiological failure




Analysis 6.3. Comparison 6: Cefixime versus chloramphenicol, Outcome 3: Time to defervescence




Comparison 7. Cefoperazone versus chloramphenicol

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.1 Clinical failure	2	81	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.10, 5.36]
7.2 Relapse	1	55	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.10, 2.60]
7.3 Time to defervescence	1	21	Mean Difference (IV, Fixed, 95% CI)	-2.30 [-2.89, -1.71]
7.4 Convalescent faecal carriage	1	56	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.03, 2.10]


Analysis 7.1. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 1: Clinical failure




Analysis 7.2. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 2: Relapse



Analysis 7.3. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 3: Time to defervescence




Analysis 7.4. Comparison 7: Cefoperazone versus chloramphenicol, Outcome 4: Convalescent faecal carriage




Comparison 8. Cefixime versus cefpodoxime

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 Clinical failure	1	40	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.07, 16.47]
8.2 Time to defervescence	1	40	Mean Difference (IV, Fixed, 95% CI)	-0.60 [-2.03, 0.83]

Analysis 8.1. Comparison 8: Cefixime versus cefpodoxime, Outcome 1: Clinical failure




Analysis 8.2. Comparison 8: Cefixime versus cefpodoxime, Outcome 2: Time to defervescence




Comparison 9. Cefixime versus aztreonam

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.1 Relapse	1	81	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.16, 5.26]
9.2 Time to defervescence	1	81	Mean Difference (IV, Fixed, 95% CI)	0.20 [-0.42, 0.82]

Analysis 9.1. Comparison 9: Cefixime versus aztreonam, Outcome 1: Relapse



Analysis 9.2. Comparison 9: Cefixime versus aztreonam, Outcome 2: Time to defervescence




Comparison 10. Ceftriaxone versus aztreonam


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.1 Relapse	1	74	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.11, 4.84]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.2 Time to defervescence	1	74	Mean Difference (IV, Fixed, 95% CI)	-1.40 [-2.44, -0.36]

Analysis 10.1. Comparison 10: Ceftriaxone versus aztreonam, Outcome 1: Relapse




Analysis 10.2. Comparison 10: Ceftriaxone versus aztreonam, Outcome 2: Time to defervescence




Comparison 11. Short versus long course ceftriaxone

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
11.1 Clinical failure	1	57	Risk Ratio (M-H, Fixed, 95% CI)	1.93 [0.19, 20.12]
11.2 Relapse	1	57	Risk Ratio (M-H, Fixed, 95% CI)	8.70 [0.49, 154.49]
11.3 Time to defervescence	1	57	Mean Difference (IV, Fixed, 95% CI)	0.20 [-1.46, 1.86]


Analysis 11.1. Comparison 11: Short versus long course ceftriaxone, Outcome 1: Clinical failure



Analysis 11.2. Comparison 11: Short versus long course ceftriaxone, Outcome 2: Relapse



Analysis 11.3. Comparison 11: Short versus long course ceftriaxone, Outcome 3: Time to defervescence



ADDITIONAL TABLES

Table 1. Cephalosporins considered in this review

Cephalosporins
Cefcapene
Cefdaloxime
Cefdinir
Cefditoren
Cefetamet
Cefixime
Cefmenoxime

Table 1. Cephalosporins considered in this review *(Continued)*

Cefodizime
Cefoperazone
Cefotaxime
Cefpimizole
Cefclidine
Cefepime
Cefluprenam
Cefoselis
Cefpodoxime
Ceftazidime
Cefteram
Ceftibuten
Ceftizoxime
Ceftriaxone
Cefozopran
Cefpirome

APPENDICES

Appendix 1. Detailed search strategies

Ovid MEDLINE(R) and In-Process, In-Data-Review & Other Non-Indexed Citations <1946 to November 23, 2021>

- 1 Typhoid Fever/
- 2 Salmonella typhi/
- 3 Typhoid fever.tw.
- 4 paratyphoid fever.tw.
- 5 enteric fever.tw.
- 6 Paratyphoid Fever/
- 7 salmonella paratyphi a/ or salmonella paratyphi b/ or salmonella paratyphi c/
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9 exp Cephalosporins/
- 10 cephalosporin*.tw.

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

- 11 (Cefcapene or Cefdaloxime or Cefdinir or Cefditoren or Cefetamet or Cefixime or Cefmenoxime or Cefodizime or Cefoperazone or Cefotaxime or Cefpimizole or Cefpodoxime or Ceftazidime or Ceferam or Ceftibutem or Ceftizoxime or Ceftriaxone or cefclidine or Cefepime or Cefluprenam or Cefoselis or Cefoprozan or Cefpirome).tw.
- 12 8 and 11
- 13 Randomized Controlled Trial.pt
- 14 Controlled Clinical Trial.pt
- 15 (randomized or placebo or randomly or trial or groups).tw.
- 16 exp Drug Therapy/
- 17 13 or 14 or 15 or 16
- 18 12 and 17

Embase <1996 to 2021 Week 46>

- 1 Typhoid Fever/
- 2 Salmonella typhi/
- 3 Typhoid fever.tw.
- 4 paratyphoid fever.tw.
- 5 enteric fever.tw.
- 6 Paratyphoid Fever/
- 7 salmonella enterica serovar paratyphi a/ or salmonella enterica serovar paratyphi b/ or salmonella enterica serovar paratyphi c/
- 8 (Cefcapene or Cefdaloxime or Cefdinir or Cefditoren or Cefetamet or Cefixime or Cefmenoxime or Cefodizime or Cefoperazone or Cefotaxime or Cefpimizole or Cefpodoxime or Ceftazidime or Ceferam or Ceftibutem or Ceftizoxime or Ceftriaxone or cefclidine or Cefepime or Cefluprenam or Cefoselis or Cefoprozan or Cefpirome).tw.
- 9 cephalosporin*.tw.
- 10 exp cephalosporin derivative/
- 11 Randomized Controlled Trial/
- 12 Controlled Clinical Trial/
- 13 (random* or placebo* or single blind* or double blind* or triple blind*).tw.
- 14 1 or 2 or 3 or 4 or 5 or 6 or 7
- 15 8 or 9 or 10
- 16 11 or 12 or 13
- 17 14 and 15 and 16

Cochrane Central Register of Controlled Trials

Issue 10 of 12, October 2021

- #1 MeSH descriptor: [Typhoid Fever] explode all trees
- #2 salmonella typhi
- #3 MeSH descriptor: [Salmonella typhi] explode all trees

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

- #4 salmonella paratyphi
- #5 MeSH descriptor: [Paratyphoid Fever] explode all trees
- #6 enteric fever
- #7 (typhoid or paratyphoid) AND fever
- #8 #1 or #2 or #3 or #4 or #5 or #6 or #7
- #9 MeSH descriptor: [Cephalosporins] explode all trees
- #10 (cephalosporin*):ti,ab,kw
- #11 (Cefcapene or Cefdaloxime or Cefdinir or Cefditoren or Cefetamet or Cefixime or Cefmenoxime or Cefodizime or Cefoperazone or Cefotaxime or Cefpimizole or Cefpodoxime or Ceftazidime or Cefteram or Ceftibutem or Ceftizoxime or Ceftriaxone or cefclidine or Cefepime or Cefluprenam or Cefoselis or Cefoprozan or Cefpirome)
- #12 #9 or #10 or #11
- #13 #8 and #12

Database: LILACS

Search on: typhoid fever or paratyphoid fever or enteric fever [Words] and cephalosporins or Cefcapene or Cefdaloxime or Cefdinir or Cefditoren or Cefetamet or Cefixime or Cefmenoxime or Cefodizime or Cefoperazone or Cefotaxime or Cefpimizole or Cefpodoxime or Ceftazidime or Cefteram or Ceftibutem or Ceftizoxime or Ceftriaxone or cefclidine or Cefepime or Cefluprenam or Cefoselis or Cefoprozan or Cefpirome [Words]

Clinicaltrials.gov, WHO ICTRP

Cephalosporins and

Typhoid and Paratyphoid Fevers /Paratyphoid Fevers/Enteric fever

HISTORY

Protocol first published: Issue 3, 2013

CONTRIBUTIONS OF AUTHORS

Nicole Stoesser and David Eyre authored the review protocol, with input from Christopher Parry and Buddha Basnyat ([Stoesser 2013](#)).

Nicole Stoesser and David Eyre screened the search results, extracted data, and completed the risk of bias assessments for trials found in the search in February 2013. Rebecca Kuehn, Christopher Parry, and Thomas Darton screened the search results and extracted data for trials found in the April 2017 and November 2021 search.

All authors contributed to examining the data, writing the review, and approved the final version prior to publication.

DECLARATIONS OF INTEREST

RK is a Cochrane Infectious Diseases Group Research Associate, and was not involved in the editorial process. She has no known conflicts of interest.

NS has no known conflicts of interest.

DE has received grants from the NIH, Gilead Sciences, and the Robertson Foundation, and has no known conflicts of interest.

TD is a previous contributor to WHO Guidance for the Surveillance of Vaccine Preventable Diseases (typhoid), and has no known conflicts of interest.

BB is a co-author on two trials included in this review ([Arjyal 2016](#); [Pandit 2007](#)).

CP is a co-author on the following trial included in this review ([Cao 1999](#)).

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins (Review)

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

SOURCES OF SUPPORT

Internal sources

- Liverpool School of Tropical Medicine, UK
Cochrane Infectious Diseases Group

External sources

- Foreign, Commonwealth, and Development Office (FCDO), UK
Project number 300342-104
- National Institute for Health and Care Research (NIHR), UK
DE was supported by a doctoral training fellowship
- Wellcome Trust, UK
NS is supported by a clinical research training fellowship
- Department for Health and Social Care/Department for International Development/Global Challenges Research Fund/Medical Research Council/Wellcome Trust, UK
BB and CP are supported by the Joint Global Health Trials Scheme (MR/TOO5033/1) awarded to the University of Oxford

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

In the original protocol, [Stoesser 2013](#), we had planned the intervention to be cephalosporins historically referred to as "third or fourth generation." In this review, the intervention was changed to a cephalosporin antimicrobial of any dose or duration to reflect the move away from the concept of "generations" of cephalosporins since the publication of the original protocol. We amended the title accordingly.

We had planned to stratify results by antimicrobial resistance type for all trials where these data are available (MDR: NaR or DCS, or both). This analysis was not possible due to data not reported or data unable to be separated by resistance type. We have described the details of trials that reported on the presence of antimicrobial resistance in the [Characteristics of included studies](#) section.

In the original protocol, [Stoesser 2013](#), we had not specified the approach that would be taken to reporting the summary of findings and assessment of the certainty of the evidence. We have now reported this approach in the [Methods](#) section under 'Summary of findings and assessment of the certainty of the evidence.'

In the original protocol, [Stoesser 2013](#), the objectives included identifying optimal antimicrobial agents and doses. This was not feasible with the data, and we have simplified the objectives by removing this objective.

The author list has changed since the publication of original protocol in 2013, to reflect the contribution and involvement of each author in the production of the final review.

INDEX TERMS

Medical Subject Headings (MeSH)

Anti-Bacterial Agents [therapeutic use]; *Anti-Infective Agents [therapeutic use]; Azithromycin [adverse effects]; Cefixime [therapeutic use]; Ceftriaxone [therapeutic use]; Cephalosporins [therapeutic use]; Chloramphenicol [therapeutic use]; Ciprofloxacin [therapeutic use]; Fluoroquinolones [therapeutic use]; Monobactams [therapeutic use]; Ofloxacin [therapeutic use]; Pakistan; *Paratyphoid Fever [drug therapy]; Recurrence; *Typhoid Fever [drug therapy]

MeSH check words

Adolescent; Adult; Child; Humans